CLINICAL STUDY PROTOCOL
Study Title: A Randomized, Double -blind, Placebo -and Active -controlled, 
Multicenter, Phase 3 Study  to Assess the Efficacy and Safet y of 
Filgotinib Administered for 52 Weeks Alone and in Combination 
with Methotrexate (MTX) to Subjects with Moderate lyto Severe ly
Active Rheumatoid Arthritis Who Are NaÃ¯ve to MTX Therap y
Sponsors: [COMPANY_009] Sciences, Inc.
[ADDRESS_580252]
Foster City , CA [ZIP_CODE]
[LOCATION_003]
IND Number :
EudraCT Number :
Clinical Trials.gov 
Identifier :115,510
2016-000570-37
TBD
Indication: Rheumatoid Arthritis
Protocol ID: GS-US-
417-0303
[COMPANY_009] Clinical 
Program Manager : Name:
[CONTACT_10880]:
[COMPANY_009] 
Medical Monitor :Name:
[CONTACT_10880]:
Fax:
Mobile :
Protocol Version/Date: Original : 22 April 2016
Amendment 1
: [ADDRESS_580253] or Independent Ethics Committee. The information is only  to be used 
by [CONTACT_454164]. You will not disclose an y of the information to others without written authorization 
from [COMPANY_009] Sciences, Inc., except to the extent necessary  to obtain informed consent from those 
persons to whom the drug may  be administered.
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003](!")" GILEAU Galapagos 
Filgotinib 
Protocol GS -US-417-[ADDRESS_580254] OF IN- TEXT FIGURES ................................................................................................
...................................... 5
PROTOCOL SYNOPSIS .............................................................................................................................................. 6
GLOSSARY OF ABBREVIATI ONS AND DEFINITION O F TERMS.................................................................... 15
1. INTRODUCTION .............................................................................................................................................. 18
1.1. Background ............................................................................................................................................ 18
1.2. Filgotinib ................................................................................................................................................ 19
1.2.1. General Information ............................................................................................................. 19
1.2.2. Nonclinical Pharmacology, Absorption, Distribution, Metabolism, and 
Excretion (ADME) and Toxicology ..................................................................................... 19
1.2.3. Clinical Trials of Filgotinib .................................................................................................. 21
1.3. Rationale for This Study ........................................................................................................................ 26
1.3.1. Rationale for Study Design .................................................................................................. 27
1.3.2. Rationale for the Outcome Measures ................................................................................... 27
1.3.3. Rationale for the Choice of Dose and Dosing Interval ......................................................... 28
1.4. Risk/Benefit Assessment for the Study .................................................................................................. 29
1.5. Com pliance ............................................................................................................................................ 30
2. OBJECTIVES ..................................................................................................................................................... 31
3. STUDY DESIGN ................................................................................................................................................ 33
3.1. Endpoints ............................................................................................................................................... 33
3.2. Study Design .......................................................................................................................................... 34
3.3. Study Treatments ................................................................................................................................... 35
3.4. Duration of Treatment ............................................................................................................................ 36
3.5. Criteria for Interruption or Discontinuation of Study Treatment ........................................................... 36
3.5.1. Study drug interruption considerations: ............................................................................... 36
3.5.2. Study drug discontinuation considerations: .......................................................................... [ADDRESS_580255] Study Care ...................................................................................................................................... 39
3.8. Biomarker Samples ................................................................................................................................ 39
3.8.1. Biomarker Samples to Address the Study Objectives: ......................................................... [ADDRESS_580256] Selection ............................................................................................ 42
4.2. Inclusion Criteria .................................................................................................................................... 42
4.3. Exclusion Criteria ................................................................................................................................... 44
5. INVESTIGATIONAL MEDI CINAL PRODUCTS ........................................................................................... 49
5.1. Randomization, Blinding and Treatment Codes .................................................................................... 49
5.1.1. Procedures for Breaking Treatment Codes ........................................................................... 49
5.2. Description and Handling of Filgotinib and PTM Filgotinib ................................................................. 49
CCI
CCI
CCI
Filgotinib 
Protocol GS -US-417-0303 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 3 05 July [ZIP_CODE].2.1. Form ulation of Filgotinib and PTM Filgotinib ..................................................................... 49
5.2.2. Packaging and Label ing for Filgotinib and PTM Filgotinib ................................................. 50
5.2.3. Storage and Handling for Filgotinib and PTM Filgotinib .................................................... 50
5.2.4. Dosage and Administration of Filgotinib ............................................................................. 50
5.3. Description and Handling of Methotrexate (MTX) and PTM MTX ...................................................... [ADDRESS_580257] Enrollment and Treatment Assignment ..................................................................................... 57
6.2. Pretreatment Assessments ...................................................................................................................... 57
6.2.1. Screening Visit ..................................................................................................................... 57
6.2.2. Day 1 Assessments ............................................................................................................... 59
6.3. Randomization ....................................................................................................................................... 60
6.4. Week 2 through Week 44 Assessments ................................................................................................. 60
6.5. Week 52/Early Termination (ET) ........................................................................................................... [ADDRESS_580258] (IRB)/Independent Ethics Committee (IEC) 
Revie w and Approval ........................................................................................................... [ADDRESS_580259] Accountability and Return ............................................. 90
9.1.8. Inspections ............................................................................................................................ 90
9.1.9. Protocol Compliance ................................................................
............................................ 90
9.2. Sponsor Responsibilities ........................................................................................................................ 91
9.2.1. Protocol Modifications ......................................................................................................... 91
9.2.2. Study Report and Publications ............................................................................................. 91
9.3. Joint Investigator/Sponsor Responsibilities ........................................................................................... 91
9.3.1. Payment Reporting ............................................................................................................... 91
9.3.2. Access to Information for Monitoring .................................................................................. 92
9.3.3. Access to Information for Auditing or Inspections .............................................................. 92
9.3.4. Study Discontinuation .......................................................................................................... 92
10. REFERENCES ................................................................................................................................................... 93
11. APPENDICES .................................................................................................................................................... 95
Appendix 1. Investigator Signature [CONTACT_3490] .................................................................................................... 96
Appendix 2. Study Procedures Table .......................................................................................................... 97
Appendix 3. Management of Clinical and Laboratory Adverse Events .................................................... 102
Appendix 4. Common Terminology Criteria for Adverse Events (CTCAE) v4.[ADDRESS_580260] of Joints to be Evaluated (66/68 Joint Count) ............................................................... 109
Appendix 8. The 2010 American College of Rheumatology â€“European League Against 
Rheumatism Collaborative Initiative Classification Criteria for Rheumatoid 
Arthritis {Aletaha et al 2010} ............................................................................................... 110
Appendix 9. American College of Rheumatology Response Evaluations/ Preliminary Definition 
of Improvement in Rheumatoid Arthritis {Felson et al 1995} ............................................. 112
Appendix 10. Disease Activity Score (DAS28) {Prevoo et al 1995} ......................................................... [ADDRESS_580261] OF IN -TEXT TABLES
Table 1-1. Summary and analysis of ACR20/50/70 response at Weeks 12 and 24 (NRI [ITT 
Population]), GLPG0634 -CL-203.......................................................................................... 22
Table 1-2. Summary and analysis of ACR20/50/70 response at Weeks 12 and 24 (NRI [ITT 
Population]); GLPG0634 -[ADDRESS_580262]
Foster City, CA [ZIP_CODE] 
[LOCATION_003]
Study Title: A Randomized, Double -blind, Placebo- and Active -controlled, 
Multicenter, Phase 3 Study  to Assess the Efficacy and Safet y of 
Filgotinib Administered for 52 Weeks alone and in Combination 
with Methotrexate (MTX) to Subjects with Moderate lyto Severe ly 
Active Rheumatoid Arthritis Who Ar e NaÃ¯ve to MTX Therap y
IND Number:
EudraCT Number:
Clinical Trials.gov 
Identifier:115,510
2016-000570-37
TBD
Study Centers Planned: Approximately  200-250 centers worldwide
Objectives: The primary  objective of this study  is:
ï‚·To evaluate the effects of filgotinib in combination with MTX 
versus MTX alone for the treatment of signs and symptoms of 
rheumatoid arthritis ( RA)as measured b y the proportion of 
subjects achieving an American College of Rheumatology  20% 
improvement response ( ACR20 )at Week 24
The secondary  objectives of this study  include : 
ï‚·T
o evaluate the effect of filgotinib in combination with MTX 
versus MTX alone on physical function as measured by  [CONTACT_454165] ( HAQ- DI) score a t Week 24.
ï‚·To evaluate the effects of filgotinib in combination with MTX 
versus MTX alone for the treatment of signs and symptoms of 
RA as measured b y the proportion of subjects achieving 
Disease Activity  Score for 28 joint count using C
-reactive 
protein (DAS28 [CRP] ) <2.6 at Week 24 
Filgotinib 
Protocol GS -US-417-0303 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 7 05 July 2016ï‚·To evaluate the effect of filgotinib alone versus MTX alone for 
the treatment of signs and sy mptoms of RA as measured b y the 
proportion of subjects achieving ACR20 at Week 24
ï‚·To evaluate the effect of filgotinib alone vers us MTX alone on 
physical function as measured by  [CONTACT_454166]- DI score at Week 24 
ï‚·To evaluate the effect of filgotinib alone versus MTX alone for 
the treatment of signs and sy mptoms of RA as measured b y the 
proportion of subjects achieving DAS28(CRP) <2.6 at Week 
24
ï‚·To evaluate the effects of filgotinib in combination with MTX
versus MTX alone on preservation of joint structure as 
measured b y change from Baseline in the van der Heijde 
modified Total Sharp Score ( mTSS )at Week 24 and 52
ï‚·To evaluate the effects of filgotinib alone versus MTX alone 
on preservation of joint structure as measured b y change from 
Baseline in mTSS at Week 24 and 52
ï‚·To evaluate the safet y and tolerability  of filgotinib alone and in 
combination with MTX 
ï‚·To evaluat e the effects of filgotinib alone and in combination 
with MTX on work productivity ,fatigue, and general qualit y 
of life as measured b y SF-36, FACIT -Fatigue , EQ-5D and 
WPAI -RA
The exploratory  objectives of this study  include:
 
 
 
Study Design: This is a randomized, double -blind, placebo -and active -controlled, 
Phase [ADDRESS_580263] 
on work productivity, fatigue, andquality  of life .
CCII 
I 
I 
Filgotinib 
Protocol GS -US-417-0303 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 8 05 July 2016Approximately 1200 subjects will be randomized in a 2:1:1:2 ratio
to filgotinib 200 mg with MTX , filgotinib 100mg with MTX, 
filgotinib 200mgalone , or MTX alone for up to 52 weeks :
ï‚·Filgotinib 200 mg+ MTX group : Filgotinib (200 mg q.d.) +
PTM filgotinib 100 mg (PTM q.d.) + MTX (once weekl y up to 
20 mg) (N= 400)
ï‚·Filgotinib 100 mg + MTX group : Filgotinib (100 mg q.d.) +
PTM filgotinib 200 mg 
(PTM q.d.) + MTX (once weekl y up to 
20 mg) (N=200)
ï‚·Filgotinib 200 mg monotherapy group : Filgotinib (200 mg 
q.d.) + PTM filgotinib 100 mg (PTM q.d.) + PTM MTX ( PTM 
once weekl y) (N=200)
ï‚·MTX monotherap ygroup : PTM filgotinib 100 mg (PTM q.d.)
+ PTM filgotinib 200 mg (PTM q.d.) + MTX (once weekl y up 
to 20 mg) (N= 400)
Randomization will be stratified b ygeographic region and 
presence of rheumatoid factor ( RF) or anti -CCP (cyclic 
citrullinated peptide) antibody  (Ab) at Screening .
At Week 24, subjects who have not achieved a t least a 20% 
improvement from Day  1 in both swollen joint count (SJC) and 
tender joint count (TJC) will discontinue investigational study  
drug dosing but will continue with study  visits and assessments per 
protocol. All subjects meeting this criterion who discontinue from 
investigational therap y are to receive standard of care treatment for 
their RA as determined by [CONTACT_093]. Subjects achieving at 
least a 20% improvement in SJC and TJC at Week [ADDRESS_580264] a 20% improvement from Day 1 in TJC 
and SJC , (which is confirmed at 2 consecutive visits ), will
discontinue from investigational study  drug 
dosing but will 
continue with study  visits and assessments per protocol. All 
subjects meeting this criterion who discontinue from 
investigatio nal study  drug dosing are to receive standard of care 
treatment for their RA as determined b y the investigator.
All subjects who have received at least one dose of study drug and 
exit the study early will complete an early  termination (ET ) visit at 
the tim e of study  discontinuation, with a post treatment visit 
four weeks after the last dose of study  drug ( Post Treatment 
Week 4) regardless of 
dosing duration.
Filgotinib 
Protocol GS -US-417-[ADDRESS_580265] not 
discontinued assigned study  drug dosing, will be provided the 
option to enroll into a separate Long T ermExtension ( LTE) study  
(GS-US-417- 0304).
Study D esign
Number of Subjects 
Planned:Approximately 1200 subjects
Target Population: Male or female subjects who are â‰¥18 y ears of age with a diagnosis 
of RA meeting the 2010 ACR/ European League Against 
Rheumatism ( EUL AR)criteria, who have active RA and had 
limited or no prior exposure to MTX.
Duration of Treatment: Up to 52 weeks
Diagnosis and Main 
Eligibility  Criteria:For a complete list of study  inclusion and exclusion criteria, please 
refer to Sections 4.2and 4.3.
Main 
Eligibility  Criteria
1)Male or female subjects who are â‰¥18 y ears of age, on the day  
of signing informed consent
2)Have a d iagnosis of RA (2010 ACR /EUL ARcriteria ), and are 
ACR functional class I -III
3)Have â‰¥6 swollen joints (from a SJC66) and â‰¥6 tender joints 
(from a TJC68) at Screening and Day  1 
DAY 1 WK24 
Primary Endpoint WK 52 
SCREENING ~ RANDOM IZATION 
28 days prior 2:1 :1 :2 
to Day 1 
(may be extended 
to 42 days if 
repea t 
radiogra phs are 
required) 
WK 24: ;, Standard of care for all subjects with 
Subjects with protocol-defined inadequate response 
inadequate 
response will 
discont inue 
study drugs 
Filgotinib 
Protocol GS -US-417-0303 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 10 05 July [ZIP_CODE]) Must meet at least one of the following parameters at 
Screening:
ï‚·positivity  for either  RF or anti- CCP Abper central 
laboratory  
OR
ï‚·Serum CRP â‰¥ 4 mg/L  based on central laboratory  value
OR
ï‚·â‰¥1 documented joint erosion on radiographs of the hands, 
wrists or feet b y central reading
5)
Limited or no prior treatment with MTX, ie, no more than 
3doses of MTX â‰¤[ADDRESS_580266] 28 day sprior to Day 1, and are an 
appropriate candidate for MTX therap y, as per investigator 
judgment
Study  Procedures/
Frequency :The subjects will visit the clinical study  center a t Screening, 
Day 1, Week
s2, 4, 8, 12, 16, 20, 24, 30, 36, 44, and52 or E T. 
For those subjects not entering the LTE, a follow -up visit will be 
planned [ADDRESS_580267] dose of study  drug (Post Treatment 
Week 4). Consequently , subject sare planned t obe in the study  for 
approximately  60weeks. 
During the Screening period, the subjectâ€™s radiographs (hands, 
wrists, and feet) will be sent for blinded
central scoring . In 
addition, information on demographics, medical 
history /concomitant diseases, prior and current RA medication s
will be collected. A ph ysical examination, a 12-lead 
electrocardiogram (ECG), and clinical laboratory  assessments will 
be conducted to determine the subjectâ€™s eligibility  for study  
participation. The screening window may  be exten ded to up to 
42days prior to the Day  [ADDRESS_580268]â€™s eligibility  for the study  has been 
confirmed, the subject will be randomized to receive one of 
4dosing regimens: filgotinib 200 mg 
q.d.plus MTX up to 20 mg 
weekl y, filgotinib 1 00 mg q.d.plus MTX up to 20 mg weekl y,
filgotinib monotherap y200 mg q.d. or MTX monotherapy up to 
20mg weekl y. 
Filgotinib 
Protocol GS -US-417-0303 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 11 05 July 2016On-treatment assessments will include: adverse events (AEs), 
concomitant medications,  review of stud y medication compliance 
through drug accountability , SJC66, TJC68, Subjectâ€™s Global 
Assessment, Subjectâ€™s Pain Assessment, HAQ -DI, Functional 
Assessment of Chronic Illness Therap y-Fatigue (FACI T-Fatigue ), 
Short -Form Health Surve y (SF-36), Work Productivity  and 
Activity  Impairment -Rheumatoid Arthritis (WPAI -RA), 
EuroQol 5 Dimensions (EQ -5D),  
Treatment Satisfaction Questionnaire for Medication 
(TSQM), Healthcare Resource Utilization, Phy sicianâ€™s Global 
Assessment, phy sical examination, weight, vital signs, serum CRP, 
blood and urine sampling for safety  laboratory  tests and 
biomarkers at selected visits, and urine pregnancy tests (females of 
child bearing potential only ).
A resting [ADDRESS_580269] -treatment Week 4 
follow -up visit . ECGs should be interpreted b y the investigator
(orqualified designee) for clinical significance. 
For all subjects, blood samples for PK an alysis should be collected 
at least [ADDRESS_580270] 
prematurel y discontinues study  participation and has had X- rays 
performed within the previous 12 weeks, then X- raysdo not need 
to be repeated at the ETvisit. Radiographs performed after 
enrollment may  be done +/ -[ADDRESS_580271] treatment follow -up assessments include AEs, concomitant 
medications, phy sical examination, 12 -lead ECG, weight, vital 
signs, blood and urine sampling for safet y laboratory tests, and 
urine pre gnancy  tests (females of child bearing potential only ).
CCI
CCI-
)LOJRWLQLE
3URWRFRO*686 )LQDO
*LOHDG6FLHQFHV,QF $PHQGPHQW
&21),'(17,$/ 3DJH  -XO\






7HVW3URGXFW'RVHDQG
0RGHRI$GPLQLVWUDWLRQ PJILOJRWLQLERUDOO\TG SOXV 07;ZHHNO\XSWRPJ
 PJILOJRWLQLERUDOO\TG SOXV 07;ZHHNO\XSWRPJPJILOJRWLQLERUDOO\TG
5HIHUHQFH7KHUDS\'RVH
DQG0RGHRI$GPLQLVWUDWLRQ07;ZHHNO\XSWR PJRU37007;ZHHNO\
370 ILOJRWLQLEPJRUDOO\TG370ILOJRWLQLEPJRUDOO\TG
&ULWHULDIRU(YDOXDWLRQ
6DIHW\ 6DIHW\ZLOOEHDVVHVVHGE\GRFXPHQWDWLRQRI$(VFOLQLFDO 
ODERUDWRU\WHVWVSK\VLFDOH[DPLQDWLRQVYLWDOVLJQVDQGOH DG
(&*VGXULQJWKHVWXG\
(IILFDF\ 7KHSULPDU\HQGSRLQWLV
â€¢7KHSURSRUWLRQRIVXEMHFWVZKRDFKLHYHDQ$&5UHVSRQVHDW
:HHNâ€¯24.
7KHNH\VHFRQGDU\HQGSRLQWVDUH
â€¢&KDQJHIURP%DVHOLQHLQWKH+$4',VFRUHDW:HHN
â€¢7KHSURSRUWLRQRIVXEMHFWVZKRDFKLHYH'$6 â€¯[CRP]DW
:HHN
â€¢&KDQJHIURP%DVHOLQHLQP766DW:HHN
3KDUPDFRNLQHWLFV 3ODVPDFRQFHQWUDWLRQVRIILOJRWLQLEDQGWKHDFW LYHPHWDEROLWH
*6ZLOOEHDQDO\]HG&&,
)LOJRWLQLE
3URWRFRO*686 )LQDO
*LOHDG6FLHQFHV,QF $PHQGPHQW
&21),'(17,$/ 3DJH  -XO\6WDWLVWLFDO0HWKRGV 7KHSULPDU\DQDO\VLVVHWIRUHIILFDF\DQDO\VHVZLOOEHWKH)XOO 
$QDO\VLV6HW)$6ZKLFKLQFOXGHVDOOUDQGRPL]HGVXEMHFWVZKRUHFHLYHGDWOHDVWRQHGRVHRIVWXG\GUXJ
7KHSULPDU\HQGSRLQWLVWKHSURSRUWLRQRIVXEMHFWVZKRDFKLHYHD Q
$&5UHVSRQVHDW:HHN â€¯24.7KHSULPDU\DQDO\VLVZLOOFRQVLVWRI
DVXSHULRULW\WHVWRIILOJRWLQLEPJLQFRPELQDWLRQZLWK07;FRPSDUHGWR07;DORQHEDVHGRQWKH$&5UHVSRQVHUDWHVDW:HHN &RFKUDQ0DQWHO+DHQV]HODSSURDFKDGMXVWLQJIRUWKHVWUDWLILFDWLRQIDFWRUVZLOOEHXVHGIRUWKHK\SRWKHVLVWHVWLQJ DWWKH
VLGHGOHYHO
7KHIROORZLQJK\SRWKHVLVWHVWLQJZLOOFRPPHQFHDIWHUWKHSULPDU \
DQDO\VLVUHDFKHVVWDWLVWLFDOVLJQLILFDQFHDQGZLOOEHWHVWHGDFFRUGLQJWRWKHKLHUDUFKLFDOWHVWLQJSULQFLSOHDWWKHVLGHG 
OHYHO,IDQXOOK\SRWKHVLVLVQRWUHMHFWHGIRUPDOVHTXHQWLDO WHVWLQJ
ZLOOEHVWRSSHGDQGRQO\QRPLQDOVLJQLILFDQFHZLOOEHUHSRUWHG IRU
WKHUHPDLQLQJNH\VHFRQGDU\K\SRWKHVHV
 6XSHULRULW\RIILOJRWLQLEPJLQFRPELQDWLRQZLWK07;
FRPSDUHGWR07;DORQHEDVHGRQWKHFKDQJHIURP%DVHOLQHLQ+$4',DW :HHN
 6XSHULRULW\RIILOJRWLQLEPJLQFRPELQDWLRQZLWK07;
FRPSDUHGWR07;DORQHEDVHGRQWKHUHVSRQVHUDWHRI'$6&53 DW:HHN
 6XSHULRULW\RIILOJRWLQLEPJLQFRPELQDWLRQZLWK07;
FRPSDUHGWR07;DORQHEDVHGRQ$&5UHVSRQVHUDWHDW:HHN
 6XSHULRULW\RIILOJRWLQLEPJLQFRPELQDWLRQZLWK07;
FRPSDUHGWR07;DORQHEDVHGRQWKHFKDQJHIURP%DVHOLQHLQ+$4',DW :HHN
 6XSHULRULW\RIILOJRWLQLEPJLQFRPELQDWLRQZLWK07;
FRPSDUHGWR07;DORQHEDVHGRQWKHUHVSRQVHUDWHRI'$6 DW:HHN
 6XSHULRULW\RIILOJRWLQLEPJDORQHFRPSDUHGWR07;DORQH
EDVHGRQ$&5UHVSRQVHUDWHDW:HHN
 6XSHULRULW\RIILOJRWLQLEPJDORQHFRPSDUHGWR07;DORQH
EDVHGRQWKHFKDQJHIURP%DVHOLQHLQ+$4',DW:HHN
 6XSHULRULW\RIILOJRWLQLEPJDORQH FRPSDUHGWR07;DORQH
EDVHGRQWKHUHVSRQVHUDWHRI'$6&53 DW:HHN
 6XSHULRULW\RIILOJRWLQLEPJLQFRPELQDWLRQZLWK07;
FRPSDUHGWR07;DORQHEDVHGRQWKHFKDQJHIURP%DVHOLQHLQP766DW :HHN
Filgotinib 
Protocol GS -US-417-0303 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 14 05 July 201610)Superiority  of filgotinib 100 mg in combination with MTX 
compared to MTX alone based on the change from Baseline in 
mTSS atWeek 24
11)Superiority  of filgotinib 200 mg alone compared to MTX alone 
based on the change from Baseline in mTSS atWeek 24
All continu ous endpoints will be summarized using an 8 -number 
summary  (n, mean, standard deviation [SD], median, 1st quartile 
[Q1], 3rd quartile [Q3], minimum, maximum) by [CONTACT_1570]. 
All categorical endpoints will be summarized by  [CONTACT_204953].
Safety  endpoints will be anal yzed by [CONTACT_454167] 
8-number summary  (n, mean, SD, median, Q1, Q3, minimum, 
maximum) for continuous data by [CONTACT_1570].
Sample size is determined based on the superiority test of 
filgotinib [ADDRESS_580272] deviation of 2.7, 400 subjects in the filgotinib 
200 mg in combination with MTX group and 
400in the MTX 
alone group are required to obtain 90% power at a 2- sided 
0.05- level.
T
he total sample size will be 1200 (400 subjects for filgoti nib 
200mg in combination with MTX group , 200 subjects for 
filgotinib 100mg in combination with MTX group, 200 subjects 
for filgotinib 200mgalone group and 400 subjects for MTX alone 
group ).This sample size will provide over 90% power to detect an 
increase in ACR20 response rate of 62% to 78% between the MTX 
alone group and each of the filgotinib groups respectivel y, using a 
2-sided 0.[ADDRESS_580273].
This study  will be conducted in accordance with the guidelines of Good Clinical Practice (GCP) 
including archiving of essential documents.
Filgotinib 
Protocol GS -US-417-0303 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 15 05 July 2016GLOSSARY OF ABBREVIATIONS AND DEFINITION OF TERMS
Ab antibody
ACPA anti-citrullinated protein antibody
ACR X American College of Rheumatology X% improvement
AE adverse event
ALT alanine aminotransferase
ANA anti-nuclear antibody
aPTT activated partial thromboplastin time
ATP adenosine triphosphate
AST aspartate aminotransferase
AUC 0-Æ® area under the plasma drug concentration -time curve of a dosing interval
bDMARD(s) biologic disease modifying antirheumatic drug(s)
b.i.d. bis in die
; twice daily
CÆ® trough plasma concentration (just before the next dosing ie ,pre-dose sample)
CCP cyclic citrullinated peptide
CD Crohnâ€™s Disease
CDAI Clinical Diagnostic Activity Index
csDMARD(s) conventional synthetic disease m odifying antirheumatic drug(s)
CES carboxylesterases
CIA collagen -induced arthritis
Cmax maximum observed plasma concentration
CMV cytomegalovirus
CNS central nervous system
CRO Contract Research Organization
CRP C-reactive protein
CV-SEAC Cardiovascular Safety Endpoint Adjudication Committee
CYP Cytochrom e 
DAS28 Disease Activity Score based on [ADDRESS_580274](s) disease -modifying anti -rheumatic drugs
DMC/DSMB data monitoring committee/data safety monitor board
dsDNA double stranded deoxyribonucleic acid
DSS dextran sulphate sodium
ECG electrocardiogram
eCRF electronic case report form
ET early termination
EU European Union
EULAR European League Against Rheumatism
EQ-5D EuroQol 5 Dimensions
FACIT -Fatigue Functional Assessment of Chronic Illness Therapy -Fatigue
FAS full analysis set
FDA Food and Drug Administration
Filgotinib 
Protocol GS -US-417-0303 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 16 05 July 2016FSH follicle stimulating hormone
GCP Good Clinical Practice
GFR glomerular filtration rate
GGT gamma glutamyl transferase
GI gastrointestinal 
GLP Galapagos 
HAQ -DI Health Assessment Questionnaire â€“Disability Index
HCV hepatitis C virus
HCG human chorionic gonadotropin
HCQ hydroxychloroquine
HDL high density lipoprotein
hERG human ether -a-gogo related gene
HIV human immunodeficiency virus
HR heart rate
IC50 half maximal inhibitory concentration
ICF informed consent form
ICH International Council for Harmonization
IEC Independent Ethics Committee
Ig immunoglobulin
IMP investigational medicinal product
INR international normalized ratio
IRB Independent Review Board
ITT Intent -to-treat
IV intravenous
IWRS interactive web response system
JAK janus kinase 
LCMS/MS liquid chromatography mass spectrometry
LDL low density lipoprotein
LH luteinizing hormone
LTE Long Term Extension
MAA Marketing Authorization Application
MACE Major adverse cardiovascular event
MCV mean corpuscular volume
MRI magnetic resonance imaging
MTX methotrexate
IR inadequate responders
mTSS modified Total Sharp Score
NDA New  Drug Application
NSAIDs nonsteroidal anti -inflammatory drugs
NYHA New  York Heart Association
OATs organic anion transporters
PBMC peripheral blood mononuclear cells
PD pharmacodynamics
Filgotinib 
Protocol GS -US-417-0303 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 17 05 July 2016PK pharmacokinetics
PP per-protocol
PT prothrombin time
PTM placebo to match
q.d. quaque die ; once daily
RA rheumatoid arthritis
RAMRIS rheumatoid arthritis magnetic resonance imaging score
RF rheumatoid factor
SAE serious adverse event
SAP Statistical Analysis Plan 
SBP systolic blood pressure
s.c. subcutaneous
SD standard deviation
SDAI Simplified Diagnostic Activity Index
SF-36 short -form health survey , 36 questions
SI international system of units
SJC66 swollen joint count based on 66 joints
TB tuberculosis
TEAEs treatment emergent adverse events
TJC68 tender joint count based on 68 joints
tmax the time of occurrence of maximum observed plasma concentration
TNFi tumor necrosis factor inhibitors
TNFÎ± tumor necrosis factor Î±
TSQM Treatment Satisfaction Questionn aire for Medication
UGTs uridine 5â€™disphosphate glucuronosyltransferase s
ULN upper limit of normal
US [LOCATION_002]
vfPBMCs viably frozen peripheral blood mononuclear cells
vs. versus
WBC white blood cell
WPAI -RA Work Productivity and Activity Im pairm ent for Rheumatoid Arthritis
Definition of Terms
QTcF QT interval corrected for HR according to Fridericiaâ€™s formula: 
QTcF = QT/(RR)^(1/3), where RR = 60/HR
RR = RR interval in seconds
HR = heart rate in beats per minute
Filgotinib 
Protocol GS -US-417-0303 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 18 05 July [ZIP_CODE]. INTRODUCTION
1.1. Background
Rheumatoid arthritis (RA) is a chronic, s ystemic inflammatory  disease that affects approximately
1.3 million adults in the [LOCATION_002] (US) {Helmick et al 2008}. Rheumatoid arthritis
manifests principall y as an attack on peripheral joints and may  lead to marked destruction and 
deformity  of joints, with considerable disabilit y and impact on quality of life. I t is characterized 
by [CONTACT_454168], synovial inflammation with formation of pannus tissue, and 
erosion of underl ying cartilage and bone. Although people of an y age can be affected, the onset 
of RA is most frequent between the ages of [ADDRESS_580275] been 
implicated in its pathogenesis.
Treatment of RA is depend ent on severit y, the patientâ€™s coâ€“morbidities and initial response to 
therap y. Methotrexate is a conventional synthetic disease modify ing anti -rheumatic drug 
(
csDMARD) and continues to be the cornerstone of RA therapy  {Singh et al 2012 }.Patients 
with an inadequate response to 
csDMARD(s) are often treated with biologic therapi[INVESTIGATOR_454151] (TNFi) as an initial second line therap y. However, approximately  
28% to 58% of RA patients with inadequate response to MTX fail TNFi as reviewed in {Redlich 
et al 2003 }.In this setting, treatment guidelines recommend either switching to another TNFi, 
alternate biologic, or to a small molecule drug {Singh et al 2012}. Despi[INVESTIGATOR_454152], there remains a need for new treatments, since not all 
patients respond adequately  to current therapi[INVESTIGATOR_014], have co
-morbidities and some patients 
experience toxicities and/or intolerance tha t limit the use of approved therapi[INVESTIGATOR_014].
In November 2012, tofacitinib (XeljanzÂ®) became the first Janus kinase (JAK )inhibitor to 
receive Food and Drug Administration (FDA) approval for the treatment of adult patients with 
RA. Tofacitinib is a small molecule, has strong binding affinity  for JAK1 and JAK3, and weaker 
affinity  for JAK2. The extensive pre -clinical and clinical development programs demonstrated its 
mechanisms of action via anti -inflammatory  and immunosuppressive effects. The drug proved to 
be ef ficacious in treating the signs and s ymptoms of RA. However, the observed side-effects and 
risk profile of tofacitinib are similar to those of several existing anti-rheumatic agents with 
cytopenias, elevated levels of liver function enzymes, increased total cholesterol levels, with 
increases in LDL typi[INVESTIGATOR_204928], and increased risk for infections including 
serious and opportunistic infections. At higher doses, tofacitinib treatment was associated with 
anemia, which is thought to be linked to inhibition of JAK2.
While the pan JAK inhibitor tofacitinib has shown an earl y onset of action and long -term 
efficacy  in RA as mono therapy  and in combination with background csDMARD therap y, dose 
levels were limited by  [CONTACT_454169] y me diated by  [CONTACT_454170] [ADDRESS_580276] profile. 
Filgotinib 
Protocol GS -US-417-0303 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 19 05 July [ZIP_CODE].2. Filgotinib
1.2.1. General Information
Janus kinases are intracellular cy toplasmic ty rosine kinases (TYKs) that transduce cy tokine 
signaling from membrane receptors through signal transducer and activator of transcription 
(STAT) to the nucleus of cells. JAK inhibitors block the signaling of various cy tokines, growth 
factors, and hormones, including the pro -inflammatory  cytokine interleukin (IL) -6. Four 
different t ypes of JAKs are known, JAK1, JAK2, JAK3, and TYK2 which co -interact with 
different sets of membrane receptors. Inhibition of JAKs is a promising therapeutic option for a 
range of inflammatory  conditio ns including RA and Crohnâ€™s Disease (CD).
Filgotinib (GS -6034, formerly  GLPG0634) is a potent and selective inhibitor of JAK1. The 
compound has shown good preliminary  efficacy  in RA and CD patients in Phase 2. No ty pi[INVESTIGATOR_204929]2 side effects such as anemia we re observed in clinical studies of up to 24 weeks duration. 
In humans, filgotinib is metabolized to form one major active metabolite, GS-829845
(formerl yG254445). Though the potency  of this metabolite is lower than the parent molecule, 
the overall exposu re and peak plasma concentration in humans is higher than seen in all tested 
animal species. As a consequence, dedicated pharmacology and toxicology studies have been 
performed with GS-829845.  Results from pharmacody namics (PD) testing in healthy  voluntee rs 
suggest that the clinical activity  of filgotinib could result from the combination of the parent 
molecule and the metabolite.
For further information on filgot i
nib, refer to the current investigatorâ€™s brochure.
1.2.2. Nonclinical Pharmacology, Absorption, Dist ribution, Metabolism, and 
Excretion ( ADME )and Toxicology
Filgotinib and its metabolite, GS -[ADDRESS_580277] JAK1; efficacy  studies in rats and mice; repeat dose tox icity studies (up to 
26weeks in the rat and 39 weeks in the dog), in vitro and in vivo safet y pharmacology  and 
genetic toxicology  studies, and reproductive toxicology  studies in rats and rabb its.Additional 
toxicology  studies conducted include phototoxicity  studies and dose -range finding studies in 
support of a definitive rat juvenile toxicity  study  and a 6 month carcinogenicity  study  in 
transgenic (TgrasH2) mice. A 2 year rat oral carcinogeni city study  is ongoing.
[IP_ADDRESS]. Primary  and Secondary  Pharmacology
Filgotinib is an adenosine triphosphate (ATP) -competitive inhibitor of JAK1. I t is highl y 
selective for inhibition of JAK1 over 451 other kinases evaluated in vitro. In cellular assay s, it 
inhibits JAK/STAT -driven processes with half maximal inhibitory  concentration (I C50) values 
from 179 nM onwards.  In human whole blood, JAK1 is inhibited by  [CONTACT_454171] I C50of 
629 nM and exhibits approximately  30-fold selectivity  over JAK2. Filgotinib demonstrated 
significant efficacy  in the rat collagen -induced arthritis (CI A) model as well as in the mouse 
dextran sulphate sodium (DSS) -induced colitis model.
Filgotinib 
Protocol GS -US-417-0303 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 20 05 July 2016Metabolite GS-829845 exhibits a similar JAK1 selectivity  profile but is approximately  
10to20-fold less potent than the parent filgotinib in in vitro assay s. GS -829845 was as effective 
as filgotinib in the rat CIA model, but at doses that required a 10 -fold higher exposure.
[IP_ADDRESS]. Safety  Pharmacology
Filgotinib and GS-829845 had no effects on the respi[INVESTIGATOR_204930] s ystem 
(CNS) up to respectivel y 40-and 5 -fold the exposure in RA subjects given filgotinib 200 mg q .d.
Filgotinib and GS-829845 had no relevant effects on cardiovas cular parameters (human 
ether -
a-gogo related gene [hERG] and dog telemetry  studies), apart from a slight non- adverse 
increase in heart rate and arterial pressure with GS-829845 at exposures 7- fold that of the C maxin 
subjects with RA treated with 200 mg q .d.filgotinib . There were no relevant effects on 
electrocardiogram (ECG) and QT.
[IP_ADDRESS]. Nonclinical ADME
Filgotinib demonstrates good oral bioavailability  in mice, rats, dogs, and minipi[INVESTIGATOR_454153] s.  Plasma protein binding is low (< 70%) in all species, including humans.
The pharmacokinetics (PK) of filgotonib is generally  dose proportional without gender 
differences.  No accumulation occurs with repeated dosing. The mean terminal half -
life after oral 
administration is 4 and 5 hours (h) in rats and dogs, respectivel y.
In the rat, filgotinib showed a r apid and even distribution throughout the body .  High 
concentrations were observed only  in the gastrointestinal (GI) tract and urinary  bladder. 
Filgotinib does not penetrate into central nervous sy stem ( CNS )tissues.  The distribution of 
filgotinib indicat es some affinity  for melanin- containing tissues.
Excretion is nearly  complete within 24 h (rat) and 48 h (dog) post -dosing.  In the rat, fecal and 
urinary  excretion accounted for 40% and 53% of the administered dose, respectivel y, with a bile 
secretion of about 15%.  In the dog, fecal excretion was the primary  route of excretion, 
accounting for 59% of the administered dose, with urinary  excretion accounting for 25% .
In vitro metabolism studies in all species revealed one major metabolite ( GS-829845). The 
formation of 
GS-829845 is mediated by  [CONTACT_454172] (CES) and is not dependent on 
cytochrome P450 (CYP).
In vitro experiments have shown that drug- drug interactions with filgotinib and GS-829845 are 
unlikely . There is no inhibition or induction of CYPs or uridine 5â€™ disphosphate 
glucuronosy ltransferase s(UGTs), and no relevant inhibition of key drug transporters, including 
the organic anion transporters (OATs) involved in the renal elimination of MTX , by [CONTACT_204959]-829845.
Filgotinib 
Protocol GS -US-417-0303 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 21 05 July [ZIP_CODE].2.2.4. Nonclinical Toxicology
In repeat oral dose toxicity  studies in both rats and dogs, the primary  target tissues identified for 
filgotinib were the l ymphoid tissues, which are expected based on the pharmacology  of JAK 
inhibition. Additional filgotinib-related findings were observed in the male reproductive organs 
of both species, and in the incisor teeth of rats only. Effects on the l ymphoid sy stem were full y 
reversible. Testicular toxicity  demonstrated partial reversibility ,however ,sperm counts remained 
low.A dose of 200 mg/day  of filgotinib results in an esti mated mean clinical AUC of 
2.80 Î¼gâˆ™h/mL , which represents an exposure margin of 2.3, 1.8, and 3.4 -fold when considering 
the mean AUC in male dogs at the no -observed- effec t - levels (NOELs) in the [ADDRESS_580278] an y effects on 
fertility  parameters in either male or female rats.
In an in vitro phototoxicity  study  in 3T3 cells, the metabolite GS-829845 was positive for 
phototoxic potential and results with filgotinib were equivocal. A follow- up in vivo rat 
phototoxicity  assay  revealed a lack of phototoxic potential for both compounds.
1.2.3. Clinical T rials of Filgotinib
Comprehensive data from the Phase 1 and 2 programs are available to support development into 
Phase 3. As of January  2016, filgotinib has been administered to more than 150 healthy  subjects, 
more than 1000 RA subjects, and more than 150 subjects with CD . A detailed description of all 
clinical studies can be found in the Investigatorâ€™s Brochure ( IB)
. 
Phase 2b G LPG [ADDRESS_580279] bo o r one o f threetotal dail y doses o f filgoti nib( 50 mg, 100 mg , or 200 mg)
on a
once or twice dailyschedule for [ADDRESS_580280] b o at 
Week 12.
Filgotinib 
Protocol GS-US-41 7-0303 
[COMPANY_009] Sciences Inc. Final 
Amendment 1 
The percentage of American College ofRheumatology (ACR) 20 responders was statistically 
significantly higher in the 100 mg and 200 mg once daily , and 100 mg twice daily dose groups 
at Week 12 and in the 100 mg and 200 mg once da.ily, and 50 mg and 100 mg twice daily 
dose groups at Week 24. The percentage of ACR50 responders was statistically significantly 
higher compared with placebo across all filgotinib dose groups and regimens at both 
Weeks 12 and 24 (Table 1-1). The percentage of ACR70 responders was statistically 
significantly higher in the filgotinib 200 mg once daily and 100 mg twice daily dose groups 
compared with placebo at Week 12 and across all filgotinib dose groups and regimens at 
Week 24. A dose-response was observed for all three parameters. In addition , the ACR20 
response appeared to plateau at Week 8 in the majority of filgotinib treatment groups and was 
maintained up to Week 24. At Week 24, the ACR50 response was maintained and the ACR70 
response continued to increase compared with Week 12. 
Sta1ting at week 2 response was observed for ACR20 and ACR50 . No statistically significant 
difference was found between the once and twice daily regimens. 
Table 1-1. 
Time 
Par-amete1 Â· Point 
W12 
ACR20 
W24 
Wl2 
ACR50 
W24 
W12 
ACR70 
W24 Summary and analysis of ACRl0/50/70 resp onse at Weeks 12 and 24 
(NRI [ITT Po pulati on]), GLPG0634 -CL-203 
Filgotinib once daily Dose Groups Filgotinib twice daily Dose Groups 
Placebo 50mg 100 mg 200mg 25 mg 50mg 100 mg 
N=86 N=82 N=8 5 =86 =86 N=85 N=84 
n(%) 
38 (44.2) 46 (56.1 ) 54 (63.5)"' 59 (68.6)""" 49 (57.0 ) 51 (60.0) 66 (78.6)"'0 
36(41.9) 45 (54.9 ) 52 (61.2)"' 63 (73.3)"'0 48 (55.8) 51 (60.0)'" 67 (79.8)"'0 
13 (15.1) 27 (32.9)"' 32 (37.6)0 37 (43.o)"'*"' 24 (27.9)"' 29 (34.1/' 46 (54.8)"'"'* 
14 (16.3) 29 (35.4)0 40 (47.1)*"'* 43 (so.o)"'*"' 30 (34.9)0 30 (35.3)"'"' 46 (54.8)0* 
7 (8.1) 13 (15.9) 18 (21.2) 21 (24.4)"' 12 (14.0) 16 (18.8) 26 (31.0)"'"' 
8 (9.3) 18 (22.0/ 28 (32.9)++ 25 (29.1/"' 18 (20.9)"' 20 (23.5)+ 33 (39.3)+++ 
Note 1: p-value s were based on a pairwise comparison s of each group vs. the placebo group using a logistic regression model 
with factors treatmen t group , geographical region , and prior use of biologic s; Honunel -con-ected p-value. Note 2: The 
denominator for the percentage calculations = the total number of subjects per group with a response (yes or no) at that time point 
Note 3: Subjec ts who switched treatment at Week 12 w ere handled as if they discontinued at Week 12. 
* p< 0.05; **p< 0. 01; **"'p <0.001 
ACR=American College of Rhell1ll8tology ; ITI=Intent-to -treat ; NRI=non-re sponder imputation ; W=week 
Source : GLPG0634-CL-20 3 
At Weeks 12 and 24 the mean decrease in DAS28(CRP) was statistically significantly 
greater across all filgotinib dose groups and regimens compared with placebo. A dose -response 
was observed. No statistically significant difference was apparent between the once and 
twice daily regimens . At Weeks 12 and 24, the mean decrease in Simplified Diagnostic 
Activity Index ( SDAI) and Clinical Disease Activity Index (CDAI) score was statistically 
significantly greater across all filgotinib dose groups and regimens compa1Â·ed with placebo 
(with the exception offilgotinib 50 mg once daily dose group at Week 12). In addition , the mean 
SDAI and CDAI scores were maintained after Week 12 in the 50 mg daily dose groups and 
continued to improve up to Week 24 in the 100 mg and 200 mg daily dose groups. 
CONFIDENTIAL Page 22 05 July 2016 I 
I 
Filgotinib 
Protocol GS -US-417-0303 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 23 05 July 2016No unexpected safety  findings were noted. Overall, no differences were observed in the 
incidence of treatment emergent adverse events ( TEAEs ) reported for subjects in an y of the 
dosing groups, including placebo, for the duration of the study . TEAEs were reported for 51.2% 
of â€œAll Placebo Exposedâ€ subjects (ie, all subjects combined who received placebo during either 
the entire [ADDRESS_580281] 12weeks) and 51.5% of â€œAll filgotinib Exposedâ€ 
subjects (ie, all subjects combined who received filgotinib during either the entire [ADDRESS_580282] 12 weeks, irrespective of dose).
A total of 15 subjects had â‰¥1 serious TEAE; 4 subjects in the placebo group (4.7%) and 
11subjects (2.0%) in one of the filgotinib groups. One of these subjects with 
â‰¥[ADDRESS_580283] discontinued the study . A total of 23 subjects had â‰¥1 AE leading to permanent 
discontinuation of the study  medication and the study ; 2 subjects (2.3%) in the placebo group 
and 21 subjects (3.9%) in one of the filgotinib groups (including a subject in the filgotinib 
100mg q .d.group who had a pre -dosing AE which was ongoing throughout the study , for which 
the study  medication was permanentl y discontinued). Most of the serious TEAEs and the AEs 
leading to discontinuation (by
 [CONTACT_11702]) were experienced b y a single subject.
For the duration of the study , the most common ( â‰¥10%) TEAEs reported by  [CONTACT_454173]. There were no differences between subjects who received placebo or 
filgotinib in the severit y of TEAEs (most TEAEs were mild or moderate; severe TEAEs were 
observed in 1.2% of â€œAll Placebo Exposedâ€ subjects and in 2.2% of â€œAll filgotinib Exposedâ€ 
subjects). Treatment-r elated TEAEs were generally  reported more often for subjects in the 
filgotinib dosing groups than in the placebo group (9.3% with placebo and 20.3% with 
filgotinib); however, within the different filgotinib dosing group s, no clear dose relationships 
were o bserved.
Sixserious infections were reported (1 in placebo arm, 5 in filgotinib arm). All 6 serious and one 
additional non- serious infection in the filgotinib group led to dosing discontinuation. Up to 
Week 24, herpes zoster infections were ob served in 5 subjects (1 placebo treated patient and
4filgotinib). No cases of tuberculosis, opportunistic infections, l ymphoma, or cancer were 
reported throughout the 24- week dosing period.
Laboratory  data were consistent with prior Phase [ADDRESS_580284], including 
hemoglobin, neutrophil, ly mphocy te, creatinine, lipid, and hormone data are summarized below. 
Up to Week 12, small increases wer e observed in mean hemoglobin concentrations in the 
filgotinib 200 mg dail y dose groups (increase of 4.4 g/L from baseline in the filgotinib 100 mg 
b.i.d group). Thereafter, hemoglobin mean concentrations appeared to plateau and remained 
stable until Week 24 (increase of 4.9 g/L from baseline in the 
filgotinib 100 mg b.i.d group). 
Filgotinib 
Protocol GS -US-417-[ADDRESS_580285] filgotinib treatment groups (up to 
Week 8 fo r the filgotinib 100 mg b .i.d group) that subsequently  plateaued and remained stable up 
to Week 24. 
Up to Week 4, dose- dependent increases were observed in mean concentrations of total 
cholesterol, LDL cholesterol, high -density  lipoprotein (HDL) cholester ol, and trigl ycerides in all 
filgotinib treatment groups. All these lipid parameters further increased up to Week 8 in the 
filgotinib 200 mg dail y dose groups. Thereafter, these increases appeared to plateau and 
maintained at stable mean concentrations up to Week 24. At Week 24, mean increases were 
observed of 0.7 mmol/L in total cholesterol, 0.3 mmol/L  in LDL cholesterol, 0.3 mmol/L  in HDL 
cholesterol, and 0.1 mmol/L  in trigl ycerides in the filgotinib 100 mg b .i.d group.
In male subjects, small non dose -dependent increases were observed in 
total and free testosterone 
during the stud y (at Week 24, mean increases were 3.4 nmol/L  for total and 51.7 pmol/L  for free 
testosterone in the filgotinib 100mg b .i.d group). For FSH, inhibin B, LH, and prolactin, small 
changes (both increases and decreases) were observed during the study , without any  trends of 
larger changes in male subjects of one or more of the different treatment groups.
G
LPG [ADDRESS_580286] acebo. At W eek24, the ACR 50
r
esponsewasmaintained an d the ACR 70 response show ed c o ntinued improvement. An e arly
onset of response wasobs erved for ACR20 (from W ee k 1 in the f ilgotinib 20 0 mg oncedaily 
dosegroup and Week4 acr ossall other dose g rou ps), ACR50 (from W eek 2 in the filgotinib 
200 mg oncedaily dosegroup an d Week 4 acrossa ll other filgot in ib dose g roups), a nd ACR 70
(Wee
k 4 in the filgotinib 200 mg once daily dose group). Thetime t o ACR20/50/[ADDRESS_580287] acebo.
Filgotinib 
Protocol GS-US-41 7-030 3 Final 
[COMPANY_009] Sciences Inc. Amendment 1 
Table 1-2. Summary and analysis of ACR20/50/70 response at Weeks 12 and 
24 (NRI [ITT Population]); GLPG0634-0204 
Placebo Filgotinib once daily Dose GI'Oups 
50mg 100mg 200mg 
Time N=72 N=72 N=70 N=69 
Paramete1Â· Point 0(%) 
W12 21 (29.2) 48 (66.7)*** 46 (65.7)*** 50 (72.5)*** 
ACR20 
W24 Not applicable 41 (56.9) 55 (78.6) 46 (66.7) 
W12 8 (11.1) 25 (34.7)*** 26 (37.1)*** 30 (43.5)*** 
ACR50 
W24 Not applicable 24 (33.3) 27 (38.6) 31 (44.9) 
W12 2 (2. 8) 6 (8.3) 13 (18.6)** 9 (13.0)* 
ACR70 
W24 Not applicable 14 (19.4) 18 (25.7) 17 (24.6) 
Note 1: p-values were based on a pairwise comparisons of each group vs. the placebo group using a logist ic regression model 
with factors treatment group , geographical region , and prior use of biologic sÂ· Honunel-co11"ected p-value . 
Note 2: The denominator for the percentage calculations= the total number of subjec ts per group with a response (yes or no) at 
that time point 
Note 3: Subjects who switched treatment at Week 12 were handled as if they discontinued at Week 12. 
* p< 0.05 ; ** p< 0.01 Â· **â€¢ p < 0. 001 
ITI=Intent- to-trea t; NRI=non-re sponder imputation ; W=week 
Source: GLPG0634-CL-204 
At Week 12, the mean decrease in DAS28 (CRP) was statistically significantly greater across all 
filgotinib dose groups compmed with placebo. At Week 24, the mean decrease in 
DAS28(CRP ) was maintained in the [ADDRESS_580288] dose groups. In addition, at Week 12 the percentage of subjects 
with DAS28 (CRP) remission was higher across all filgo tinib dose groups compared with 
placebo. Differences vs. placebo were not statistically significant for any of the filgotinib dose 
groups. The numbers of subjects with DAS28(CRP) < 2.6 and< 3.2 were higher acrnss all 
filgotinib dose groups compared with placebo at Week 12; differences vs. placebo were 
statistically significant for the filgotinib [ADDRESS_580289] 12 weeks of treatment and the full 
24 weeks of treatment. TEAEs were rep01ied for 38.9% of "All Placebo Exposed" subjects 
(ie, all subjects combined who received placebo during the first 12 weeks) and 41.3% of "All 
filgotinib Exposed" subjec ts (i.e., all subjects combined who received filgotinib during either the 
entire [ADDRESS_580290] 12 weeks , inespective of dose) . 
No deaths were rep01ied and a total of 9 subjects had a serious TEAE ; [ADDRESS_580291] (1.4%) during 
placebo dosing and 8 subjects (2.9%) during filgotinib dosing. No serious TEAE (by [CONTACT_454174]1m) was experienced by [CONTACT_726] [ADDRESS_580292] discontinued the study. There were no differences 
in incidences of AEs leading to discontinuation among all the different dosing groups , including 
placebo. A total of 11 subjects had :::1 TEAE leading to discontinuation of the study medication ; 
4 subjects (5.6%) during placebo dosing and 7 subjects (2.5%) during filgotinib dosing. 
CONFIDENTIAL Page [ADDRESS_580293] common TEAEs reported b y System Organ Class in subjects 
from both the placebo and filgotinib treatment groups, were â€˜Infections and I nfestationsâ€™ and 
â€˜Gastrointestinal disordersâ€™. There were no differences between subjects who re ceived placebo or 
filgotinib in the severit y of TEAEs (most TEAEs were mild or moderate; severe TEAEs were 
observed in 1.4% of â€œAll Placebo Exposedâ€ subjects and in 1.1% of â€œAll filgotinib Exposedâ€ 
subjects). Treatment- related TEAEs were generally  reported more often for subjects in the 
filgotinib treatment groups than in the placebo group (9.7% with placebo and 16.7% with 
filgotinib); however, within the different filgotinib treatment group, no clear dose relationships 
were observed.
Low numbers of infecti ons were reported as serious (4 subjects with filgotinib ) or led to 
discontinuation of the study  medication (2 serious infections; ie, cellulitis and pneumonia). Up to 
Week 24, [ADDRESS_580294] ( filgotinib 50mg q .d. group) had a herpes zoster infection. No cases of 
tuberculosis, opportunistic infections, l ymphoma, or cancer were reported throughout the 
24-week dosing period.
Laboratory  data were consistent with prior studies and no new safet y findings were observed .
Please refer to the IB for additional data regarding efficacy  and safet y .
1.3. Rationale for This Study
Over the last decade, changes in RA treatment strategies, accompanied b y advances in drug 
development and the addition of targeted biological therapi[INVESTIGATOR_014], have greatl y improved the 
outcomes for subjects with RA. Despi[INVESTIGATOR_204932], therapeutic challenges remain. The 
current conventional and biologic DMARDs may be ineffective or produce only  partial 
responses in some subjects and may  beassociated with significant safet y and tolerability 
concerns. There is a medical need for simple, orally  administered therapi[INVESTIGATOR_204933] y improve the disease course while being safe 
and well -tolerate d. MTX- naÃ¯ve patients with RA have several medications to choose from, 
however, it is clear that as patients progress through the available therapi[INVESTIGATOR_014], they  may  be left with 
active disease and a need for additional options. Development of another drug for these patients 
is appropriate, since participation in this study  will not preclude the use of approved RA 
therapi[INVESTIGATOR_454154]. Moreover, all subjects in this study wil l receive active 
drug: MTX, fil gotinib, or a combination of the two , as well as frequent monitoring of their health 
and RA status. Any  subjects considered to be non -responders at Week [ADDRESS_580295] of 
care medications.
Filgotinib is an orall y administered, small molecule inhibitor of JAK1 ,an intracellular t yrosine 
kinase that is dy sregulated in subjects with inflammatory  disorders ,including RA. Filgotinib has 
demonstrated clinical activity  and a favorable safety  and tolerability  profile in Phase 2 studies in 
subjects with moderatel y to severel y active RA.
Filgotinib 
Protocol GS -US-417-0303 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 27 05 July [ZIP_CODE].3.1. Rationale for Study Design
The current study  (GS-US-417-0303) is a P hase [ADDRESS_580296] son phy sical function and radiographic progression, and to assess work 
productivity , fatigue, andquality  of life .In addition, the saf ety, tolerability andpharmacokinetics 
(PK) of filgotinib will be assessed.
The active comparator in this study  is oral MTX. Methotrexate is the most commonly  
prescribed first line cs DMARD in the treatment of moderatel y to severel y active RA and has 
been shown to reduce the signs and s ymptoms of disease as well as to inhibit radiographic 
progression {Lopez -Olivo et al 2014}. The inclusion of MTX will allow comparison of the 
efficacy  and safet y of filgotinib to an approved and frequentl y prescribed product indicated for 
use in treatment -naÃ¯ve patients {Lopez-Olivo et al 2014}. In this study , MTX will be titrated up
tothe maximal tolerated dose over a period of 8 weeks. Non-responders 
at Week 24 (as defined 
in Section 3.2)will discontinue investigational therapy  but will continue with study  visits and 
assessments per protocol.
All subjects who discontinue from investigational therap y will receive 
standard of care treatment for their RA as determined by  [CONTACT_093]. 
Given that all subjects will receiv e at least one active drug in this study , determining non -
responder status at 
[ADDRESS_580297] over an 8 week period . The study eligibility criteria are consistent with those of recent 
clinical trials evaluating novel investigational treatments for RA. Subjects should meet the 
2010 ACR/ European League Against Rheumatism (EULAR) criteria for RA,andare required to 
have active disease ,defined as â‰¥6swollen and 
â‰¥6tender joints at both Screening and Day  1, as 
well as one of the following: the presence of at least 1joint erosion on radiographs of the hands, 
wrists, 
orfeet,or apositive test for ant i-citrullinated peptide antibod y (anti-CCP Ab)or 
rheumatoid factor (RF) , or an elevated CRP level .The study  duration of up to 52 weeks allows 
sufficient time to evaluate safet y, reduction in disease activity , and confirmation that clinical 
benefit is sustained over time.
1.3.2. Rationale for the Outcome Measures
Safety  and tolerability  will be assessed by  [CONTACT_204964] (AEs), selected 
clinical laboratory  parameters, vital signs, phy sical examinations, and 
electro cardiograms 
(ECGs) , all of which are standard safet y evaluations in clinical trials of RA.
The ACR20, ACR50, and ACR70 responses and the DAS28 (CRP) are considered reliable 
measures of response to treatment and disease activity , respectivel y,in subjects with RA. 
Comparison between the treatment arms of the proportions of subjects achieving an ACR20 
response at Week 12 and the proportions of subjects achieving low disease activity  in 
DAS28 (CRP) allows for interpretation of a clinic ally meaningful response and these measures 
have been shown to achieve high discriminatory  capacit y.
Filgotinib 
Protocol GS -US-417-0303 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 28 05 July 2016Evaluation of continuous outcome measures of DAS28 (CRP) and American College of 
Rheumatology  N (ACR -N)as secondary  endpoints enables the demonstration of improvement 
and magnitude of benefit. The EULAR /ACR remission response criteria classify  subjects as non, 
moderate -, or good responders depending on the extent of change and the level of disease 
activity  reached. These response criteria are useful when de scribing clinically  meaningful 
therapeutic results. The CDAI  and the SDAI have been widely  used in clinical studies to 
demonstrate the impact of a study  drug on controlling disease activit yin patients with RA .
Assessing qualit y of life (measured b y the Fu nctional Assessment of Chronic I llness 
Therap y-Fatigue [FACIT -Fatigue ], 36-item short form health survey  [SF-36], and Euro Qol 
5-Dimension [EQ -5D]) at Day [ADDRESS_580298] on dail y living . Treatment satification 
will be assessed b y using the Treatment Satisfaction Questionnaire for Medication (TSQM) at 
Day [ADDRESS_580299] 
(Work Productivity  and Activity  Impairment [WPAI ] and Healthcare Resource Utilization) of 
RA over the course of the study  provides insight into the subjectâ€™s ability  to work and other daily  
activities as well as the impact on the burden of healthcare resources.
Radiographs have been widely  used in assessing structural joint damage associated with RA and 
are therefore essential in evaluating the efficacy  of a study  drug. Reduction in radiographic 
evidence of structural damage progression is an important predictor of long -term benefits in 
delay ing or preventing the progression to disability  related to RA. While X -ray remains the 
widely  accepted method for assessing progression of structural joint damage, evaluation by  [CONTACT_454175] .
1.3.3. Rationale for the Choice of Dose and Dosing Interval
Enrolled su
bjects will be randomized to receive filgotinib or active comparator MTX , or a 
combination thereof . The [ADDRESS_580300] been selected 
for Phase 3 evaluation based on non-clinical data and information concerning efficacy , 
tolerability , and safet y data derived from the Phase 1 and Phase 2 studies , and are supported by  
[CONTACT_105]-clinical safety  studies .
In seven Phase 1 studies conducted in healthy  subjects ( GPLG0634
-CL-101, -102, âˆ’103, - 104, 
-
105, -107, and - 110), fil gotinib administered at doses up to 450 mgq.d. for up to 10 days was 
safe and well tolerated.
In the 2 Phase 2a studies in subjects with RA (Study GLPG0634- CL-201 and -202), dosing with 
filgotinib was well tolerated and achieved a high level of efficacy  at a 200 mg dail y dose 
(ACR20 response of 75 -92% at Week 4). Administration of a higher filgotinib dose (300 mg) did 
not demonstrate greater efficacy , therefore, the highest dose to be tested in this study  will be 
200mg q.d . 
CCI
Filgotinib 
Protocol GS -US-417-0303 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 29 05 July 2016In two Phase 2b studies, filgo tinib at doses of 50 mg, 100 mg, or 200 mg daily , administered in 
addition to a background therap y with  MTX (GL PG0634 -CL-203) or as monotherap y 
(GLPG0634 -CL-204) was shown to be safe and efficacious in subjects with moderatel y to 
severel y active RA who had an inadequate response to MTX alone (Section 1.2.3 ). 
Exposure -response anal ysis based on data from all Phase 2 studies indicated a dose -dependent 
increase in efficacy  (ACR20/50/70, DAS28[ CRP ]), with a plateau at/above the 200 mg total 
daily  dose on the dose-response curve. Addition
ally, in Study  GLPG0634- CL-203, no 
statistically  significant difference in efficacy  was observed at 200 mg dail y dose, administered as 
200 mg q.d. or 100 mg b.i.d. These results are consistent with the relationship observed bet ween 
filgotinib exposures and pSTAT1 activation (ex -
vivo) following single and multiple filgotinib 
doses, where maximal inhibition of pSTAT1 (~78%) was achieved at or above 200 mg total 
daily  dose and intermediate inhibition (~ 47%) at 100 mg {Namour et al 2015 }. 
Overall, 
the [ADDRESS_580301] favorable risk:benefit 
profile in these populations.
Safety  data collected across Phase [ADDRESS_580302] gastrointestinal AEs (eg, nausea, vomiting, abdominal pain, and 
upper abdominal pain). This numerical increase was observed in the [ADDRESS_580303] favorable risk:benefit 
profile in these populations.
1.4. Risk/Benefit Assessment for the St udy
As of January  2016, Filgotinib has been administered to more than 150 healthy  subjects as single 
doses ranging from 1 to 200 mg, and as multiple doses at 25 to 100 mg twice dail y, and 200, 300, 
and 450 mg daily  for 10 day s. In addition, filgotinib has been administered to more than 1000
RA subjects and more than 150 subjects with Crohnâ€™s Disease at daily  doses ranging from 
50-[ADDRESS_580304] sensitive species. A dose of 200 mg/day of filgotinib results in an estimated mean 
clinical AUC of 2.80 Î¼g âˆ™h/mL , which represents an exposure margin of 2.3, 1.8, and 3.4- fold 
when considering the mean AUC in male dogs at the no -observed- effect -levels (NOELs) inthe 
26week and39 week chronic toxicity  studies , and the 39 week t argeted exposure toxicity  study , 
respectivel y.Decreased ly mphocy tes observed in nonclinical studies ha ve not been shown in 
clinical studies.
Filgotinib has shown an increased risk of embry ofetal malformations at exposures similar to 
human doses; the use of highl y effective contraception in the subject population will be 
implemented in the study to mitigate this risk.
No clinically  relevant impact on cardiovascular parameters (including vital signs and E CG), 
respi[INVESTIGATOR_204934] 1 and 2 trials of filgotinib.  Across 
the phase 2 trials in RA, filgotinib was well -tolera ted. I n the RA studies (including the open label 
extension Darwin 3), infections were reported more commonly  in the filgotinib groups, including 
serious infections leading to hospi[INVESTIGATOR_059], and even death. The most common sy stem organ 
classes (SOC) with 
AEs were infections and infestations, and gastrointestional disorders. Dose 
dependent decreases in the phase 2b studies were observed in mean neutrophil counts and 
platelet counts (but mean changes in both remained within normal laboratory  reference ranges ), 
and there were no decreases in ly mphocy tes or l ymphocyte subsets. Hemoglobin levels slightl y 
improved (increased) with filgotinib treatment, confirming that no anemia was induced. Mild and 
clinically  insignificant serum creatinine increases were noted in both Phase 2b studies, with 
stabilization by  [CONTACT_10585] 24.  N eutrophil decreases (in the RA population) and a potential increased 
risk of infection may be considered risks consistent with the mechanism of JAK inhibition.  
Overall clinical findings and labora tory changes are consistent with 
selective JAK inhibition and 
based on Phase 2 data the expected benefit of using filgotinib as proposed in this study  is 
considered to outweigh any  associated risks.
An independent data monitoring committee ( DMC )appointed to monitor the study (with an 
interim safet y anal ysis after approximately 100 subjects complete Week 12)will provide an 
additional level of risk mitigation.
The overall risk:benefit balance of this study  is considered favorable. For additional information
about the risks of filgotinib, reference is made to the IB.
1.5. Compliance
This study  is to be conducted in compliance with this protocol, Good Clinical Practice (GCP), 
and all applicable regulatory  requirements.
Filgotinib 
Protocol GS -US-417-0303 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 31 05 July [ZIP_CODE]. OBJECTIVES
The primary  objective of this study is as follows:
ï‚·To evaluate the effects of filgotinib in combination with MTX versus MTX alone for the 
treatment of signs and s ymptoms of RA as measured by [CONTACT_454176]20 at Week 24
The secondary  objectives of this study  are as follows: 
ï‚·To evaluate the effect of filgotinib in combination with MTX versus MTX alone on ph ysical 
function as measured b y change from Baseline in the Health Assessment Questionnaire 
Disability  Index (HAQ -DI) score at Week 24 
ï‚·To evaluate the effects of filgotinib in combination with MTX versus MTX alone for the 
treatment of signs and s ymptoms of RA as measured by [CONTACT_454177] 28 joint count using CRP (DAS28 [CRP] )<2.6 at Week 24 
ï‚·To evaluate the effects o f filgotinib alone versus MTX alone for the treatment of signs and 
symptoms of RA as measured by  [CONTACT_454178]20 at Week 24
ï‚·To evaluate the effect of filgotinib alone versus MTX alone on ph ysical function as measured 
by [CONTACT_454179] -DI score at Week 24 
ï‚·To evaluate the effects of filgotinib alone versus MTX alone for the treatment of signs and 
symptoms of RA as measured by  [CONTACT_454180]28 (CRP)<2.6 at 
Week 24 
ï‚·To evaluate the effects of fi lgotinib in combination with MTX versus MTX alone on 
preservation of joint structure as measured b y change from Baseline in the mTSS at 
Week 24and 52
ï‚·To evaluate the effects of filgotinib alone versus MTX alone on preservation of joint 
structure as measur ed by [CONTACT_454181] 24 and 52
ï‚·To evaluate the safet y and tolerability  of filgotinib alone and in combination with MTX 
ï‚·To evaluate the effects of filgotinib alone and in combination with MTX on work 
productivity , fatigue, and general quality  of life as measured b y SF-36, FACIT -Fatigue , 
EQ-5D and WPAI -RA
Filgotinib 
Protocol GS -US-417-0303 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 32 05 July 2016The exploratory  objectives of this study  are as follows:
 
 
CCII 
I 
I 
)LOJRWLQLE
3URWRFRO*686 )LQDO
*LOHDG6FLHQFHV,QF $PHQGPHQW
&21),'(17,$/ 3DJH  -XO\ 678'<'(6,*1
 (QGSRLQWV
7KHSULPDU\HQGSRLQWLVWKHSURSRUWLRQRIVXEMHFWVZKRDFKLHYH DQ$&5UHVSRQVHDW:HHN
7KHNH\VHFRQGDU\HQGSRLQWVDUH
â€¢&KDQJHIURP%DVHOLQHLQWKH+$4',VFRUHDW:HHN
â€¢7KHSURSRUWLRQRIVXEMHFWVZKRDFKLHYH'$6 â€¯&53DW:HHN
â€¢&KDQJHIURP%DVHOLQHLQP766DW:HHN
2WKHUVHFRQGDU\HQGSRLQWVLQFOXGH
â€¢&KDQJH IURP%DVHOLQHLQWKHP766DW:HHN â€¯52
â€¢7KHSURSRUWLRQRIVXEMHFWVZKRDFKLHYH$&5DQG$&5DW:HHNV â€¯4, 12, 24 and 52, 
$&5DW:HHNV â€¯4, 12, and 52, and ACR20/50/70 over time from Day 1 through Week â€¯52
â€¢&KDQJHIURP%DVHOLQHLQLQGLYLGXDOFRPSRQHQWVRIWKH$&5UHVSRQ VHDW:HHNV â€¯4, 12, 2
DQGDQGRYHUWLPHIURP'D\WKURXJK:HHN â€¯52
â€¢7KHSURSRUWLRQRIVXEMHFWVZKRDFKLHYHLPSURYHPHQWLQ+$4',RI Â•DW:HHNV â€¯4, 12, 
DQGDQGRYHUWLPHIURP'D\WKURXJK:HHN â€¯52
â€¢&KDQJHIURP%DVHOLQHLQ'$6 â€¯(CRP) at Weeks â€¯4, 12, 24, and 52, DQGRYHUWLPHIURP
'D\WKURXJK:HHN â€¯52
â€¢7KHSURSRUWLRQRIVXEMHFWVZKRDFKLHYH'$6 â€¯&53Â”DW:HHNV â€¯4, 12, 24, and 52, and 
RYHUWLPHIURP'D\WKURXJK:HHN â€¯52
â€¢7KHSURSRUWLRQRIVXEMHFWVZKRDFKLHYH'$6 â€¯&53DW:HHNV â€¯4, 12, and 52, and over 
WLPHIURP'D\WKURXJK:HHN â€¯52
â€¢$&51DQG(8/$5 UHVSRQVHDW:HHNV â€¯4, 12, 24, and 52, and over time from Day WKURXJK
:HHN
â€¢&KDQJHIURP%DVHOLQHLQ&'$,DW:HHNV â€¯4, 12,DQGDQGRYHUWLPHIURP 'D\
WKURXJK:HHN
â€¢&KDQJHIURP%DVHOLQHLQ6'$,DW:HHNV â€¯4,DQGDQGRYHUWLPHIURP'D\
WKURXJK:HHN
)LOJRWLQLE
3URWRFRO*686 )LQDO
*LOHDG6FLHQFHV,QF $PHQGPHQW
&21),'(17,$/ 3DJH  -XO\â€¢7KHSURSRUWLRQRIVXEMHFWVZKRKDG QR UDGLRJUDSKLFSURJUHVVLRQIUR P%DVHOLQHDW
:HHNâ€¯24DQG
â€¢$EVROXWHYDOXHDQGFKDQJHIURP%DVHOLQHLQ6) )$&,7)DWLJXH D QGWKH(4'RYHU
WLPHDW:HHNV â€¯4, 12, 24 and 52, DQGRYHUWLPHIURP'D\WKURXJK:HHN â€¯52
â€¢$EVROXWHYDOXHDQGFKDQJHIURP%DVHOLQHLQ:3$,5$ DW:HHNV â€¯4, 12,DQGDQG
RYHUWLPHIURP'D\WKURXJK:HHN â€¯52
 6WXG\'HVLJQ
7KLVLVDUDQGRPL]HGGRXEOHEOLQGSODFHER DQG DFWLYHFRQWUROOH G3KDVH VWXG\LQDGXOWPDOH
DQGIHPDOHVXEMHFWVZLWKPRGHUDWHO\WRVHYHUHO\DFWLYH5$ZKRK DYHOLPLWHGRUQRSULRU
H[SRVXUHWR07;WKHUDS\7KHVWXG\LVGHVLJQHGWRHYDOXDWHWKH HIILFDF\VDIHW\DQGWROHUDELOLW\
RIILOJRWLQLEDVZHOODVLWVHIIHFWRQSDWLHQWUHSRUWHGRXWFRPH VLQFOXGLQJZRUNSURGXFWLYLW\
IDWLJXH DQG TXDOLW\RIOLIH,QDGGLWLRQ3.ZLOOEHDVVHVVHG
$GXOWPDOHDQGIHPDOHVXEMHFWVZLWKDFWLYH5$ZLOOEHVFUHHQHG WRGHWHUPLQHHOLJLELOLW\DVSHU
WKHLQFOXVLRQDQGH[FOXVLRQFULWHULDVHH6HFWLRQ DQGUHVSHFWLYHO\7KH6FUHHQLQJSHULRG
ZLOOEHXSWRGD\V7KHVFUHHQLQJZLQGRZPD\EHH[WHQGHGWRX SWRGD\VSULRUWRWKH'D\
YLVLWIRUVXEMHFWVZKRUHTXLUHUHSHDWFROOHFWLRQRIUDGLRJUDSKV 
:ULWWHQLQIRUPHGFRQVHQWPXVWEHREWDLQHGEHIRUHDQ\ VWXG\UHOD WHGSURFHGXUHVWDNHSODFH
'XULQJWKH6FUHHQLQJSHULRGIROORZLQJVLJQLQJRIWKHLQIRUPHG FRQVHQWIRUP,&)WKHVXEMHFWÂ¶V
UDGLRJUDSKVKDQGVZULVWVDQGIHHWZLOOEHVHQWWRFHQWUDOU HYLHZIRUFRQILUPDWLRQRIMRLQW
HURVLRQVHHLQFOXVLRQFULWHULRQ 6HFWLRQ 1RWHWKDWWKHVXEMHFWÂ¶VUDGLRJUDSKVQHHGWREH
VHQWWRFHQWUDOUHYLHZDVVRRQDVSRVVLEOHDIWHUFRPSOHWLRQDQG SULRUWR'D\WRDOORZIRUFHQWUDO
UHDGLQJDQGFRQILUPDWLRQRIRQHRUPRUHMRLQWHURVLRQ LQVXEMHFWV WKDWDUHVHURQHJDWLYH
6XEMHFWV ZLOOEHUDQGRPL]HGLQD UDWLRWRILOJRWLQLEP JSOXV 07;ILOJRWLQLEPJ
SOXV 07;ILOJRWLQLEPJDORQHRU07;DORQHIRUXSWRZHH NVLQDGRXEOHEOLQGIDVKLRQ
$W:HHNVXEMHFWVZKRKDYHQRWDFKLHYHGDLPSURYHPHQWIU RP'D\LQERWK6-&DQG
7-&ZLOOGLVFRQWLQXHLQYHVWLJDWLRQDOWKHUDS\EXWZLOOFRQWLQXH ZLWKVWXG\YLVLWVDQGDVVHVVPHQWV
SHUSURWRFRO$OOVXEMHFWVZKRGLVFRQWLQXHIURPLQYHVWLJDWLRQDO WKHUDS\DUHWRUHFHLYHVWDQGDUGRI
FDUHWUHDWPHQWIRUWKHLU5$DVGHWHUPLQHGE\WKHLQYHVWLJDWRU
5HVSRQGHUVDW:HHNZLOOFRQWLQXHRQWKHWUHDWPHQWUHJLPHQVW RZKLFKWKH\ZHUHUDQGRPL]HG
WKURXJK:HHN
$OOVXEMHFWVZLOOEHHYDOXDWHGIRUORVVRIWKHUDSHXWLFUHVSRQVH IURP:HHN WKURXJKWKH
:HHNVWXG\YLVLW6XEMHFWVIDLOLQJWRPDLQWDLQDWOHDVWD LPSURYHPHQWIURP'D\LQ7-&
DQG6-& DV FRQILUPHGDWFRQVHFXWLYHYLVLWVZLOOGLVFRQWLQXHLQY HVWLJDWLRQDOWKHUDS\EXWZLOO
FRQWLQXHZLWKVWXG\YLVLWVDQGDVVHVVPHQWV $OOVXEMHFWVZKRGLV FRQWLQXHIURPLQYHVWLJDWLRQDO
WKHUDS\DUHWRUHFHLYHVWDQGDUGRIFDUHWUHDWPHQWIRUWKHLU5$DV GHWHUPLQHGE\WKHLQYHVWLJDWRU
Filgotinib 
Protocol GS -US-417-[ADDRESS_580305] dose of study  drug 
(post treatment Week 4) regardless of 
dosing duration.
At completion of the 52 -week treatment period, subjects (who did not discontinue assigned stud y 
drug or have not met criteria for loss of therapeutic response) will be provided the option to enter 
a Long Term Extension ( LTE)study  (GS-US-
417-0304).
For those subjects not entering the LTE, a follow -
up visit will be planned at Post Treatment 
Week 4.
To enhance the safet y monitoring during the study , a D MCconsisting of independent experts 
will be convened to periodically  review the accumulating safet y data for the study. In addition, a 
cardiovascular safet y endpoint adjudication committee (CV -SEAC) will be convened to 
periodicall y review and adjudicate all possible major cardiovascular events (MACE).
The assessments planned to be performed at each visit are detailed in the study  procedures table 
(Appendix 2). A schedule of the stud y design is provided below.
Figure 3
-1. Study D esign
3.3. Study Treatments
Approximately  1200 subjects with active RA will be randomized in a 2:1:1 :2ratio to filgotinib
200 mg plus MTX , filgotinib 100 mg plus MTX, filgotinib 200 mg alone, or MTX alone ,for up 
to 52weeks: 
ï‚·Filgotinib 200 mg + MTX group : Filgotinib (200 mg q.d.) +PTM filgotinib 100 mg 
(PTM q.d.) + MTX (once weekl y up to 20 mg) (N= 400)
DAY 1 WK24 
Primary Endpo i nt WK 52 
SCREENING ~ RANDOM IZATION 
28 days prior 2 :1 :1 :2 
to Day 1 
(may be exten ded 
to 42 days if 
repea t 
radiographs are 
required) 
WK 24: ;, Standard of care for all subjects with 
Subjects with protocol-defined inadequate response 
inadequate 
response will 
discont inue 
study drugs 
Filgotinib 
Protocol GS -US-417-0303 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 36 05 July 2016ï‚·Filgotinib 100 mg + MTX group : Filgotinib (100 mg q.d.) + PTM filgotinib 200 mg 
(PTM q.d.) + MTX (once weekl y up to 20 mg) (N=200)
ï‚·Filgotinib 200 mg monotherap ygroup : Filgotinib (200 mg q.d.) + PTM filgotinib 100 mg 
(PTM q.d.) + PTM MTX ( PTM once weekl y) (N=200 )
ï‚·MTX monotherap ygroup : PTM filgotinib 100 mg (PTM q.d.) + PTM filgotinib 200 mg 
(PTM q.d.) + MTX (once weekl y up to 20 mg) (N= 400)
NOTE: on study  visit day s, subjects should wait to take their 
regularl y scheduled dose of stud y 
drug until instructed b y site personnel, in case there are pre -dose blood draws or other pre -dose 
procedures required on that day .
3.4. Duration of Treatment
Subjects are planned to participate in the stud y for approximately 60weeks (from the Screening 
visit to Follow -up visit or entry into the LTE ); the duration of dosing is up to 52 weeks.
3.5. Criteria for Interruption or Discontinuation of Study Treatment
3.5.1.
Study drug interruption considerations:
The [COMPANY_009] Medical Monitor should be consulted prior to study  drug interruption when 
medically  feasible. 
Study  drug interruption should be considered in the following circumstances; prior to resumption 
of study drug, the investigator should discuss the case with the [COMPANY_009] medical monitor :
ï‚·Intercurrent illness that would, in the judgment of the investigator, affect assessments of 
clinical status to a significant degree.   
ï‚·Subject is scheduled for elective or emergency  surgery  (excluding minor skin procedures 
under local or no anesthesia); timing of study  drug pausing should be determined in 
consultation with the [COMPANY_009] medical monitor.    
ï‚·Any subject who develops a new infe ction during the study should undergo prompt and 
complete diagnostic testing appropriate for an immuncompromised individual , and the 
subject should be closel y monitored.
NOTE: During the time of study drug interruption for any of the above, the subject may
continue to have study visits and to take part in procedures and assessments, if deemed 
medically appropriate by [CONTACT_093].
Filgotinib 
Protocol GS -US-417-0303 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 37 05 July [ZIP_CODE].5.2. Study drug discontinuation considerations:
The [COMPANY_009] Medical Monitor should be consulted prior to study  drug discontinuation when 
medically  feasible. 
Study  medication should be permanently  discontinued in the following instances:
ï‚·Any opportunistic infection
ï‚·Any serious infection that requires antimicrobial therap y or hospi[INVESTIGATOR_059], or an y infection 
that meets SAE reporting criteria. 
ï‚·Complicated herpes zoster infection (with multi
-dermatomal, disseminated, ophthalmic, or 
CNS involvement)
ï‚·Evidence of active HCV during the study , as evidenced b y HCV RNA positivity
ï‚·Evidence of active HBV during the stud y, as evidenced b y HBV DNA positivity
ï‚·Unacceptable toxicity , ortoxicity  that, in the judgment of the investigator, compromises the 
subjectâ€™s ability  to continue study -specific procedures or is considered to not be in the 
subject â€™s best interest
ï‚·Non-responder at Week 14 OR at 2 consecutive visits after Week 30 as outlined in 
Section 3.2
ï‚·Subject request to discontinue for an y reason
ï‚·Subject noncompliance
ï‚·Pregnancy  during the study  (Section [IP_ADDRESS] and Appendix 5)
ï‚·Discontinuation of the study  at the request of [COMPANY_009], a regulatory  agency  or an institutional 
review board or independent ethics committee (IRB/IEC)
ï‚·Subject use of prohibited concurrent therap y may trigger study  drug discontinuation; 
consultation should be made with the [COMPANY_009] medical monitor.
ï‚·Laboratory  criteria:
After becoming aware of any  of the below described abnormal laboratory  changes occurring at 
any one time, an unscheduled visit (ie sequential visit) should occur to retest within 3 to 
7days
(except creatinine, which should be retested 7 -14 day s apart) . 
ï‚¾2sequential neutrophil counts < 750neutrophils/mm3(SI: <0.75x109cells/L )after dose 
adjustment of MTX/PTM (Section 5.3.4)
Filgotinib 
Protocol GS -US-417-0303 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 38 05 July 2016ï‚¾2sequential platelet counts < 75,000 platelets/mm3(SI:<75.0x109cells/L )after dose 
adjustment of MTX/PTM (Section 5.3.4)
ï‚¾2sequential AST or ALT elevations >3xUL N andâ‰¥1 total bilirubin value >2xULN
oraccompanied b y symptoms consistent with hepatic injury1after dose adjustment of 
MTX/PTM (Section 5.3.4)
ï‚¾2sequential AST or ALT elevations >5xUL Nafter dose adjustment of MTX/PTM
(Section 5.3.4)
ï‚¾2sequential values for estimated creatinine clearance <35 mL/min based on the Cockroft 
Gault formula
Subjects who permanently discontinue study medication foranyreason aretoreceive standard of
care treatment fortheir RAasdetermined by[CONTACT_36705] ,andthose subjects should be
encouraged tocontinue study visits andprocedures, ifdeemed medica llyappropriate by[CONTACT_31035] . Subjects who permanentl ydiscontinue study medication forpregnancy should not
continue inthestudy ;ifthere areanyquestions regarding permanent discontinuation, these
should bediscussed with theSponsor.
Subjects withdrawing from thestudy should complete ETandPost Treatment Week 4visits.
Subjects arefreetowithdraw from thestudy atanytime without providing reason(s) for
withdrawal andwithout prejudice tofurther treatment. Thereason(s) forwithd rawal willbe
documented intheelectronic case report form (eCRF).
Reasonable efforts will be made to contact [CONTACT_63381] -up. These must be 
documented in the subjectâ€™s file. 
The sponsor has the right to terminate the study  at any  time in case of safet y concerns or if 
special circumstances concerning the stud y medication or the compan y itself occur, making 
further treatment of subjects impossible. I n this event, the investigator(s) and relevant authorities 
will be informed of the reason for stud y termination.
3.6. End of Study
End of Study  is defined as when the last subject has completed [ADDRESS_580306] treatment visit or has entered the LTE. 
                                                  
1In each case, there is a need for additional investigations, such as revie w of ethanol, recreational drug and 
dietary supplement consum ption; testing for acute hepatitis A, B or C infection and biliary tract imaging should 
be pro mptly discussed with the study Medical M onitor
Filgotinib 
Protocol GS -US-417-[ADDRESS_580307] Study Care
All subjects who meet criteria for clinical response (per p rotocol), and who complete 52 weeks 
of study  assessments will be offered an opportunity  to partici pate in a LTE study  
(GS-US-417- 0304). Subjects who discontinue early  from the main study , or switch to standard of 
care treatment during the study , are not el igible for the LTE. The long term care of subjects who 
do not qualify  for the LTE or choose not to participate in the LTE will remain the responsibility  
of their primary  treating phy sician. 
3.8. Biomarker Samples
3.8.1. Biomarker Samples to Address the Study Objectives
:
The following biological specimens will be collected in this study  which may  be used to evaluate 
the association of exploratory s ystemic and/or tissue specific biomarkers with study  drug 
response, including efficacy  and/or adverse events, and help info rm the mechanism of action and 
mechanism of intrinsic and acquired resistance to f ilgotinib in RA . The specific samples to be 
collected 
from all subjects (unless otherwise stated) include the following:
ï‚·Plasma ,serum , and urine samples for potential analy sis of circulating factors including but 
not limited to cy tokines, metabol ome, biomarkers of joint damage, and miRNA
ï‚·Paxgene blood samples for potential gene expression analy ses
 
ï‚·Whole blood sample for potential B
-/T-cell receptor sequencing
ï‚·Viably  frozen PBMCs (vfPBMCs) and Leukocy te subsets to profile immune cell subset s and 
inflammatory  signaling pathway s
The biomarker sample collection schedule is described in Study  Procedures Table (Appendix 2). 
Since biomarker science is a rapi[INVESTIGATOR_204935], it is not possible to specify  
prospectivel y all tests that may be performe d on the specimens collected
.  The testing outlined 
above is based upon the current state of scientific knowledge. It may  be modified during or after 
the end of the stud y to remove tests no longer indicated and/or to add new parameters based 
upon the growi ng state of art knowledge. Any  future testing of new tests not described above 
must be approved b y local authorities as applicable according to specific local regulations.
The biomarker samples will be destroy ed no later than [ADDRESS_580308] meet all of the following inclusion criteria to be eligible for participation in this 
study .
1)Male or female subjects who are â‰¥18 y ears of age, on the day  of signing informed consent. 
2)Have a diagnosis of RA (2010 ACR/ EUL AR criteria ) (Appendix 8), and are ACR functional 
class I -III
3)Have â‰¥6swollen joints (from a SJC66) and â‰¥6tender joints (from a TJC68 ) at both 
Screening and Day 1(need not be the same joints) (Appendix 7)
4)Must meet at least one of the following parameters at Screening:
ï‚·â‰¥1 documented joint erosion on radiographs of the hands, wrists or feet by  [CONTACT_454182]
ï‚·positivity  for either  RF or anti
-CCP Ab(based on central laboratory )
OR
ï‚·Serum CRP â‰¥ 4 mg/L (based on central laboratory )
5)Have l imited or no prior treatment with MTX, ie, no more than 3 doses of MTX â‰¤[ADDRESS_580309]â€™s lifetime for the treatment of RA, with thelast dose 
at least 28 day sprior to 
Day 1, and are an appropriate candidate for MTX therapy , as per investigator judgment 
6)Females of childbea ring potential (as defined in Appendix 5)must hav e a negative pregnancy 
test at S creening and Day 1
7)Male subjects and female subjects of childbearing potential who engage in heterosexual 
intercourse must agree to use protocol specified method(s) of contra ception as described in 
Appendix 5
8)Lactating female subject s must agree to discontinue nursing from Screening through the end 
of their study  participation . 
Filgotinib 
Protocol GS -US-417-0303 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 43 05 July [ZIP_CODE])Meet one of the following tuberculosis (TB) Screening criteria:
a)No evidence of active or latent TB:
ï‚·A negative QuantiFERONÂ®TB-Gold In -Tube test at Screening and 
ï‚·A chest radiograph (view s as per local guidelines)  taken at Screening or within the 
3months prior to Screening (with the report or films available for investigator 
review) without evidence of active or latent TB infection and
ï‚·No history  of either untreated or inadequatel y treated latent or active TB infection
b)Previously  treated for TB :ie,if a subject has previously  received an adequate course of 
therap y as per local standard of care for either latent TB (9months of isoniazid in a 
location where rates of primary  multi- drug resistant TB infections are <5% or an 
acceptable alternative regimen) or active TB (acceptable multi -drug regimen). In these 
cases , noQuantiFERONÂ® TB -Gold In -Tube test (or equivalent assay )need be obtained, 
but a chest radiograph must be obtained if not done so within 3 months prior to Screening
(with the report or films available for investigator review) . It is the responsibility  of the 
investigator to verif y the adequacy  of previous anti -tuberculosis treatment and provide 
appropriate documentation.
c)Newl y identified latent TBduring Screening: ie, a subject who has a newl y identified 
positive diagnostic TB test result (defined as a pos itive QuantiFERONÂ® TB Gold in Tube
test [ or equivalent assay ]) in which active TB has been ruled out and for which 
appropriate , ongoing, prophy lactic treatment for latent tuberculosis has been initiated 
prior to the first administration of study  medication . Adequate treatment for latent TB is 
defined according to local country guidelines for immunocompromised subjects.
Cases falling under category  â€œbâ€ and â€œcâ€ need to be approved b y the Sponsor prior to  
enrollment in the study . No subject with currently ACTIVE TB may  be enrolled in the 
study , regardless of past or present anti- TB medication use.
10)Able and willing to sign the informed consent as approved b y the IEC/IRB. Written consent 
must be provided before initiating an y screening evaluations. Subjects m ust have read and 
understood the informed consent form (I CF), must fully  understand the requirements of the 
trial, and must be willing to comply  with all trial visits and assessments ; subjects who cannot 
read or understand the ICF may  not be enrolled by a guardian or an y other individual .
11)Subjects receiving non -prohibited medication for any  reason should be be on a stable dose 
(defined as 
no change in prescription ) within 7 day s or 5 half-lives (whichever is longer) 
prior to the first administration of study drug on Day 1.
Filgotinib 
Protocol GS -US-417-0303 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 44 05 July [ZIP_CODE].3. Exclusion Criteria
Subjects who meet any of the following exclusion criteria are not to be enrolled in this study .
1) Prior t reatments for RA as follows:
a)Alky lating agents, eg ,chlorambucil or cy clophosphamide, at any  time
b) Previous treatment with any  JAK inhibitor 
c)Previous therap y with csDMARDs other than MTX or h ydrox ychloroquine 
(eg,gold salts, cy closporine, leflunomide, azathioprine, sulfasalazine or any  other 
immunosuppressive). 
NOTE: Subjects with prior exposure to c sDMARD may  be enrolled if the subject had 
limited exposure (less than 3 months of total exposure). Washout periods need to be 
satisfied per protocol (section 5.4).
d)Use of an y licensed or investigational biologic DMARDs (eg, B -cell deplet ing agents,
tumor n
ecrosis factor (TNF) alpha inhibitors, and/or interleukin (IL) -1, IL -6, IL - 17, 
IL-12/23 inhibitors, including but not limited to abatacept, anakinra, certolizumab pegol, 
etanercept, golimumab, infliximab, rituximab, secukinumab, ustekinumab or tocilizumab 
2)Known hy persensitivity  or allergy  tostudy  drug , its metabolites, or formulation excipi[INVESTIGATOR_840].
3)Known hy persensitivity  or allergy  to the MTX, its metabolites, or formulation excipi[INVESTIGATOR_840].
4) Oral steroids at a dose >10 mg/day  of prednisone ( or equivalent )or a prescription for oral 
steroids which has changed within 4 weeks of Day 1.
5)Receipt of an intra -articular or other injectable corticosteroid within 4 weeks prior to Day  1.
6)Use of nonsteroidal anti
-inflammatory  drugs (NSAIDs) which have not been at a stable dose 
(defined as no change in prescription) for at least 2 weeks prior to Day 1.  NOTE: subjects 
are permitted to take acety lsalicy lic acid at a dose of â‰¤325mg daily for cardiac proph ylaxis, 
or occasional NSAIDs for non -RA indications (eg, headache) .  
7)Administration of a live /attenuated vaccine within 30 day sfrom Day  1, or planned during the 
study .
8)Participation in any  clinical study  of an investigational drug/device within 4 weeks or 
5half-lives prior to Screening, whichever is longer. Exposure to inve stigational biologics are 
excluded as outlined in 1d .
9)Have undergone surgical treatments for RA ,including s ynovectomy orarthroplasty  in 
>4joints 
Filgotinib 
Protocol GS -US-417-0303 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 45 05 July 201610)Have an y chronic, uncontrolled medical condition, which would put the subject at increased 
risk during stu dy participation, such as uncontrolled: diabetes, hy pertension, morbid obesity ,
thyroid, adrenal , pulmonary , hepatic , renal, neurologic or ps ychiatric disease , or other disease 
of concern, as per judgment of investigator.
11)Have a h istory  of major surgery  (requiring regional block or general anesthesia) within the 
last 3 months prior to Screening or planned 
major surgery  during the study .
12)Have a moderatel y to severely active, generalized musculoskeletal disorder that would 
interfere with assessment of study parameters or increase risk to the subject by  [CONTACT_204968] , eg, generalized osteoarthritis, sy stemic inflammatory  condition other than RA 
such as, but not limited to: anky losing spondy litis, reactive arthritis, psoriatic arthritis, 
inflammat ory bowel disease associated arthropat hies, sy stemic lupus ery thematosus, 
scleroderma ,inflammatory  myopath y, mixed connective tissue disease, overlap s yndrome, or 
gout. Subjects with any history  ofFeltyâ€™s syndrome or juvenile idiopathic arthritis are 
excluded, regardless of the disease activity level at Screening . (NOTE: subjects with 
concurrent Sjogren's s yndrome or limited cutaneous vasculitis associated with RA are not 
excluded, and may  be enrolled, based on investigator judgment ). 
13)Active autoimmune d isease other than those listed above, that would interfere with 
assessment of study  parameters or increase risk to the subject by  [CONTACT_6231] , 
eg, inflammatory  bowel disease, uncontrolled th yroiditis, sy stemic vasculitis, transverse 
myelitis or uveitis.
14)Any known condition or contraindication as addressed in the local labeling or local clinical 
practice for MTX that would preclude the subject from participating in this study .
15)History  of or c urrent moderate to severe congestive heart failure (NYHA class III or IV), or 
within the last [ADDRESS_580310] at risk by  
[CONTACT_293973].
16)History  of malignancy  within the past 5 years prior to Screening (except for adequatel y 
treated basal cell carcinoma or non -metastatic squamous cell carcinoma of the skin or 
cervica l carcinoma in situ with no evidence of recurrence). 
17)History  of lymphoproliferative disease or current ly mphoproliferative disease .
18)History  of gastrointestinal perforation.
19)History  of organ or bone marrow transplant.
20)Positive serology  for human immunodefi ciency  virus (HIV) 1 or 2. 
Filgotinib 
Protocol GS -US-417-0303 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 46 05 July 201621)Evidence of active Hepatitis C Virus (HCV) infection . Subjects with positive HCV Ab at 
screening, require reflex testing for HCV RNA. Subjects with positive Hep C RNA viral load 
(VL) at screening will be excluded. Subjects with positive HCV Ab, but negative HCV RNA 
VL are eligible per investigator judgment , but require ongoing monitoring as outlined in the 
schedule of assessments. Subject with active 
HCV during the study , as evidenced b y RNA 
positivity  will be discontinued from st udy drug as outlined in the protocol . 
22)Evidence of active Hepatitis B Virus (HBV) infection .Subjects with positive HBV surface 
antigen (HBsAg) at screening are excluded from the study . Subjects with positive HBV core 
Ab and negative HBsAg , require reflex testing for HBV DNA. Subjects with positive HBV
DNA at screening will be excluded. Subjects with positive HBV core Ab, and negative HBV 
DNA are eligible per investigator judgment , but may  require prophy lactic treatment in 
accordance with HBV treatment guidelines /local standard of care and require ongoing
monitoring with blood test sfor HBV DNA every  [ADDRESS_580311] with evidence of active Hepatitis B 
during the study ,as evidenced b y 
DNA positivity ,will be discontinued from study  drug as outlined in the protocol .
23)History  of opportunistic infection or immunodeficiency  syndrome which would put the 
subject at risk, as per investigator judgment
.
24)Active infection that is clinically  significant , as per judgment of the investigator , or any  
infection requiring hospi[INVESTIGATOR_204936] -infectives within 
60days of Screening ; or any  infection requiring oral anti -infective therap y within 30 day sof 
Screening .
25)Currently  on any therap y for chronic infection (such as pneumocystis, cytomegalovirus, 
herpes zoster, and aty pi[INVESTIGATOR_110411]). Past history  of disseminated staphy lococcus 
aureus or disseminated Herpes simplex infection.
26)History  of symptomatic herpes zoster within [ADDRESS_580312] history  of 
disseminated/complicated herpes zoster infection (multi dermatomal involvement, 
ophthalmic zoster, central nervous sy stem involvement or postherpetic neuralgia)
27)History  of an infected joint prosthesis or other implanted device with retention of the 
prosthesis or device in situ.
28)Current d
rug, tobacco or alcohol abuse, per investigator judgment.
29)Any condition including active fibrom yalgia that based on the investigatorâ€™s opi[INVESTIGATOR_454155] .
30)Any condition or circumstances which in the opi[INVESTIGATOR_454156] a subject unlikel y or unable to complete the study or compl y with study  procedures and 
requirement s.
31)Use of prohibited medication as outlined in section 5.4
Filgotinib 
Protocol GS -US-417-0303 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 47 05 July 201632)Significant blood loss (>450 mL ) or transfusion of blood product within 12 weeks prior to 
Day 1.
33)
Tests performed at the central laboratory  at Screening that meet any  of the criteria below
(out of r ange lab values may  be rechecked one time, after consultation wi th the sponsor or 
itâ€™s designee , before subject is considered a screen- failure):
a)Hemoglobin <8.0 g/dL (International Sy stem of Units [SI ]: <80 g/L);
b)White blood cells <3.0 x 103cells/mm3(SI: <3.0 x 109cells/L); 
c)Neutrophils <1.5 x 103cells/mm3(SI: <1.5 x 109cells/L );
d)Lym phocy tes <0.5 x 103cells/mm3(SI: <0.5 x 109cells/L );
e)Platelets <100 x 103cells/mm3(SI: <100 x 109cells/L );
f)Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) â‰¥1.5x ULN;
g)Total bilirubin level â‰¥2x ULN unless the subject has been diagnosed with Gilbertâ€™s 
disease and this is clearly documented;
h)Estimated creatinine clearance <40mL/min based on the Cockroft -Gault formula.
 
 
 
 
CCI
CCI-
-
Filgotinib 
Protocol GS -US-417-0303 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 48 05 July 2016 
  
CCI
Filgotinib 
Protocol GS -US-417-0303 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 49 05 July [ZIP_CODE]. INVESTIGA TIONAL  MEDI CINAL  PRODUCTS
5.1. Randomization, Blinding and Treatment Codes
An Interactive Web Response Sy stem (I WRS) will be employ ed to manage subject 
randomization and treatment assignments . It is the responsibility  of the investigator to ensure that 
the subject is eligible for the study  prior to enrollment. Subjects will be assigned a Screening
number at the time of consent. 
5.1.1. Procedures for Breaking Treatment Codes
In the event of a medical emergency  where breaking the blind is required to provide medical care 
to the subject, the investigator may  obtain individual subject treatment assignment directly  from 
the IWRS sy stem .
[COMPANY_009] recommends but does not require that the investigator contact [CONTACT_454183] M onitor before breaking the blind. Treatment assignment should remain blinded 
unless that knowledge is necessary  to determine emergency  medical care for the subject . The 
rationale for unblinding must be clearl y explained in source documentation and on the electronic 
case report form (eCRF), along with the date on which the treatment assignment was
unblinded. The investigator is requested to c ontact the [COMPANY_009] Medical Monitor promptly  in case 
of an y treatment unblinding .
Blinding of stud y treatment is critical to the integrity  of this 
Phase [ADDRESS_580313]â€™s treatment assignment is disclosed to the investigator, the subject will have study  drug
discontinued. 
[COMPANY_009] Drug Safet y and Public Health (DSPH) may independentl y unblind cases for expedited 
reporting of suspected unexpected serious adverse reactions (S[LOCATION_003]Rs) to Regulatory  
Authorities.
5.2.
Description and Handling of Filgotinib and PTM Filgotinib
5.2.1. Formulation of Filgotinib and PTM Filgotinib
Filgotinib is provided as 100 mg and 200 mg strength tablets. Filgotinib tablets, 100 mg and 
200mg tablets ,are beige, capsule -shaped, debossed with "GSI" on one side and â€œ100â€ or â€œ200â€ 
on the other, biconvex, film -coated tablets for clinical use. Each tablet contains the equivalent of 
100 mg or 200 mg filgotinib free base in the form of filgotinib maleate. In addition to the active 
ingredient, filgotinib tablets contain the foll owing inactive ingredients: microcry stalline 
cellulose, lactose monohy drate, fumaric acid, pregelatinized starch, silicon dioxide, magnesium 
stearate, macrogol/PEG 3350, poly vinyl alcohol, talc, titanium dioxide, iron oxide y ellow, and 
iron oxide red.
Placebo to match filgotinib tablets, 100 mg and 200 mg ,will be identical in appearance to the 
respective active tablets .Placebo to match filgotinib tablets contain the following inactive 
ingredients: microcry stalline cellulose, lactose monohy drate, croscarmellose sodium, magnesium 
stearate, macrogol/PEG 3350, poly vinyl alcohol, talc, titanium dioxide, iron oxide y ellow, and 
iron oxide red.
Filgotinib 
Protocol GS -US-417-0303 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 50 05 July [ZIP_CODE].2.2. Packaging and Labeling for Filgotinib and PTM Filgotinib
Filgotinib tablets, 100 mg and 200 mg, and PTM filgotinib tablets, 100 mg and 200 mg, are 
packaged in white, high density  polyethylene (HDPE) bottles. Each bottle contains 30 tablets, 
silica gel desiccant and poly ester packing material. Each bottle is enclosed with a white, 
continuous thread, child -resistant poly propylene screw cap fitted with an induction- sealed , 
aluminum -faced liner.
Study  drugs to be distributed to participating centers ,shall be labeled to meet applicable 
requirements of the [LOCATION_002] Food and Drug Administration (FDA), the EU Guideline to
Good Manufacturing Practice -Annex 13 (I nvestigational Medicinal Products) and/or other local 
regulations, as applicable.
Sufficient quant ities of filgotinib tablets, 100 mg and 200mg , and PTM filgotinib tablets to 
complete the entire stud y will be shipped to the investigator or qualified designee from the 
[COMPANY_009] Supply  Management Team (or its designee).
5.2.3. Storage and Handling for Filgotinib and PTM Filgotinib
Filgotinib tablets, 100 mg and 200 mg, PTM filgotinib tablets should be stored at controlled 
room temperature of 25Â°C (77ï‚°F); excursions are permitted between 15 ï‚°Cand30ï‚°C 
(59ï‚°Fto86ï‚°F).
Until dispensed to the subjects, all drug products should be stored in a securely  locked area, 
accessible only  to authorized site personnel. To ensure the stability  of the study  drug and to 
ensure proper product identification, the drug product should not be stored in a container other 
than the container in which they  are supplied. Consideration should be given to handling, 
preparation, and disposal through measures that minimize drug contact [CONTACT_10850] . 
Appropriate precautions should be followed to avoi d direct ey e contact [CONTACT_279383].
5.2.4. Dosage and Administration of Filgotinib
Filgotinib tablets, [ADDRESS_580314] should be given instructions to maintain ap proximately  the same 
daily  time of administration to ensure a similar dosing interval between study  drug doses. 
For missed dose(s) of study  medication, subjects should be instructed to take the missed dose(s) 
of study  medication as soon as possible during the same day
. If the missed dose is not taken on 
the original day , subjects should be cautioned not to double the next dose with the missed dose of 
study  drug under an y circumstances. In those cases, the missed dose should be returned to the 
study  drug bottle.
Filgotinib 
Protocol GS -US-417-0303 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 51 05 July [ZIP_CODE].3. Description and Handling of Methotrexate ( MTX ) and PTM MTX
5.3.1. Formulation for MTX and PTM MTX
MTX is available as 2.5 -mg strength capsules. MTX capsules are white opaque capsules. Each 
capsule contains one commercially  sourced MTX tablet, 2.5 mg, and microcry stalline cellulose. 
Information regarding the formulation can be found in the current prescribing information.
Placebo to match MTX capsules is visually  identical to the MTX capsule. Each PTM MTX 
capsule contains a placebo tablet a nd microcry stalline cellulose. The placebo tablet contains the 
inactive ingredients: microcry stalline cellulose, lactose monohy drate, croscarmellose sodium, 
magnesium stearate, and iron oxide y ellow.
5.3.2. Packaging and Labeling for MTX and PTM MTX
Methotrexate and PTM methotrexate capsules are packaged in white, high density  polyethylene 
(HDPE) bottles. Each bottle contains 100 capsules and is enclosed with a white, continuous 
thread, child
-resistant poly propy lene screw cap fitted with an induction-sealed, alum inum -faced 
liner.
Study  drugs to be distributed to centers in the US and other participating countries shall be 
labeled to meet applicable requirements of the [LOCATION_002] Food and Drug Administration 
(FDA), EU Guideline to Good Manufacturing Practice -Annex 13 (I nvestigational Medicinal 
Products) and/or other local regulations, as applicable.
5.3.3. Storage and Handling for MTX and PTM MTX
Methotrexate and PTM methotrexate capsules should be stored at 25
Â°C(77Â°F), until required for 
administration; excursions are permitted between 15 â€“ 30Â°C (59 â€“86Â°F) . 
Storage conditions are specified on the label. Until dispensed to the subjects, all drug products 
should be stored in a securely  locked area, accessible only  to authorized site personnel. 
To ensure the stabili ty of the study  drug and to ensure proper product identification, the drug 
product should not be stored in a container other than the container in which they  are supplied. 
Consideration should be given to handling, preparation, and disposal through measure s that 
minimize drug contact [CONTACT_10850] . Appropriate precautions should be followed to avoid direct 
eye contact [CONTACT_90265].
5.3.4. Dosage and Administration of MTX
The titration period forMTX wil l
be 8 weeks.  Subjects will be started on 10 mg (4 capsules ) of 
either MTX or PTM, in a blinded fashion. In the absence of an y lack of tolerance as specified 
below ,subjects will be advanced to 15 mg (6 capsules ) of M TX or PTM at their 4 week visit and 
advanced to 20 mg (8 capsules ) of MTX or PTM at their8 week visit. Subjects should be on an 
adequate dose of folic acid (as per local practice) which should b e confirmed or initiated at 
Day 1, and continued throughout the stud y. 
Filgotinib 
Protocol GS -US-417-[ADDRESS_580315] -of-care practices for the administration of MTX, including follow -up care and 
contraindications should be performed according to local standards of care throughout the stud y. 
Events that might indicate a lack of tolerance may include, but are not limited to :
ï‚·Moderate to severe headaches not responding to sim ple medical management;
ï‚·Moderate to severe nausea not responding to simple medical management;
ï‚·Moderate to severe fatigue;
ï‚·Mucocutaneous problems: oral ulcers or stomatitis not responding to simple medical 
management;
ï‚·Alopecia not responding to simple 
medical management;
ï‚·Elevated transaminases, confirmed b y two consecutive blood tests (3-7 days apart) ;
ï‚·Cytopenia , on blood samples taken 3
-7 day s apart:
ï‚¾Thrombocy topenia ,defined as two sequential platelet counts<100,000 platelets/mm3;
ï‚¾Neutropenia ,defined as two sequential neutrophil counts <1.0 x 109/L;
ï‚¾Leukopenia ,defined as two sequential white blood cell count <3.0 x 109/L;
Simple medical management of adverse events t ypi[INVESTIGATOR_454157] (e .g., anti- emetic medication), or replacing folic acid 
with up to 5 mg dose of leucovorin (foli c acid) dosed [ADDRESS_580316] 4 weeks, a single dose reduction of MTX/ PTM by5mg (2 capsules weekl y) is 
allowed during the stud y, as long the patient remains on a dose of at least 4 capsules of 
MTX/PTM weekly . Lack of tolerance an d dose reductions are to be documented by  [CONTACT_1275] .Should significant laboratory abnormalities or sy mptoms persist after dose 
adjustment, please refer to the discontinuation guidelines as outlined in Section 3.5.If the subject 
cannot tolerate the MTX/PTM tablets within the first [ADDRESS_580317] 4 weeks
.
5.4. Prior and Concomitant Medications
Concomitant therapi[INVESTIGATOR_454158] -existing conditions can continue during the 
study provided they  are in accordance with the inclusion and exclusion criteria 
(seeSecti on4.2and 4.3). It is preferred that these medications be continued without variation of 
Filgotinib 
Protocol GS -US-417-0303 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 53 05 July 2016dose or regimen during the study , as much as possible . All non- RAmedication use dwithin 
30days of consent (including an y changes) is to be documented in the eCRF .All prior 
medication used in the treatment for RA, are to be documented in the eCRF.
At each stud
y visit, the site will capture an y and all medications taken b y the subject since the 
last visit or during the visit (as applicable). Concomitant medications include prescription, non -
prescription medications, therapi[INVESTIGATOR_014], dietary  supplements, and minerals.
In case new (non -prohibited) therapi[INVESTIGATOR_454159] s tudy, the risk/benefit 
to the subject should be carefull y assessed and consideration given to the timing of an y necessary  
introduction of new medications.
Permitted concomitant medications should be kept stable for the study  duration , as much as 
possible, and include: 
ï‚·NSAIDs, at a stable dose and regimen, as much as possible; NSAI D doses should be held 
starting [ADDRESS_580318], 
as much as possible
ï‚·Anti- malarial DMARDs (hydroxy chloroquine   â‰¤400mg/day  or chloroquine â‰¤250mg/day ) 
provided that the prescription has been stable for at least 4weeks prior to Day  1
ï‚·Oral prednisone â‰¤10mg/day  or equivalent, provided that the prescription has been stable for 
at least [ADDRESS_580319]'s steroid dose can be reduced or 
tapered based on investigator judgment ( and may  also be adjusted back up as needed ), but 
should NOT exceed the stable dose identified at Baseline 
  
ï‚·Analgesics, including opi[INVESTIGATOR_204941] -NSAID based therapi[INVESTIGATOR_014], at a stable dose and 
regimen, as much as possible ; analgesic   dose s should be held starting [ADDRESS_580320], as much as possible 
ï‚·Dose adjustments for man agement of 
toxicity of the above medications are allowed and 
should be documented, along with documentation of the AE which led to the change in the 
medication
Female subjects of childbearing potential must agree to use highl y effective birth -control 
methods as outlined in A ppendix 5and must agree to continue their use during the stud y and for 
at least [ADDRESS_580321] dose of study  medication. The use of hormonal contraceptives will 
be recorded in the Concomitant Therap y section of the eCRF. Applicable procedures and 
treatment guidance based on package inserts will be respected. 
Hormone replacement therap y
, thyroidreplacement andother chronic therapi[INVESTIGATOR_014] (such as those 
for well -controlled diabetes or hy pertension) are permitted during the study, and should be kept 
at a stable dose and regimen, as much as possible.
Filgotinib 
Protocol GS -US-417-0303 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 54 05 July 2016Vitamin, mineral or herbal supplementations are permitted during the study per judgment of 
investigator , and should be kept at a stable dose and regimen, as much as possible .
Prohibited concomitant medications (and their wash out period as applicable) while on study  
drugs include: 
ï‚·Use of csDMARDs (other than the study -provided MTX /PTM or ongoing 
hydroxychloroquine  â‰¤400 mg/day  or chloroquine â‰¤250 mg/day )
ï‚·Use of an y biologic DMARD
ï‚·Any cytotoxic agent, including chlorambucil, cy clophosphamide, nitrogen mustard, and other 
alkylating agents.
ï‚·Use of an y other JAK inhibitor or other small molecule immunomodulator
ï‚·Any injectable corticosteroids and r eceipt of an intra -articular or parenteral co rticosteroid 
injection within 4 weeks prior to Day  1 is prohibited.
ï‚·Potent Pg-pi[INVESTIGATOR_454160] (e.g. rifampin, phen ytoin, carbamazepi[INVESTIGATOR_050], and St. Johnâ€™s wort) within 
3weeks prior to Day  [ADDRESS_580322] other than HCQ or MTX may be enrolled if there is 
documented evidence of limited exposure (less than 3 months). Washout period of â‰¥ 8 weeks for 
leflunomide, or â‰¥[ADDRESS_580323](s) prior to Day  1need to be satisfied.
Any prior use of biologic DMARDs for RA is prohibi ted
Previous treatment at an y time with a cytotoxic agent is prohibited. 
Previous use of JAK inhibitors is prohibited.
For subjects who are treated with isoniazid, 
consideration should be given to supplementation with vitamin B6 (py ridoxine) to reduce the 
risk of peripheral neuropathy .
Vaccine Guidelines:
ï‚·Prior to study  participation, it is recommended that the subjectâ€™s vaccinations be brought up 
to date according to local vaccination standards.
ï‚·Live or attenuated vaccines (including, but not limited to va ricella and inhaled flu vaccine) 
are prohibited within [ADDRESS_580324] 
dose of study  drug.
Filgotinib 
Protocol GS -US-417-0303 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 55 05 July 2016ï‚·Subjects should be advised to avoid routine household contact [CONTACT_204972]/attenuated vac cine components. General guidelines suggest that a study subjectâ€™s 
exposure to household contacts should be avoided for the below stated time periods:
ï‚¾Varicella or attenuated typhoid fever vaccination â€“ avoid contact [INVESTIGATOR_8178] 4 weeks following 
vaccination
ï‚¾Oral polio vaccination --avoid contact [INVESTIGATOR_8178] 6 weeks following vaccination
ï‚¾Attenuated rotavirus vaccine --avoid contact [INVESTIGATOR_8178] 10 day s following vaccination
ï‚¾Inhaled flu vaccine --avoid contact [INVESTIGATOR_8178] 1 week following vaccination
ï‚·Inactivated vaccines (such as inactivated flu vaccines) should be administered according to 
local vaccination standards whenever medicall y appropriate; however, there are no available 
data on the concurrent use of filgotinib and its impact on immune responses following 
vaccination.
5.5. Accountability forStudy Drugs
The investigator is responsible for ensuring adequate accountability  of all used and unused study  
drugs . This includes acknowledgement of receipt of each shipment of study  drugs (quantity  and 
condition). All used and unused s tudy drugs dispensed to subjects must be returned to the site.
Filgotinib and MTX accountability  records will be provided to each study  site to:
ï‚·Record the date received and quantity  of study  drugs
ï‚·Record the date, subject number, subject initials, the study drug number dispensed
ï‚·Record the date, quantity of used and unused study  drugs returned, along with the initials of 
the person recording the information.
ï‚·Dispensing records will include the initials of the person dispensing the study  drug or 
supplies.
5.5.1. Investigational Medicinal Product Return or Disposal
At study  initiation, the monitor will evaluate the siteâ€™s standard operating procedure for 
investigational medicinal product disposal/destruction in order to ensure that it complies with 
[COMPANY_009]â€™s requirements. Study  drug may  be returned or destro yed on an ongoing basis during the 
study  if appropriate. At the end of the stud y, following final drug inventory reconciliation b y the 
monitor, the study  site will dispose of and/or destroy  all unused investigational medicinal 
product supplies, including empty containers, according to these procedures. If the site cannot 
meet [COMPANY_009]â€™s requirements for disposal, arrangements will be made between the site and 
[COMPANY_009]â€™s or its representative for destruction or r eturn of unused investigational medicinal 
product supplies.
Filgotinib 
Protocol GS -US-417-[ADDRESS_580325] research organization ( CRO ).
The study  assessments as described below will be performed at the time points specified in th e 
Study  Procedures Table ( Appendix 2). Visits are to be scheduled within a window as specified in 
the schedule of assessment and in such a way  that the total study  duration from Day  [ADDRESS_580326] -
reported outcomes, including
Global Assessment, HAQ- DI and Pain Scale are recommended to be done be fore an y other stud y 
procedures. Invasive study procedures such as blood draws should be done at the end of a stud y 
visit, as much as possible . The following will be performed and documented at screening:
ï‚·Obtain written informed consent
ï‚·Obtain 
demographics and medical history   (including onset of RA, disease characteristics, 
smoking habits, average weekly alcohol consumption, and family history of coronary heart 
disease)
ï‚·Complete phy sical examination including height
ï‚·Weight
ï‚·Vital Signs
Filgotinib 
Protocol GS -US-417-0303 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 58 05 July 2016ï‚·Perform 66 swollen and 68 tender joint count assessment (SJC66/TJC68)
ï‚·Physicianâ€™s global assessment
ï‚·Subjectâ€™s global assessment
ï‚·HAQ- DI and Pain Scale
ï‚·Radiographs of hands, wrists, and feet to be sent to central review for confirmation of joint 
erosion(s)
ï‚·12-Lead ECG
ï‚·TB test and 
Chest X -ray(if applicable) 
ï‚·Obtain blood samples for: 
ï‚¾Serology
ï‚¾Hematology  and Chemistry
ï‚¾Serum CRP
ï‚¾Serum Pregnancy  Test (if applicable)
ï‚¾Rheumatoid factor, anti- CCP Ab
ï‚¾Quantitative immunoglobulin (Ig)
ï‚¾FSH (for females onl y), TSH, Hemoglobin A1c
ï‚·Urinaly sis(including pregnancy  test, if applicable)
ï‚·Review of concomitant medications
ï‚·Record an y serious adverse events and all adverse events related to protocol mandated 
procedures occurring after signing of the consent form.
Subjects meeting all of the inclusion criteria and none of the exclusion criteria will return to the 
clinic after screening for randomization into the study .
Subjects who do not meet the eligibility  criteria will be excluded from randomization ; subjects
may be considered for rescreening one time for the study in consultation with the Sponsor or its 
designee.
Filgotinib 
Protocol GS -US-417-[ADDRESS_580327] all serious adverse events (SAEs), as well as 
any adverse events related to protocol-mandated procedures on the adverse events case report 
form (eCRF). All other untoward medical occurrences observed during the screening period, 
including exacerbation o r changes in medical history  are to be captured on the medical history  
eCRF.  See Section [ADDRESS_580328]â€™s eligibility  for the study  has been confirmed, the sub ject will be 
randomized into the study  to receive one of four study  dosing regimens. 
Subjectâ€™s Global Assessment, HAQ- DIand Pain Scale , FACIT - Fatigue ,andSF-36are 
recommended to be done before any  other stud y procedures. Invasive study procedures such as 
blood draws should be done at t he end of a study  visit. The following will be performed and 
documented at Day  1 prior to dosing:
ï‚·Subjectâ€™s global assessment
ï‚·HAQ- DI and Pain Sc ale FACIT -Fatigue andSF-36
ï‚·WPAI -RAandEQ-5D, where available
ï‚·TSQM , when and where available
ï‚·Healthcare resource utilization questionnaire
ï‚·Symptom -driven physical e
xamination
ï‚·Weight
ï‚·Vital signs
ï‚·SJC66/TJC68
ï‚·Physicianâ€™s global assessment
ï‚·Obtain blood samples for: 
ï‚¾Hematology  and Serum Chemistry
ï‚¾Lipid profile (fasting)
ï‚¾Serum CRP
CCII 
Filgotinib 
Protocol GS -US-417-0303 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 60 05 July 2016ï‚¾Biomarker blood samples
ï‚¾Pre-dose vfPBMC and leuk ocyte subsets samples  ( US and Canada onl y) 
ï‚·Urina lysis (including pregnancy  test,if applicable)
ï‚·Urine stored for biomarker anal ysis
ï‚·Review of concomitant medications
ï‚·Record an y serious adverse events and all adverse events related to protocol mandated 
procedures occurring after signing of the consent form
 
6.3. Randomization
Subjects will be randomly allocated to a dosing group according to a pre -specified randomization 
scheme prepared b y an independent statistician. Upon qualification for the study, subjects will be 
randomized using a computerized I WRS sy stem. Randomization will be stratified b ygeographic
region and presence of RF or anti -CCP A
bat Screeni ng.
For each subject at each visit , the clinic will contact [CONTACT_454184]. The kit will contain the relevant study drugs for the period until the next 
dispensation visit.
 
6.4. Week 2 through Week 44 Assessments 
The following assessments will be completed at each visit or as specified. All assessments are 
summarized in the Study  Procedures Table ( Appendix 2).
Subjectâ€™s Global Assessment, HAQ- DIand Pain Scale , FACI T- Fatigue , and SF- 36 are
recommended t o be done before an y other stud y procedures. Invasive study procedures such as 
blood draws should be done at t he end of a study  visit. 
ï‚·Subjectâ€™s global assessment
ï‚·HAQ- DI and Pain Scale
ï‚·FACIT -Fatigue andSF-36 at Weeks 4 , 12, and 24
CCI
CCI
CCII 
Filgotinib 
Protocol GS -US-417-0303 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 61 05 July 2016ï‚·WPAI -RA and EQ-5D at Weeks 4, 12, and 24, where available
ï‚·TSQM at Weeks 12, 24 and 36, when and where available
ï‚·Healthcare resource utilization questionnaire at Weeks 12, 24 and 36
ï‚·SJC66/TJC68
ï‚·Vital s igns
ï‚·Weight
ï‚·Complete phy
sical exam ination at Week 24 (s ymptom -driven PE conducted at all other 
visits)
ï‚·Physicianâ€™s global assessment
ï‚·12-lead ECG at Week s12, 24, and 36
ï‚·Assessment of serious AE(s) ,(S)AE(s) and concomitant medication
ï‚·Obtain blood sampl esfor:
ï‚¾Hematology  and Serum Chemistry
ï‚¾Serum CRP
ï‚¾Pre-dose vfPBMCand leuk ocyte subset samples sample satWeeks 4, 8, 12, 24, and 
36 (US and Canada only)
ï‚¾Blood sampling for PK at Weeks 4, 12 and 24
ï‚¾Biomarker samples at Weeks 4, 8, 12, 24, and 36   
ï‚¾Lipid profile (fasting) at Weeks 12 and 24
ï‚¾Quantitative Ig at Week 24
ï‚·Radiographs of hands, wrists, and feet at Week 24
ï‚·Urinaly sis at Week 24
ï‚·Urine stored for biomarker anal ysis at Week 12 and Week 24
CCII 
Filgotinib 
Protocol GS -US-417-0303 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 62 05 July 2016ï‚·Urine pregnancy  test (for women of childbearing poten tial, as defined per protocol). During
theperiods where study visits areevery [ADDRESS_580329] theinformation inthesource documents andCRF .
 
6.5. Week 52/Early Termination (ET)
If asubject discontinues the study , every  attempt should be made to perform the required 
study-related ETand Post Treatment Week [ADDRESS_580330]â€™s Global Assessment, HAQ- DI and Pain Scale, FACIT - Fatigue , and SF -36are
recommended to be done before an y other stud y procedures. Invasive study procedures such as 
blood draws should be done at the end of a stud y visit. 
ï‚·Subjectâ€™s global assessment
ï‚·HAQ- DI and Pain Scale
ï‚·FACIT -Fatigue andSF-36, 
ï‚·WPAI -RAandEQ-5D, where availa ble
ï‚·TSQM , when and where available
ï‚·Healthcare resource utilization questionnaire
ï‚·Complete physical examination
ï‚·Weight
ï‚·Vital signs
ï‚·SJC66/TJC68
ï‚·Physicianâ€™s global assessment
ï‚·12-Lead ECG
ï‚·Radiographs of hands, wrists, and feet
CCI
CCII 
I 
Filgotinib 
Protocol GS -US-417-0303 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 63 05 July 2016ï‚·Obtain blood samples for: 
ï‚¾Hematology  and Serum Chemistry
ï‚¾Lipid profile (fasting)
ï‚¾Serum CRP
ï‚¾Pregnancy  test (serum required if subject is entering into LTE)
ï‚¾Blood sampling for PK 
ï‚¾Biomarker blood samples
ï‚¾Quantitative Ig
ï‚¾vfPBMC and l eukocy te subset sample s (US and Canada only)
ï‚·Urinaly sis(including pregnancy  test if applicable)
ï‚·Urine stored for biomarker anal ysis
ï‚·Assessment of AE(s) /serious (S)AE(s) and concomitant medication
ï‚·Review Entry  criteria for LTE (if applicable)
6.6. Post Treatment Week [ADDRESS_580331]â€™s last dose of study  
treatment .This visit is not applicable if the subject is continuing onto the LTE study . 
ï‚·Symptom -driven p hysical examination
ï‚·Weight
ï‚·Vital signs
ï‚·Urinaly sis (including pregnancy  test if applicable)
ï‚·12-lead ECG
ï‚·Obtain blood samples for: 
ï‚¾Hematology  and Serum Chemistry
ï‚·Urinaly sis
ï‚·Assessment of AE(s)/SAE(s) and concomitant medication
Filgotinib 
Protocol GS -US-417-0303 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 64 05 July [ZIP_CODE].7. Study Assessments
6.7.1. Efficacy
Efficacy  assessments will be carried out at Day  1and at Weeks 2, 4, 8, 12, 16 , 20, 24, 3 0, 36, 44, 
and 52, or at ET(if applicable). 
Assessments of 
RAwill include the derived ACR (ACR20, 50, 70 as well as ACR -N and 
EULAR response criteria, DAS28 [CRP], CDAI , and SDAI  as well as the individual components 
of the ACR response criteria [TJC68, SJC66 ], HAQ- DI, Phy sicianâ€™s Global assessment, 
Subjectâ€™s Global Assessment, Subjectâ€™s Assessment of Arthritis Pain and CRP]) and radiographs 
of hands, wrists and feet (mTSS and mTSS components of erosion score and joint space 
narrowing).
Additionally ,
subjects will be asked to complete questionnaires, including the FACIT-Fatigue
scale, SF -36, EQ -5D,TSQM, WPAI -RA at Day 1 and at Weeks 4, 12, 24, 36, and 52, or at ET
(if applicable). Healthcare resource utilization will be assessed at the Day 1 and at Weeks 
12, 24,
36and 52, or at ET (if applicable).
[IP_ADDRESS]. Evaluation of Dise ase Activity : Tender and Swollen Joint Counts
Assessment of tender and swollen joints will take place at the time points indicated in the study  
procedures table ( Appendix 2) and according to the assessment sdescribed in Section 6.4.
Each of 68 joints will be evaluated for tenderness and each of 66 joints will be evaluated for 
swelling (a list of joints to be evaluated is provided in Appendix 7). 
An independent joint assessor with adequate training and experience in perform
ing joint 
assessments will be designated at each stud y site to perform all joint assessments , and should be 
blinded to the other study assessments performed on that day . The joint assessor should 
preferabl y be a rheumatologist; however, if a rheumatologist is not available, it should be a 
health care worker with experience in performing joint assessments. The assessor should remain 
the same throughout the study  per subject, as much as possible. I t is required that the designated 
joint assessor identify  an appropriate back up assessor to provide coverage if the designated joint 
assessor is absent.
[IP_ADDRESS]. Subjectâ€™s Global Assessment of Disease Activity
The Subjectâ€™s Global assessment of Disease Activity  will be performed at the time points 
indicated in the study  procedures table ( Appendix 2).The Subjectâ€™s Global assessment of 
Disease Activity  should be completed before any  other study  procedures .
The Subjectâ€™s Global Assessment of Disease Activity  will be recorded on a 0
-100 mm visual 
analog scale (VAS), with 0 indicating â€œ no arthritisâ€ and 100 indic ating â€œsevere arthritis â€.
Filgotinib 
Protocol GS -US-417-0303 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 65 05 July [ZIP_CODE].7.1.3. Physicianâ€™s Global Assessment of Disease Activity
The Phy sicianâ€™s Global assessment of Disease Activity  will be performed at the time points 
indicated in the study  procedures table ( Appendix 2).
The Phy sicianâ€™s Global Assessment o f Disease Activity  will be recorded on a 0
-100 mm VAS, 
with 0 indicating â€œno disease activity â€ and 100 indicating â€œ maximum disease activit yâ€. The 
evaluating ph ysician and the subject should complete the global assessments independently  of 
each other.
[IP_ADDRESS]. Serum CRP
The subjectâ€™s serum CRP will be measured at the time points indicated in the study  procedures 
table ( Appendix 2).
[IP_ADDRESS]. Health Assessment Questionnaire â€“Disability  Index and Pain Scale
The functional status of the subject will be assessed using the HAQ -DI at the time points 
indicated in the study  procedures table ( Appendix 2) and should becompleted before an y other 
study  procedures. The HAQ -DI is a 20 -question instrument that assesses the degree of difficulty  
a person has in accomplishing tasks in 8 domain s (dressing, arising, eating, walking, h ygiene, 
reaching, grippi[INVESTIGATOR_204942]/chores). Responses are scored on a [ADDRESS_580332] week 
on a 0-100 mm VAS, with 0 indicating â€œno painâ€ and 100 indicating â€œsevere painâ€. This 
assessment should be completed before the joint examination. This pain score will be used to 
drive the ACR20/50/70.
[IP_ADDRESS]. FACIT -Fatigue Scale
The FACIT -Fatigue scale (version 4) will be completed at the time points indicated in the study  
procedures table ( Appendix 2) and should be completed before an y other study procedures where 
local language question
naires are available .
The FACIT -Fatigue scale measures an individualâ€™s level of fatigue during thei r usual daily  
activities over the past week. It consists of 13 questions with a 7 -day recall period on a 5- point 
Likert scale, with 0 indicating â€œnot at allâ€ and 4 indicating â€œvery  muchâ€ . The total score ranges 
from 0 to 52. Higher scores indica te a better the quality  of life .
[IP_ADDRESS].
36-Item Short -form Health Survey  
The SF -36 (version 2) will be completed at the time points indicated in the study  procedures 
table ( Appendix 2) and should be done before an y other study procedures .
Filgotinib 
Protocol GS -US-417-0303 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 66 05 July 2016The SF -36 is a health related qual ity of life instrument consisting of 36 questions belonging to 
8domains in 2 components and covers a 4 -week recall period:
ï‚·physical well -being: 4 domains: phy sical functioning (10 items), role phy sical (4 items), 
bodily  pain (2 items), and general health perceptions (5 items)
ï‚·mental well -being: 4 domains: vitality  (4items), social functioning (2 items), role emotional 
(3items), and mental health (5 items).
The remaining item (health transition) is not part of the above domains but is kept separately . 
These scales will be rescaled from 0 to 100 (converting the lowest possible score to [ADDRESS_580333] possible score to 100), with higher scores indicating a better quality  of life.
[IP_ADDRESS]. EuroQol 5 Dimensions
The EQ -5D questionnaire will be completed at the time points indicated in the study  procedures 
table ( Appendix 2) and should be completed before an y other study procedures where local 
language question
naires are available .
The EQ -5D is a standard measure of health status developed by [CONTACT_454185], generic measure of health for clinical and economical appraisal {The EuroQol Group 
1990}. The EQ -5D is not disease sp ecific and has been validated in numerous health states.
The tool consists of the EQ -5D descriptive sy stem and the EQ VAS. The descriptive part 
comprises 5 dimensions (mobility , self -
care, usual activities, pain/discomfort, and 
anxiety /depression). Each of these 5 dimensions has 3 levels (no problem, some problems, and 
severe problems). Results for each of the [ADDRESS_580334]â€™s health state. The VAS records the subjectâ€™s health on a 0 -100 mm VAS 
scale, with 0 indicating â€œthe worst health y ou can imagineâ€ and 100 indicating â€œthe best health 
you can imagineâ€.
[IP_ADDRESS]. Work Productivity  and Activity  Impairment 
The WPAI -RA is a questionnaire developed to measure impairments in work activities in 
subjects with RA {Zhang et al 2010 } and will be completed at the time points indicated in the 
study  procedures table ( Appendix 2) and should be done before an y other study procedures
where local language question naires are available .
The questionnaire consists of 6 questions (currently emplo yed, work time missed due to RA, 
Work time missed due to other reasons, hours actually worked, degree RA affected productivity 
while working [0 -
10 VAS; with [ADDRESS_580335] from working], and degree RA affected productivity in regul ar unpaid 
activities [0 -10 VAS; with [ADDRESS_580336]â€™s daily  activities]). The recall period for questions 2 to 6 is 7 days.
Filgotinib 
Protocol GS -US-417-0303 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 67 05 July 2016Four main outcomes (expressed in percentages) can be obtained from the WPAI -RA: percentage 
of work time missed due to RA, percentage of impairment due to RA, percentage of overall work 
impairment due to RA, percentage of activity impairment due to RA. Note that for subjects who 
did not work during the 7 days covered by  [CONTACT_941] W PAI-RA, the percent overall work impairment 
will be equal to the percent of work time missed due to RA.
[IP_ADDRESS]. Healthcare Resource Utilization
The Healthcare Resource Utilization Questionnaire is designed to assess healthcare usage during 
the previous three months across a number of direct medical cost domains. 
This questionnaire should be completed b y the patient prior to any procedures being p erformed 
at the visit, if possible where local language questionnaires are available . 
[IP_ADDRESS]. Hand s, Wrist s, and Feet Radiographs
Hands, wrists, and feet radiographs will be taken at the time points indicated in the study  
procedures table ( Appendix 2).Note that if a subject discontinues the study  early  and has had 
X-rays performed in the <12 weeks prior to discontinuation, these do not need to be repeated at 
ET. R adiographs performed after enrollment may be done +/ -[ADDRESS_580337] radiographs performed as outlined in the study  procedure 
table ( Appendix 2). 
The radiographs will be evaluated through central review b y 2 independent blinded assessors 
using the mTSS. 
[IP_ADDRESS]. Exploratory  Patient Reported Outcomes
 
 
[IP_ADDRESS] Treatment Satisfaction Questionnaire for Medication (TSQM) 
The TSQM will assess the overall level of satisfaction or dissatisfaction with medication subjects 
are taking. Subje cts will be asked to rate their t reatment satisfaction at the time points indicated 
in the study  procedures table ( Appendix 2).The TSQM will implemented when and where local 
language TSQM  are available .
CCI
Filgotinib 
Protocol GS -US-417-0303 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 68 05 July [ZIP_CODE].7.2. Safety and Tolerability
Adverse events, ph ysical examinations, vital signs, ECG and laboratory  assessments (standard 
hematology, serum/plasma chemistry , and urinaly sis)will be collected .
6.7.3. Clinical Laboratory Evaluations
The hematology  and serum chemistry  laboratory  analy ses will be performed at a central
laboratory . Reference ranges will be supplied by  [CONTACT_204973].
Blood samples will be collected b y venipuncture  
 in the arm at the time points indicated in the study  procedures 
table ( Appendix 2) In addition, urine samples for the clinical laboratory  assessments will be 
collected. Subjects onl y need to be fasted at days were lipid profiling is scheduled. 
Please refer to Appendix 6for table of Clinical laboratory
 tests.
The laboratory  values outside the normal range will be flagged and clinical relevance will be 
assessed b y the investigator. More frequent sampling a s well as additional tests may  be 
performed as deemed necessary  by [CONTACT_204974] . 
Note that in thecase where clinicall y significant laboratory test results are a potential reason for 
discontinuation from the study  drug and withdrawal from the study , retesting of the affected 
parameter(s) should be prompt (within 3 to 7 days) after the investigator has consulted with the 
medical monitor. A decision regarding subject discontinuation should be made after the results 
from the retest are availa ble (see Section 3.5for additional information).
The details of sample handling and shipment instructions will be provided in a separate 
laboratory  manual.
6.7.4. Vital Signs
Vital signs will be measured at the time points indicated in the study  procedures table
(Appendix 2).
Vital signs should be taken after the subject has been resting for 5 min and will include heart 
rate, respi[INVESTIGATOR_2842], SBP, DBP, and body  temperature.
6.7.5. Physical Examination
A phy sical examination should be performed at the time points indic ated in the study  procedures 
table ( Appendix 2). 
Any changes from the 
Day 1will be recorded. Height should be measured at Screening onl y. 
At Screening, Week 24 and Week 52 (or at ET), a complete phy sical examination should be 
performed . Symptom -driven physical exams should be performed at all other visits. Weight is 
measured at all visits.
CCI
Filgotinib 
Protocol GS -US-417-0303 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 69 05 July [ZIP_CODE].7.6. Other Safety Assessments
[IP_ADDRESS]. 12-lead Electrocardiogram
A resting 12 -lead ECG will be performed at the time points indicated in the study  procedures 
table ( Appendix 2). 
The ECG 
should be obtained after the subject has been resting in the supi[INVESTIGATOR_19636] 5 min 
and will include heart rate (HR), R -Rinterval , QRS, uncorrected QT, morphology , and rhy thm 
analysis. QT interval corrected for HR according to Fridericia (QTcF) will be derived during the 
statistical analy sis. ECGs will be interpreted by  [CONTACT_454186].
6.8. Pharmacokinetics Assessments
For all subjects, blood samples for PK anal ysis will be collect ed at least [ADDRESS_580338] study  
drug dosing at Week 4, prior to study  drug dose atWeek 12 andWeek 24, and atWeek 52 or ET.
 
 
Plasma concentrations of filgotinib and GS-829845 will be anal yzed.
Additional analy ses (e .g., for MTX and its metabolites) may be performed.
6.9. Biomarker Assessments
Blood and urine samples for biomarker anal ysis will be collected at Day  1, Week s
4, 8, 12, 24, 
36, and Week [ADDRESS_580339] .  
Specific 
information regarding th e collection and processing o f biomarker samples (if applicable) will be 
provide to each site in a separate laboratory  manual.
CCI
CCI
Filgotinib 
Protocol GS -US-417-0303 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 70 05 July [ZIP_CODE]. ADVERSE EVENTS AND T OXICITY  MANAGEMENT
7.1. Definitions of Adverse Events, Adverse Reactions, and Serious Adverse 
Events
7.1.1. Adverse Event s
An adverse event (AE) is any  untoward medical occurrence in a clinical study  subject 
administered a medicinal product, which does not necessarily  have a causal relationship with the 
treatment. An AE can therefore be an y unfavorable and/or unintended sign , symptom, or disease 
temporally  associated with the use of a medicinal product, whether or not considered related to 
the medicinal product. AEs may  also include pre -or post -treatment complications that occur as a 
result of protocol specified procedures, lack of efficacy , overdose, drug abuse/misuse reports, or 
occupational exposure. Preexisting events that increase in severit y or change in nature during or 
as a consequence of participation in the clinical study  will also be considered AEs.
An AE does not include the following:
ï‚·Medical or surgical procedures such as surgery , endoscopy , tooth extraction, and transfusion. 
The condition that led to the procedure may be an adverse event and must be reported.
ï‚·Pre-existing diseases, conditions, or laboratory  abno rmalities present or detected before the 
screening visit that do not worsen .
ï‚·Situations where an untoward medical occurrence has not occurred (eg, hospi[INVESTIGATOR_10800] , social and/or convenience admissions)
ï‚·Overdose without clinical sequela e (see Section 7.7.1 )
ï‚·Any medical condition or clinically  significant laboratory  abnormality  with an onset date 
before the consent form is signed and not related to a protocol -associated procedure. It is 
considered to be pre -existing and should be document ed on the medical history  CRF.
7.1.2. Serious Adverse Events
A serious adverse event (SAE) is defined as an event that, at an y dose, results in the following:
ï‚·Death
ï‚·Life-threatening (Note: The term â€œlife -threateningâ€ in the definition of â€œseriousâ€ refers to an 
event in which the subject was at risk of death at the time of the event; it does not refer to an 
event that h ypotheticall y might have caused death if it were more severe.)
ï‚·In-patient hospi[INVESTIGATOR_454161] -US-417-0303 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 71 05 July 2016ï‚·Persistent or significant disability /incapacit y
ï‚·A congenital anomal y/birth defect
ï‚·A medicall y important event or reaction: such events may not be immediately 
life-threatening or result in death or hospi[INVESTIGATOR_454162] n to prevent one of the other outcomes constituting SAEs. Medical and 
scientific judgment must be exercised to determine whether such an event is a reportable 
under expedited reporting rules. Examples of medically important events include intensive 
treatme nt in an emergency  room or at home for allergic bronchospasm; blood dy scrasias or 
convulsions that do not result in hospi[INVESTIGATOR_059]; and development of drug dependency  or 
drug abuse. For the avoidance of doubt, infections resulting from contaminated medici nal 
product will be considered a medicall y important event and subject to expedited reporting 
requirements.
7.1.3. Clinical Laboratory Abnormalities and Other Abnormal Assessments as 
Adverse Events or Serious Adverse Events
Laboratory abnormalities without clinic al significance are not to be recorded as AEs or SAEs. 
However, laboratory  abnormalities (e .g., clinical chemistry , hematology , and urinaly sis) that 
require medical or surgical intervention or lead to IMP interruption, modification, or 
discontinuation must be recorded as an AE, as well as an SAE, if applicable. I n addition, 
laboratory  or other abnormal assessments (e
.g., electrocardiogram, x -rays, vital signs) that are 
associated with signs and/or sy
mptoms must be recorded as an AE or SAE if they  meet the 
definition of an AE or SAE as described in Sections 7.1.[ADDRESS_580340] the s yndrome or diagnosis (e .g., anemia), not the 
laboratory  result (i .e., decreased hemoglobin).
For specific information on ha ndling of clinical laboratory  abnormalities in this study , please 
refer to Section 7.5.
7.2. Assessment of Adverse Events and Serious Adverse Events
The investigator or qualified subinvestigator is responsible for assessing AEs and SAEs for 
causality  and severi ty, and for final review and confirmation of accuracy  of event information 
and assessments.
7.2.1. Assessment of Causality for Study Drugs and Procedures
The investigator or qualified subinvestigator is responsible for assessing the relationship to IMP 
therap y using clinical judgment and the following considerations:
ï‚·No: Evidence exists that the adverse event has an etiology  other than the IMP. For SAEs, an 
alternative causality  must be provided (e .
g., pre - existing condition, underl ying disease, 
intercurrent illne ss, or concomitant medication).
ï‚·Yes: There is reasonable possibility  that the event may  have been caused by [CONTACT_10853].
Filgotinib 
Protocol GS -US-417-0303 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 72 05 July 2016It should be emphasized that ineffective treatment should not be considered as causall y related in 
the context of adverse event reporting. 
The relationship to study  procedures (e.g., invasive procedures such as venepuncture or biopsy ) 
should be assessed u sing the following considerations:
ï‚·No: Evidence exists that the adverse event has an etiology  other than the study  procedure.
ï‚·Yes: The adverse event occurred as a result of protocol procedures, (eg., venipuncture )
7.2.2. Assessment of Severity 
The severit y of A
Es will be graded using the modified CTCAE, version 4.03. For each epi[INVESTIGATOR_1865], 
the highest grade attained should be reported.
If a CTCAE criterion does not exist, the investigator should use the grade or adjectives: 
Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), Grade 4 (life -threatening) or 
Grade 5(fatal) to describe the maximum intensity  of the adverse event. For purposes of 
consistency  with the CTCAE, these intensity  grades are defined in Table 7-1and Appendix 4.
Table 7-1. Grading of Adverse Event Severity
Grade Adjective Description
Grade 1 MildAsymptomatic or mild symptoms; clinical or diagnostic observations only; 
intervention not indicated
Grade 2 ModerateLocal or noninvasive intervention indicated; limiting age -appropriate 
instrumental ADL
Grade 3 SevereSevere or medically significant but not immediately life -threatening; 
hospi[INVESTIGATOR_3111]; disabling; 
limiting self -care ADL
Grade 4 Life-threatening Urgent intervention indicated
Grade 5 Death Death related AE
* Activities of Daily Living (ADL) Instrumental ADL refer to opening preparing meals, shoppi[INVESTIGATOR_3112], 
using the telephone, managing money, etc. 
7.3. Investigator Requirements and Instructions for Reporting Adverse Events 
and Serious Adverse Events to [COMPANY_009]
Requirements for collection prior to study  drug initiation:
After informed consent, but prior to initiation of study  medication, the following t ypes of events 
should be reported on the case report form (eCRF): all SAEs and adverse events related to 
protocol -mandated procedures.
Filgotinib 
Protocol GS -US-417-[ADDRESS_580341] consents to 
participate in the stud y (ie, signing the informed consent) and throughout the duration of the 
study , including the protocol -required post treatment follow -up period, must be reported to the 
eCRF database and [COMPANY_009] Drug Safet y and Public Health (DSPH) as instructed. This also 
includes an y SAEs resulting from protocol- associated procedures performed after informed 
consent is signed.
Any SAEs and deaths that occur after the post treatment follow -up visit but within [ADDRESS_580342] dose of study  IMP, regardless of causalit y, should also be reported. 
Investigators are not obligated to activel y seek SAEs after the protocol defined follow up period
however, if the investigator learns of an y SAEs that occur after stud y participation has concluded 
and the event is deemed relevant to the use of IMP, he/she should promptly  document and report 
the event to Gile ad DSPH.
ï‚·All AEs and SAEs will be recorded in the eCRF database within the timelines outlined in the 
eCRF completion guideline. 
Electronic Serious Adverse Event (eSAE) Reporting Process
ï‚·Site personnel record all SAE data in the eCRF database and from there transmit the SAE 
information to [COMPANY_009] DSPH within 24 hours of the investigatorâ€™s knowledge of the event. 
Detailed instructions can be found in the eCRF completion guidelines.
ï‚·If for an y reason it is not possible to record the SAE information electro nically , ie, the eCRF 
database is not functioning, record the SAE on the paper serious adverse event reporting 
form and submit within 24 hours as described above.
[COMPANY_009] DSPH: Fax:
E-mail: 
ï‚·As soon as it is possible to d o so, any  SAE reported via paper must be transcribed into the 
eCRF Database according to instructions in the eCRF completion guidelines.
ï‚·If an SAE has been reported via a paper form because the eCRF database has been locked, no 
further action is necessary.
[COMPANY_003]
[COMPANY_003]
Filgotinib 
Protocol GS -US-417-0303 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 74 05 July 2016ï‚·All AEs and SAEs will be recorded in the eCRF database within the timelines outlined in the 
eCRF completion guideline. 
ï‚·For fatal or life -threatening events, copi[INVESTIGATOR_3103], autops y reports, and other 
documents are also to be submitted by e-mail or fax when requested and applicable. 
Transmission of such documents should occur without personal subject identification, 
maintaining the traceability  of a document to the subject identifiers.
ï‚·Additional information may  be requested to ensure the timely  completion of accurate safet y 
reports.
ï‚·Any medications necessary  for treatment of the SAE must be recorded onto the concomitant 
medication section of the subjectâ€™s eCRF and the event description section of the SAE form.
7.4. [COMPANY_009] Reporting Requirements
Depending on relevant local legislation or regulations, including the applicable US FDA Code of 
Federal Regulations, the EU Clinical Trials Directive (2001/20/EC) and relevant updates, and 
other country -specific legislation or regulations, [COMPANY_009] may  be required to expedite to 
worldwide regulatory  agencies reports of SAEs, serious adverse drug reactions (SADRs), or 
suspected unexpected serious adverse reactions (S[LOCATION_003]Rs). I n accordance with the EU Clinical 
Trials Directive (2001/20/EC), [COMPANY_009] or a specifie d designee will notify  worldwide regulatory  
agencies and the relevant I EC in concerned Member States of applicable S[LOCATION_003]Rs as outlined in 
current regulations.
Assessment of expectedness for SAEs will be determined by  [CONTACT_454187] n specified in the investigatorâ€™s brochure or relevant local label as applicable. 
All investigators will receive a safet y letter notifying them of relevant S[LOCATION_003]R reports associated 
with any  study  IMP. The investigator should notify  the IRB or IEC of S[LOCATION_003]R reports as soon as 
is practical, where this is required b y local regulatory agencies, and in accordance with the local 
institutional policy . 
7.5. Clinical Laboratory Abnormalities and Other Abnormal Assessments as 
Adverse Events or Serious Adverse Events
Labo ratory  abnormalities are usuall y not recorded as AEs or SAEs. However, laboratory  
abnormalities (eg, clinical chemistry , hematology , and urinal ysis) independent of the 
underly ingmedical condition that require medical or surgical intervention or lead to 
investigational medicinal product interruption or discontinuation must be recorded as an AE, as 
well as an SAE, if applicable. In addition, laboratory  or other abnormal assessments 
(eg,electrocardiogram, X -rays, vital signs) that are associated with signs a nd/or sy mptoms must 
be recorded as an AE or SAE if they  meet the definition of an AE (or SAE) as described in 
Sections 7.1.[ADDRESS_580343] the 
syndrome or diagnosis (ie, anemia) not the laboratory  result (ie, decreased hemoglobin).
Filgotinib 
Protocol GS -US-417-[ADDRESS_580344] recent version of the Medical Dictionary  for 
Regulatory  Activities (MedDRA). Severity  should be recorded and graded according to the 
Common Terminology  Criteria for Adverse Events (CTCAE) Version 4.03, which can be 
found at:
http://www.hrc.govt.nz/sites/default/files/CTCAE%20manual%20 -%20DMCC.pdf
For AEs associated with laboratory  abnormalities, the event should be graded on the basis of the 
clinical severit y in the context of th e underly ing conditions; this may  or may not be in agreement 
with the grading of the laboratory  abnormality .
All clinical and clinically significant laboratory toxicities will be managed according to uniform 
guidelines detailed in Appendix 3and as outline d below.
7.5.1. Grades 1 and 2 Laboratory Abnormality or Clinical Event
Continue study  drug at the discretion of the investigator.
7.5.2. Grades 3 Laboratory Abnormality or Clinical Event
ï‚·For Grade [ADDRESS_580345].
ï‚·For a Grade [ADDRESS_580346] should be withheld until the toxicity  returns to â‰¤Grade 2.
If a laboratory  abnormality  recurs to â‰¥ Grade [ADDRESS_580347] may not require permanent discontinuation.
7.5.3. Grades 4 Laboratory Abnormality or Clinical Event
ï‚·For a Grade [ADDRESS_580348] may  be continued without dose interruption for a clinically  
non-significant Grade 4 laboratory  abnormality  (eg, Grade 4 CK after strenuous exercise or 
triglyceride elevation that is nonfasting or that can be medicall y managed) or a c linical event 
considered unrelated to investigational medicinal product.
Filgotinib 
Protocol GS -US-417-[ADDRESS_580349] labelling (as it applies to the daily  dose of the subject in 
question). In cases of a discrepancy  in drug accountability , overdose will be established only  
when it is clear that the subject has taken the excess dose(s). Overdose cannot be established 
when the subject cannot account for the discrepancy  except in cases in which the investigator has 
reason to suspect that the subject has taken the additional dose(s).
Product complaint is defined as complaints arising from potential deviations in the manufacture, 
packaging, or distributi on of the medicinal product.  
Occupational exposure is defined as exposure to a medicinal product as a result of one's 
professional or non- professional occupation.  
Filgotinib 
Protocol GS -US-417-0303 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 77 05 July [ZIP_CODE].7.2. Instructions for Reporting Special Situations
[IP_ADDRESS]. Instructions for Reporting Pregnancies
The investigator should report pregnancies in female study subjects that are identified after 
initiation of study  medication and throughout the study , including the post study  drug follow -up 
period, to [COMPANY_009] DSPH using the pregnancy  report form within 24 hours of becoming aware of 
the pregnancy . 
Refer to Section 7.3and the eCRF completion guidelines for full instructions on the mechanism 
of pregnancy  reporting.
The pregnancy  itself is not considered an AE nor is an induced elective abortion to terminate a 
pregnancy  without medical reasons.
Any premature termination of pregnancy  (eg, a spontaneous abortion, an induced therapeutic 
abortion due to complications or other medical reasons) must be reported within [ADDRESS_580350] information is as follows:
Email:  and Fax:  
Pregnancies of female partners of male stud y subjects exposed to stud y drugs must also be 
reported and relevant information should be submitted t o [COMPANY_009] DSPH using the pregnancy  and 
pregnancy  outcome forms within [ADDRESS_580351] should continue until the 
conclusion of the pregnancy . If the end of the pr egnancy  occurs after the study  has been 
completed, the outcome should be re ported directly  to [COMPANY_009] DSPH,
fax number  or email  
Refer to Appendix 5for Pregnancy  Precautions, Definition for Female of Childbearing Potential, 
and Contraceptive Requirements.
[IP_ADDRESS]. Reporting Other Special Situations
All other special situation reports must be reported on the special situations report form and 
forwarded to or [COMPANY_009] DSPH within [ADDRESS_580352] of situations that involve study  IMP and/or [COMPANY_009] 
concomitant medications, but do not apply  to non-[COMPANY_009] concomitant medications. 
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
Filgotinib 
Protocol GS -US-417-0303 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 78 05 July 2016Special situations involving non- [COMPANY_009] concomitant medications does not need to be reported on 
the special situations report form; however, for special situations that result in AEs due to a non -
[COMPANY_009] concomitant medication, the AE should be reported on the AE form. 
Any inappropriate use of concomitant medications prohibited by  [CONTACT_10857] â€œmisuse,â€ but may  be more appropriately  documented as a protocol deviation.
Refer to Section 7.3and the eCRF completion guidelines for full instructions o n the mechanism 
of special situations reporting.
All clinical sequelae in relation to these special situation reports will be reported as A Es or SAEs 
at the same time using the AE eCRF and/or the SAE report form. Details of the sy mptoms and 
signs, clinical management, and outcome will be reported, when available.
Filgotinib 
Protocol GS -US-417-0303 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 79 05 July [ZIP_CODE]. STATISTICAL  CONSIDER ATIONS
8.1. Analysis Objectives and Endpoint
8.1.1. Analysis Objectives
The primary  objective of this study  is as follows:
ï‚·To evaluate the effects of filgotinib in combination with MTX vers us MTX alone for the 
treatment of signs and s ymptoms of RA as measured by [CONTACT_454176]20 at Week 24
The secondary  objectives of this study  are as follows: 
ï‚·To evaluate the effect of filgotinib in combination with MTX versus MTX alone on ph ysical 
function as measured b y change from Baseline in the HAQ -DI score at Week 24 
ï‚·To evaluate the effects of filgotinib in combination with MTX versus MTX alone for the 
treatment of signs and s ymptoms of RA as measured by [CONTACT_454188] 28 joint count using CRP (DAS28 [CRP ])<2.6 at Week 24 
ï‚·To evaluate the effect of filgotinib alone versus MTX alone for the treatment of signs and 
symptoms of RA as measured by  [CONTACT_454178]20 at Week 24
ï‚·To evaluate the effect of filgotinib in dose of 200 mg  q.d. alone versus MTX alone on 
physical function as measured by  [CONTACT_454189]- DI score at Week 24 
ï‚·To evaluate the effect of filgotinib alone versus MTX alone for the tr eatment of signs and 
symptoms of RA as measured by  [CONTACT_454180]28 (CRP)<2.6 at 
Week 24
ï‚·To evaluate the effects of filgotinib in combination with MTX versus MTX alone on 
preservation of joint structure as measured b y change from Baseline in the mTSS at Week 24 
and 52
ï‚·To evaluate the effects of filgotinib versus MTX alone on preservation of joint structure as 
measured b y change from Baseline in mTSS at Week 24 and 52
ï‚·To evaluate the safet y and tolerability  of filgotinib alone and in combination with MTX 
ï‚·To evaluate the effects of filgotinib alone and in combination with MTX on work 
productivity , fatigue, and general quality  of life as measured b y SF-36, FACIT -Fatigue , 
EQ-5D and WPAI -RA
)LOJRWLQLE
3URWRFRO*686 )LQDO
*LOHDG6FLHQFHV,QF $PHQGPHQW
&21),'(17,$/ 3DJH  -XO\7KHH[SORUDWRU\REMHFWLYHVRIWKLVVWXG\DUHDVIROORZV


 3ULPDU\(QGSRLQW
7KHSULPDU\HQGSRLQWLVWKHSURSRUWLRQRIVXEMHFWVZKRDFKLHYH DQ$&5 UHVSRQVHDW:HHN
 6HFRQGDU\(QGSRLQWV
7KHNH\VHFRQGDU\HQGSRLQWVDUH
â€¢&KDQJHIURP%DVHOLQHLQWKH+$4',VFRUHDW:HHN
â€¢3URSRUWLRQRIVXEMHFWVZKRDFKLHYH'$6 â€¯&53DW:HHN
â€¢&KDQJH IURP%DVHOLQHLQWKHP766DW:HHN
2WKHUVHFRQGDU\HQGSRLQWVLQFOXGH
â€¢&KDQJH IURP%DVHOLQHLQWKHP766DW:HHN
â€¢7KHSURSRUWLRQRIVXEMHFWVZKRDFKLHYH$&5DQG$&5DW:HHNV â€¯4, 12, 24 and 52, 
$&5DW:HHNV â€¯4, 12, and 52, and ACR20/50/70 over time from 'D\ WKURXJK:HHN â€¯52
â€¢&KDQJHIURP%DVHOLQHLQLQGLYLGXDOFRPSRQHQWVRIWKH$&5UHVSRQV HDW:HHNV â€¯4, 1
DQGDQGRYHUWLPHIURP'D\WKURXJK:HHN â€¯52
â€¢7KHSURSRUWLRQRIVXEMHFWVZKRDFKLHYHFKDQJHLQ+$4',RIÂ• DW:HHNV â€¯4, 12, 24, and 
DQGRYHUWLPHIURP'D\ WKURXJK:HHN â€¯52
â€¢&KDQJHIURP%DVHOLQHLQ'$6 â€¯(CRP) at Weeks â€¯4, 12, 24, and 52, and over time from 
'D\ WKURXJK:HHN â€¯52
â€¢7KHSURSRUWLRQRIVXEMHFWVZKRDFKLHYH'$6 â€¯&53Â”DW:HHNV â€¯4, 12, 24, and 52, and 
RYHUWLPHIURP'D\ WKURXJK:HHN â€¯52
â€¢7KHSURSRUWLRQRIVXEMHFWVZKRDFKLHYH'$6 â€¯&53DW:HHNV â€¯4, 12, and 52, and over 
WLPHIURP'D\WKURXJK:HHN â€¯52&&,
)LOJRWLQLE
3URWRFRO*686 )LQDO
*LOHDG6FLHQFHV,QF $PHQGPHQW
&21),'(17,$/ 3DJH  -XO\â€¢$&51DQG(8/$5 UHVSRQVHDW:HHNV â€¯4, 12, 24, and 52, and over time from 'D\WKURXJK
:HHN
â€¢&KDQJHIURP%DVHOLQH LQ&'$,DW:HHNV â€¯4, 12,DQGDQGRYHUWLPHIURP 'D\
WKURXJK:HHN
â€¢&KDQJHIURP%DVHOLQH LQ6'$,DW:HHNV â€¯4,DQGDQGRYHUWLPHIURP'D\
WKURXJK:HHN
â€¢7KHSURSRUWLRQRIVXEMHFWVZKRKDG QR UDGLRJUDSKLFSURJUHVVLRQIUR P%DVHOLQHDW
:HHNâ€¯24DQG
â€¢$EVROXWHYDOXHDQGFKDQJHIURP%DVHOLQHLQ 6) )$&,7)DWLJXH DQG WKH(4'RYHU
WLPHDW:HHNV â€¯4, 12, 24 and 52, DQGRYHUWLPHIURP'D\WKURXJK:HHN â€¯52
â€¢$EVROXWHYDOXHDQGFKDQJHIURP%DVHOLQH LQ:3$,5$DW:HHNV â€¯4, 12,DQGDQG
RYHUWLPHIURP'D\ WKURXJK:HHN â€¯52
 $QDO\VLV&RQYHQWLRQV
 $QDO\VLV6HWV
 $OO5DQGRPL]HG
7KHDOOUDQGRPL]HGDQDO\VLVVHWLQFOXGHVDOOVXEMHFWVZKRDUHU DQGRPL]HGLQWKHVWXG\7KLVLVWKH
SULPDU\DQDO\VLVVHWIRUE\VXEMHFWOLVWLQJV
 (IILFDF\ )XOO$QDO\VLV6HW)$67KHSULPDU\DQDO\VLVVHWIRUHIILFDF\DQDO\VHVZLOOEHWKH)XOO $QDO\VLV6HW)$6ZKLFK
LQFOXGHVDOOUDQGRPL]HGVXEMHFWVZKRUHFHLYHGDWOHDVWRQHGRVH RIVWXG\GUXJ
 3HU3URWRFRO33$QDO\VLV6HW7KHVHFRQGDU\DQDO\VLVVHWIRUHIILFDF\DQDO\VHVZLOOEHWKH3H U3URWRFRO33$QDO\VLVVHW
ZKLFKLQFOXGHVDOOVXEMHFWVLQWKH)XOO$QDO\VLV 6HWZKRKDYHQR WFRPPLWWHGDQ\PDMRUSURWRFRO
YLRODWLRQLQFOXGLQJWKHYLRODWLRQRINH\ HQWU\FULWHULD
 6DIHW\7KHSULPDU\DQDO\VLVVHWIRUVDIHW\DQDO\VHVZLOOEHWKH6DIHW\ $QDO\VLV6HW ZKLFKLQFOXGHVDOO
VXEMHFWVZKRUHFHLYHGDWOHDVWRQHGRVHRI VWXG\GUXJ
)LOJRWLQLE
3URWRFRO*686 )LQDO
*LOHDG6FLHQFHV,QF $PHQGPHQW
&21),'(17,$/ 3DJH  -XO\ 3KDUPDFRNLQHWLF



 3KDUPDFRNLQHWLF3.$QDO\VLV6HW
7KHSULPDU\DQDO\VLVVHWIRUJHQHUDO3.DQDO\VHVZLOOEHWKH3. DQDO\VLVVHWZKLFKLQFOXGHVDOO
VXEMHFWVLQWKH6DIHW\$QDO\VLV6HWZKRKDYHDWOHDVWQRQPLVV LQJFRQFHQWUDWLRQGDWDIRU
ILOJRWLQLEDQGRULWVPHWDEROLWH*6
 'DWD+DQGOLQJ&RQYHQWLRQV
3.FRQFHQWUDWLRQYDOXHVDQG3.SDUDPHWHUYDOXHVEHORZWKHOLPLW RITXDQWLWDWLRQ%/4ZLOOEH
SUHVHQWHGDVÂ³%/4Â´LQWKHGDWDOLVWLQJV%/4YDOXHVWKDWRFFXU SULRUWRWKHILUVWGRVHZLOOEH
WUHDWHGDV%/4YDOXHVDWDOORWKHUWLPHSRLQWVZLOOEHWUHDW HGDVRIWKHORZHUOLPLWRI
TXDQWLWDWLRQ//24
/DERUDWRU\GDWDWKDWDUHFRQWLQXRXVLQQDWXUHEXWDUHOHVVWKDQ WKHORZHUOLPLWRITXDQWLWDWLRQRU
DERYHWKHXSSHUOLPLWRITXDQWLWDWLRQZLOOEHLPSXWHGWRWKHYD OXHRIWKHORZHURUXSSHUOLPLW
PLQXVRUSOXVRQHVLJQLILFDQWGLJLWUHVSHFWLYHO\HJLIWKHU HVXOWRIDFRQWLQXRXVODERUDWRU\WHVWLV
DYDOXHRIZLOOEHDVVLJQHGLIWKHUHVXOWRIDFRQWLQ XRXVODERUDWRU\WHVWLVDYDOXH
RIZLOOEHDVVLJQHG
 'HPRJUDSKLF'DWDDQG%DVHOLQH&KDUDFWHULVWLFV
'HPRJUDSKLFDQGEDVHOLQHFKDUDFWHULVWLFVZLOOEHVX[COMPANY_003]UL]HGE\ WUHDWPHQWJURXSXVLQJVWDQGDUG
GHVFULSWLYHVWDWLVWLFV LQFOXGLQJVDPSOHVL]HPHDQ6'PHGLDQ 44PLQLPXPDQGPD[LPXP
IRUFRQWLQXRXVYDULDEOHVDQGQXPEHUDQGSHUFHQWDJHVRIVXEMHFWV IRUFDWHJRULFDOYDULDEOHV
'HPRJUDSKLFGDWDZLOOLQFOXGHVH[UDFHHWKQLFLW\DQGDJH%DVHOLQHFKDUDFWHULVWLFVPD\LQFOXGHSULRUH[SRVXUHWR07;\HVQR 5)VWDWXVDQWL&&3 $E
VWDWXV'$6 &53+$4',P7666'$,&'$,DQGRWKHUYDULDEO HVRILQWHUHVW
 (IILFDF\$QDO\VLV
 3ULPDU\$QDO\VLV
7KHSULPDU\HQGSRLQWIRUWKHVWXG\LVWKHSURSRUWLRQRIVXEMHFWV ZKRDFKLHYHDQ $&5 UHVSRQVH
DW:HHNâ€¯24.7KHSULPDU\K\SRWKHVLVZLOOFRQVLVWRIDVXSHULRULW\WHVWRIILOJ RWLQLEPJLQ
FRPELQDWLRQZLWK07;FRPSDUHGWR07;DORQHEDVHGRQWKH$&5UHV SRQVHUDWH DW:HHN 
&RFKUDQ0DQWHO+DHQV]HO&0+DSSURDFKDGMXVWLQJIRUWKHUDQGRP L]DWLRQVWUDWLILFDWLRQIDFWRUV&&,
Filgotinib 
Protocol GS -US-417-[ADDRESS_580353] 
sufficient measurements to establish efficacy  at Week 24 will be c onsidered as failures 
(i.e.non-responder imputation [NRI ]).  Sensitivity  anal yses will be conducted and described in 
the statistical analy sis plan ( SAP).
8.5.2. Secondary Analyses
The following h ypothesis testing will commence after the primary  anal ysis reaches statistical 
significance, and will be tested according to the hierarchical testin g principle at the 2 -sided 
0.05 level. If a null h ypothesis is not rejected, formal sequential testing will be stopped and only  
nominal significance will be reported for the remaining h ypotheses.
1)Superiority  of filgotinib 200 mg in combination with MTX compared to MTX alone based on 
the change from Baseline in HAQ -DI at Week 24. 
2)Superiority  of filgotinib 200 mg in combination with MTX compared to MTX alone based on 
the response rate of DAS28 (CRP)<2.6 at Week 24.
3)Superiority  of filgotinib 100 mg in combination with MTX compared to MTX alone based on 
ACR20 response rate at Week 24. 
4)Superiority  of filgotinib 10 0 mg in combination with MTX compared to MTX alone based on 
the change from Baseline in HAQ -DI atWeek 24. 
5)Superiority  of filgotinib 100 mg in combination with MTX compared to MTX alone based on 
the response rate of DAS28 (CRP)<2.6 at Week 24.
6)Superiority  of filgotinib 200 mg alone compared to MTX alone based on ACR20 response 
rate at Week 24.
7)Superiority  of filgotinib 200 mg alone compared to MTX alone based on the change from 
Baseline in HAQ -DI to Week 24.
8)Superiority  of filgotinib 200 mg al one compared to MTX alone based on the response rate of 
DAS28 (CRP)<2.6 at Week 24.
9)Superiority  of filgotinib 200 mg in combination with MTX compared to MTX alone based on 
the change from Baseline in mTSS atWeek 24.
10)Superiority  of filgotinib 100 mg in combination with MTX compared to MTX alone based on 
the change from Baseline in mTSS atWeek 24.
11)Superiority  of filgotinib 200 mg alone compared to MTX alone based on the change from 
Baseline in mTSS atWeek24.
Filgotinib 
Protocol GS -US-417-0303 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 84 05 July 2016For categ orical endpoints ( the response rate of DAS28 [CRP]<2.6 ), the same CMH approach 
with NRI  as in the primary  anal ysis will be adopted.  For continuous endpoints (HAQ- DIand 
mTSS ), mixed- effects model for repeated measures (MMRM) will be used to evaluate treat ment 
effect on change from Baseline, with treatment, visit, stratification factors and baseline value 
included as fixed effects and subject being the random effect.  Missing change scores in HAQ -DI
and mTSS due to earl y withdrawal or treatment reassignment will not be otherwise imputed 
using the MMRM approach. Sensitivity  anal yses will be conducted b y imputing missing data 
via, for example, last observation carried forward (LOCF) and multiple imputation (MI) 
methods.  More details will be specified in the S AP.
For other secondary  endpoints listed under Section 8.1.3, summary  statistics will be provided by  
[CONTACT_1570]. Differences across treatment groups will be summarized and treatment 
comparisons may  be performed. 
Details on efficacy  analy ses will be described in the SAP. 
8.6. Safety Analysis
All safet y anal yses will be performed using the safety  anal ysis set.
Safety  will be evaluated by  [CONTACT_199618], phy sical examinations, vital 
signs measure ments at various time points during the study , and by  [CONTACT_123306].
All safet y data collected on or after the first dose of study drug administration up to [ADDRESS_580354]â€™s extent of exposure to study  drug will be generated from the study  drug 
administration page of the eCRF. Exposure data will be summarized by  [CONTACT_1570]. 
Duration of exposure to study  drug will be expressed as the number of weeks between the first 
and last dose of the stud y drug, inclusive, regardless of temporary interruptions in study  drug 
administration and summarized by  [CONTACT_1570]. 
8.6.2. Adverse Events
Clinical and laboratory  adverse events will be coded using the Medical Dictionary  for 
Regulatory  Activities (MedDRA). Sy stem Organ Class (SOC), High -Level Group Term 
(HLGT), High -Level Term (HL T), Preferred Term (PT), and Lower -Level Term (LLT) will be 
attached to the clinical database.
Treatment -Emergent Adverse Events (TEAEs) are:
ï‚·Any AEs with an onset date of on or after the study  drug start date and no later than 30 day s
after permanent discontinuation of study  drug or
ï‚·Any AEs leading to premature discontinuatio n of study  drug.
Filgotinib 
Protocol GS -US-417-0303 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 85 05 July 2016Summaries (number and percentage of subjects) of TEAEs b y SOC and PT will be provided by  
[CONTACT_1570]. TEAEs will also be summarized by  [CONTACT_454190] . In 
addition, TEAEs leading to premature discontinuation of study  drug will be summarized and 
listed .
8.6.3. Laboratory Evaluations
Selected laboratory  data will be summarized (n, mean, SD, median, Q1, Q3, minimum, and
maximum) by  [CONTACT_454191]. 
The incidence of treatment -emergent graded laboratory  abnormalities will be summarized 
similarly .
Graded laboratory  abnormalities will be defined using CTCAE 4.03 grading scale ( Appendix 4).
8.7.
Pharmacokinetic Analysis
Plasma concentrations of filgotinib and itsmetabolite ( GS-829845) will be listed and 
summarized for all subjects by  [CONTACT_53846] ( eg,sample size, arithmetic 
mean, geometric mean, % coefficient of variation, standard deviation, median, minimum, and 
maximum).
 
 
Exposure -response anal ysis may  be performed.
8.8.
Biomarker Analysis
Exploratory  anal yses may  be performed to evaluate the association of each biomarker or 
combination of biomarkers with clinical outcomes, the modulation of biomarkers related to 
mechanism of action and disease progression, and biomarker or combination of biomarkers 
predictive of treatment response.
Exploratory  biomarkers analy ses that may  enhance the understanding of the biological effects, 
the mechanism o f action, or safet y, ma y be performed. Biomarker objectives may be further 
described and updated based on evolving scientific knowledge of filgotinib. If an exploratory  
biomarker anal ysis is to be performed, biomarker anal ysis plan, with details on objecti ves and 
analysis methods, will be issued prior to the actual data anal ysis.
8.9. Sample Size
Sample size is determined based on the superiority test of filgotinib [ADDRESS_580355] deviation of 2.7, 
400 subjects in the filgotinib 200 mg in combination with MTX group and 400 in the MTX alone 
group are required to obtain 90% power at a 2- sided 0.05 -level.
CCI
Filgotinib 
Protocol GS -US-417-0303 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 86 05 July 2016The total sample size will be 1200 (400 subjects for filgotinib 200 mg in combination with MTX 
group , 200 subjects for filgotinib 100mg in combination with MTX , 200 subjects for filgotinib 
200mgalone group and 400 subjec ts for MTX alone group ).This sample size will provide over 
90% power to detect an increase in ACR20 response rate of 62% to 78% between the MTX 
alone group and each of the filgotinib groups respectivel y, using a [ADDRESS_580356] interests of the participants, whether the stud y should continue as planned, or 
the study  should continue with modifications. 
The initial reviews will be conducted after approximately 100 subjec ts enrolled complete 
12weeks treatment. The DMCâ€™s specific activities will be defined by a mutually agreed charter, 
which will define the DMCâ€™s membership, conduct and meeting schedule.
While the DMC will be asked to advise [COMPANY_009] regarding future conduct of the study , including 
possibl e earl y study termination, [COMPANY_009] retains final decision -making authority  on all aspects of 
the study .
8.11. Cardiovascular Endpoint Adjudication Committee
A Cardiovascular Endpoint Adjudication Committee (CV -SEAC) consisting of at least 
2cardiologists and gove rned by  a Charter will be set up to perform adjudication of Major 
Adverse Cardiovascular Events occurring during the study . The adjudication of these events will 
be performed in a blind edfashion for the purposes of data analy sis, and not for monitoring of
subject safet y. 
8.12. Analysis Schedule
The primary  and secondary  anal yses will be conducted after all subjects either complete their 
Week 24 visit or prematurely  discontinue from the study . The final anal ysis will be performed 
when all subjects complete the s tudy or prematurely  discontinue from the study .
Filgotinib 
Protocol GS -US-417-0303 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 87 05 July [ZIP_CODE]. RESPONSIBILITIES
9.1. Investigator Responsibilities
9.1.1. Good Clinical Practice
The investigator will ensure that this study  is conducted in accordance with the principles of the 
Declaration of Helsinki (as amended in Edinburgh, Toky o, Venice, Hong Kong, and 
South Africa), International Conference on Harmonisation (I CH) guidelines, or with the laws and 
regulations of the country in which the research is conducted, whichever affords the greater 
protection to the study su bject. These standards are consistent with the European Union Clinical 
Trials Directive 2001/20/EC and Good Clinical Practice Directive 2005/28/EC.
The investigator will ensure adherence to the basic principles of Good Clinical Practice, as 
outlined in 21 CFR 312, subpart D, â€œResponsibilities of Sponsors and Investigators,â€ [ADDRESS_580357] be provided prior to 
the investigatorâ€™s (and any  subinvestigatorâ€™s) participation in the study . The investigator and 
subinvestig ator agree to notify  [COMPANY_009] of an y change in reportable interests during the stud y and 
for [ADDRESS_580358] (IRB)/Independent Ethics Committee (IEC) 
Review and Approval
The investigator (or sponsor as appropriate according to local regulations) will submit this 
protocol, informed consent form, and an y accompanying material to be provided to the subject 
(such as advertisements, subject information sheets, or descriptions of the study  used to obtain 
informed consent) to an. The investigator will not begin any  study  subject activities until 
approval from IRB/IEC has been documented and provided as a letter to the investigator.
Before implementation, the investigator will submit to and receive documented approval from 
theIRB/IEC any modifications made to the protocol or any accompan ying material to be 
provided to the subject after initial IRB/IEC approval, w ith the exception of those necessary  to 
reduce immediate risk to study  subjects.
9.1.3. Informed Consent
The investigator is responsible for obtaining written informed consent from each individual 
participating in this study after adequate explanation of the aims , methods, objectives, and 
potential hazards of the study  and before undertaking an y stud y-related procedures. The 
investigator must use the most current IRB/IEC â€“approved consent form for documenting written 
Filgotinib 
Protocol GS -US-417-0303 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 88 05 July 2016informed consent. Each informed consent (or ass ent as applicable) will be appropriatel y signed 
and dated b y the subject and the person conducting the consent discussion, and also b y an 
impartial witness if required b y local requirements. The consent form will inform subjects about 
genomic testing and s ample retention, and their right to receive clinically  relevant genomic 
analysis results.
9.1.4. Confidentiality
The investigator must assure that subjectsâ€™ anon ymity  will be strictly  maintained and that their 
identities are protected from unauthorized parties. O nly subject initials, date of birth, another 
unique identifier (as allowed b y local law) and an identification code will be recorded on any  
form or biological sample submitted to the Sponsor, IRB/IEC ,or laboratory . Laboratory  
specimens must be labeled in such a way  as to protect subject identity  while allowing the results 
to be recorded to the proper subject. Refer to specific laboratory  instructions. NOTE: The 
investigator must keep a screening log s howing codes, names, and addresses for all subjects 
screened and for all subjects enrolled in the trial. Subject data will be processed in accordance 
with all applicable regulations. 
The investigator agrees that all information received from [COMPANY_009], including but not limited to the 
investigator brochure, this protocol, eCRF, the study  drug , and any  other study  information, 
remain the sole and exclusive propert y of [COMPANY_009] during the conduct of the study and thereafter. 
This information is not to be disclose d to an y third party (except emplo yees or agents directly  
involved in the conduct of the study  or as required by  [CONTACT_2371]) without prior written consent from 
[COMPANY_009]. The investigator further agrees to take all reasonable precautions to prevent the 
disclosure b yany employee or agent of the stud y site to any  third party  or otherwise into the 
public domain.
9.1.5.
Study Files and Retention of Records
The investigator must maintain adequate and accurate records to enable the conduct of the stud y 
to be fully  documented and the study  data to be subsequently  verified. These documents should 
be classified into at least the following two categories: (1) investigatorâ€™s study  file, and 
(2)subject clinical source documents.
The investigatorâ€™s stud y file will contain the protocol/ amendments, CRF and query  forms, 
IRB/IEC and governmental approval with correspondence, informed consent, drug records, staff 
curriculum vitae and authorization forms, and other appropriate documents and correspondence.
The required source data should include sequential notes containing at least the following 
information for each subject:
ï‚·Subject identification (name, date of birth, gender);
ï‚·Documentation that subject meets eligibility  criteria, i .e., history , phy sical examination, and 
confirmation of diagn osis (to support inclusion and exclusion criteria);
Filgotinib 
Protocol GS -US-417-0303 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 89 05 July 2016ï‚·Documentation of the reason(s) a consented subject is not enrolled
ï‚·Participation in study  (including study  number);
ï‚·Study  discussed and date of informed consent;
ï‚·Dates of all visits;
ï‚·Documentation that pr otocol specific procedures were performed;
ï‚·Results of efficacy  parameters, as required b y the protocol;
ï‚·Start and end date (including dose regimen) of IMP, including dates of dispensing and return;
ï‚·Record of all adverse events and other safety  parameters ( start and end date, and including 
causality  and severity );
ï‚·Concomitant medication (including start and end date, dose if relevant; dose changes);
ï‚·Date of stud y completion and reason for earl y discontinuation, if it occurs.
All clinical study documents must be retained b y the investigator until at least [ADDRESS_580359] approval of a marketing application in 
an ICH region (i .e., [LOCATION_002], Europe, or Japan) and until there are no pending or planned 
m
arketing applications in an I CH region; or, if no application is filed or if the application is not 
approved for such indication, until [ADDRESS_580360] been received.  Subsequent to data entry , a study  monito r will perform source 
Filgotinib 
Protocol GS -US-417-0303 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 90 05 July 2016data verification within the EDC system. Original entries as well as any  changes to data fields 
will be stored in the audit trail of the sy stem.  Prior to database lock (or any  interim time points 
as described in the clinical data management plan), the investigator will use his/her log in 
credentials to confirm that the forms have been reviewed, and that the entries accuratel y reflect 
the information in the source documents. The eCRF captures the data required per the protocol 
schedu le of events and procedures. System -generated or manual queries will be issued to the 
investigative site staff as data discrepancies are identified by  [CONTACT_110105], 
who routinely  review the data for completeness, correctness, and c onsistency . The site 
coordinator is responsible for responding to the queries in a timel y manner, within the system, 
either b y confirming the data as correct or updating the original entry, and providing the reason 
for the update (e .g.,data entry  error). At the conclusion of the trial, [COMPANY_009] will provide the site 
with a read -only archive copy  of the data entered by  [CONTACT_10867]. This archive must be stored in 
accordance with the records retention requirements outlined in Section 9.1.[ADDRESS_580361] Accountability and Return
Where possible, IMP should be destro yed at the site. At the start of the study, the stud y monitor 
will evaluate each stud y centerâ€™s IMP disposal procedures and provide appropriate instruction for 
disposal or return of unused IMP supplies. If the site has an appropriate standard operating 
procedure (SOP) for drug destruction as determined by  [CONTACT_10869], the site may  destroy  
used (empt y or partially empty) and unused IMP supplies as long as performed in accordance
with the siteâ€™s SOP. This can occur onl y after the study  monitor has performed drug 
accountability  during an on -site monitoring visit. 
A cop y of the siteâ€™s IMP Disposal SOP or written procedure (signed and dated by  [CONTACT_978] 
[INVESTIGATOR_204944]) will be obtained fo r [COMPANY_009] site files. If the site does not have acceptable 
procedures in place, arrangements will be made between the site and [COMPANY_009] Sciences 
(or[COMPANY_009] Sciencesâ€™ representative) for return of unused study  drug supplies. 
If IMP is destro yed on site, the i nvestigator must maintain accurate records for all IMPs 
destroy ed. Upon study  completion, copi[INVESTIGATOR_279372]. Another cop y will be returned to [COMPANY_009].
The study  monitor will review IMP supplies and associated records at periodic intervals.
9.1.8. Inspections
The investigator will make available all source documents and other records for this trial to 
[COMPANY_009]â€™s appointed stud y monitors, to IRB/IEC , or to regulatory  authorit y or health authorit y 
inspectors.
9.1.9. Protocol Com pliance
The investigator is responsible for ensuring the study  is conducted in accordance with the 
procedures and evaluations described in this protocol.
Filgotinib 
Protocol GS -US-417-[ADDRESS_580362] submit all protocol modifications to the IRB/IEC in 
accordance with local requirements and receive documented IRB/ IEC approval before 
modifications can be implemented.
9.2.2. Study Report and Publications
A clinical study  report (CSR) will be prepared and provided to the regulatory  agency . [COMPANY_009] will 
ensure that the report meets the standards set out in the I CH Guideline for Structure and Content 
of Clinical Study  Reports (I CHE3). Note that an abbreviated report may  be prepared in certain 
cases. 
Investigators in this study  may  communicate, orally  present, or publish in scientific journals or 
other scholarl y media only after the following conditions have been met:
the results of the study  in their entiret y have been publicly disclosed b y or with the consent of 
[COMPANY_009] in an abstract, manuscript, or presentation form or the stud y has been completed at all 
study  sites for at least [ADDRESS_580363] 30 day s before submission of the 
publication or presentation. 
No such communication, presentation, or publication will include [COMPANY_009]â€™s confide ntial 
information (see Section 9.1.4).
The investigator will comply  with [COMPANY_009]â€™s request to delete references to its confidential 
information (other than the study  results) in any  paper or presentation and agrees to withhold 
publication or presentation for an additional 60 days in order to obtain patent protection if 
deemed necessary .
9.3. Joint Investigator/Sponsor Responsibilities
9.3.1.
Payment Reporting
Investigators and their study  staff may  be asked to provide services performed under this 
protocol, e .g.,attend ance at I nvestigator â€™s Meetings.  If required under the applicable statutory  
and regulatory  requirements, [COMPANY_009] will capture and disclose to Federal and State agencies any  
expenses paid or reimbursed for such services, including an y clinical trial payments, meal, travel 
expenses or reimbursements, consulting fees, and any  other transfer of value.
Filgotinib 
Protocol GS -US-417-[ADDRESS_580364] access to the 
investigatorâ€™s source documentation in order to verify  the accuracy  of the data recorded in the 
eCRF.
The monitor is responsible for routine review of the eCRF at regular intervals throughout the 
study  to verify  adherence to the protocol and the completeness, consistency, and a ccuracy  of the 
data being entered on them. The monitor should have access to an y subject records needed to 
verify  the entries on the eCRF. The investigator agrees to cooperate with the monitor to ensure 
that any  problems detected through any  type of monitoring (central, on site) are resolved.
9.3.3. Access to Information for Auditing or Inspections
Representatives of regulatory  authorities or of [COMPANY_009] may  conduct inspections or audits of the 
clinical study . If the investigator is notified of an inspection by  a regulatory authority  the 
investigator agrees to notify  the [COMPANY_009] medical monitor immediately . The investigator agrees to 
provide to representatives of a regulatory  agency  or [COMPANY_009] access to records, facilities, and 
personnel for the effective conduct of any inspection or audit.
9.3.4. Study Discontinuation
Both the sponsor and the investigator reserve the right to terminate the stud y at an y time. Should 
this be necessary , both parties will arrange discontinuation procedures and notify  the appropriate 
regulatory  authorit y(ies), I RBs, and IECs. In terminating the study , [COMPANY_009] and the investigator 
will assure that adequate consideration is given to the protection of the subjectsâ€™ interests
Filgotinib 
Protocol GS -US-417-[ADDRESS_580365], et al. 2010 
Rheumatoid arthritis classification criteria: an American College of 
Rheumatology /European L eague Against Rheumatism collaborative initiative. 
Arthritis Rheum 2010;62 (9):2569-81.
Cockcroft DW, Gault MH. Prediction of cr
eatinine clearance from serum creatinine. Nephron 
1976;16:31-41.
Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College 
of Rheumatology . Preliminary  definition of improvement in rheumatoid arthritis. 
Arthritis Rheum 1995;38 (6):727-35.
Helmick CG, Felson DT, L awrence RC, Gabriel S, Hirsch R, Kwoh CK, et al. Estimates of the 
prevalence of arthritis and other rheumatic conditions in the [LOCATION_002]. Part I . 
Arthritis Rheum 2008;58 (1):15-25.
Lopez -Olivo MA, Siddhanamath
a HR, Shea B, Tugwell P, Wells GA, Suarez -Almazor ME. 
Methotrexate for treating rheumatoid arthritis. Cochrane Database S yst Rev 
2014;6:CD000957.
Namour F, Diderichsen PM, Cox E, Vay ssiere B, Van der Aa A, Tasset C, et al. 
Pharmacokinetics and Pharmacokine tic/Pharmacody namic Modeling of Filgotinib 
(GLPG0634), a Selective JAK1 I nhibitor, in Support of Phase IIB Dose Selection. 
Clin Pharmacokinet 2015;54 (8):859-74.
Prevoo ML , van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL . 
Modified dis ease activity scores that include twenty -eight -joint counts. 
Development and validation in a prospective longitudinal study  of patients with 
rheumatoid arthritis. Arthritis Rheum 1995;38 (1):44-8.
Redlich K, Schett G, Steiner G, Hay er S, Wagner EF, Smolen JS. Rheumatoid arthritis therap y 
after tumor necrosis factor and interleukin -1 blockade. Arthritis Rheum 2003;48 
(12):3308-19.
Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 
2008 American College of Rheumatology recommendations for the use of 
disease -modify ing antirheumatic drugs and biologic agents in the treatment of 
rheumatoid arthritis. Arthritis care & research 2012;64 (5):625-39.
The EuroQol Group. EuroQol --a new facility  for the measurement of health- related quality  of 
life. . Health Policy  1990;16 (3):199-208.
Filgotinib 
Protocol GS -US-417-0303 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 94 05 July 2016Zhang W, Bansback N, Boonen A, Young A, Singh A, Anis AH. Validity  of the work 
productivity  and activity  impairment questionnaire --general health version in 
patients with rheumatoid arthritis. Arthri tis research & therap y 2010;12 (5):R177.
Filgotinib 
Protocol GS -US-417-0303 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 95 05 July 201611. APPENDICES
Appendix 1. Investigator Signature [CONTACT_10882] 2. Study Procedures Table
Appendix 3. Management of Clinical and Laboratory Adverse Events
Appendix 4. Common Terminology Criteria for Adverse Events (CTCAE) v4.[ADDRESS_580366] of Joints to be Evaluated (66/68 Joint Count)
Appendix 8. The 2010 American College of Rheumatology â€“European League Against 
Rheumatism Collaborative Initiative Classification Criteria for Rheumatoid 
Arthritis {Aletaha et al 2010}
Appendix 9. American College of Rheum atology  Response Evaluations/ Preliminary Definition 
of Improvement in Rheumatoid Arthritis {Felson et al 1995}
Appendix 10. Disease Activity Score (DAS28) {Prevoo et al 1995}
Appendix 11. Procedures and Specifications
[COMPANY_003]
[COMPANY_003]Filgotinib 
Protocol GS-US-417-[ADDRESS_580367] 
FOSTER CITY, CA [ZIP_CODE] 
STUDY ACKNOWLEDGEMENT 
A Randomized, Doub1e-blin~, Placebo- and Active-controlled, Multicenter, Phase 3 Study to 
Assess the Efficacy and Safety of Filgotinib Administered for 52 Weeks Alone and in 
Combination with Methotrexate (MTX) to Subjects with Moderately to Severely Active 
Rheumatoid Arthritis Who Are Na1ve to MTX Therapy 
GS-US-417-0303, Amendment 1 Protocol, 05 July 2016 
This protocol has been approved by [CONTACT_10869], Inc. The following signature [CONTACT_10883]. 
Name (Printed) 
Author 
) d-O Ill 
Date UJ 
INVESTIGATOR ST A TEMENT 
I have read the protocol, including all appendices, and I agree that it contains all necessary 
details for me and my staff to conduct this study as described . I will conduct this study as 
outlined herein and will make a reasonable effort to complete the study within the time 
designated. 
I will provide all study personnel under my supervision copi[INVESTIGATOR_10805], Inc. I will discuss this material with them to ensure 
that they are fully informed about the drugs and the study. 
Principal Investigator [CONTACT_5627] (Printed) Signature 
[CONTACT_454194] 96 05 July 2016 
Filgotinib 
Protoco l GS-US-417 -030 3 Fina l 
[COMPANY_009] Sciences Inc. Amendment 1 
Appendix 2. Study Procedures Table 
EVENT T1Â·eatment Pe1iod Follow-Up4 
Post 
W52 / T1Â·eatmeot 
Visits Day lb W2 W4 W8 W12 W16 W20 W24 W30 W36 W44 ET' Week4 
(Â±3 (Â±3 (Â±3 (Â±3 (Â±3 (Â±3 (Â±3 (Â±7 (Â±7 (Â±7 (Â±7 
Visit window (Days) Screening" days) days) days) days) days) days) days) days) days) days) days) (Â±7 days) 
Infonm:d Consent X 
Inclusion/Exclusion Criteria X X" 
,,, -Demographics and Baseline = X Disease Characteri stics E ,,, 
f!s RA diagnosis and Prior RA ,.,, ,,, X < Treatment , Me.dical History f 
!:IJ) = Â· = Complete Physical Examination g X X X 
i.. 
rJ5 
TB test and Chest X-Ray h X 
RF/anti-CCP Ab X 
CONFIDENTIAL Page 97 05 July 2016 
CCII 
I 
I Filgotinib 
Protoco l GS-US-417 -030 3 
[COMPANY_009] Sciences Inc. 
EVENT 
Visits 
Visit window (Days) 
Subject 's global assessment i 
,,, 
I-
HAQ-DI and Pain Scale i Â·; = = = .: FACIT -Fatigue , SF-36, WPAI-"-' 
RAEQ -5D1 = 0 ... = Healthcare Resource Utilization 
Questionnaire and TSQM i e,: 
=--
Physician 's global assessment 
I-
Vital sigusi -~ = I-
Q., ,,, Symptom -driven physical -= examination = e,: E e e,: 12-LeadECG io< ,,, 
::: < = u SJC66 /TJC68 ";j ..... -= Q., 
Weight 
CONFIDENTIAL T1Â·eatment Period 
Day lb W2 W4 ws W12 W16 W20 
(Â±3 (Â±3 (Â±3 (Â±3 (Â±3 (Â±3 
Screening" days) days) days) days) days) days) 
X X X X X X X X 
X X X X X X X X 
X X X 
X X W24 W30 W36 
(Â±3 (Â±7 (Â±7 
days) days) days) 
X X X 
X X X 
X X 
X X W44 
(Â±7 
days) 
X 
X Fina l 
Amendment [ADDRESS_580368] 
W52 / T.-eatment 
ET< Week4 
(Â±7 
days) (Â±7 days) 
X 
X 
X 
X 
------------------------------------------
X X X X X X X X X X X X X 
X X X X X X X X X X X X X X 
X X X X X X X X X X X 
X X X X X X 
X X X X X X X X X X X X X 
X X X X X X X X X X X X X X 
Page 98 05 July 2016 
CCIFilgotinib 
Protocol GS-US-41 7-0303 Final 
[COMPANY_009] Sciences Inc. Amendment 1 
EVENT T1Â·eatment Period Follow -Upd 
Post 
W52 / T.-eatment 
Visits Day lb W2 W4 ws W12 W16 W20 W24 W30 W36 W44 ET< Week4 
(Â±3 (Â±3 (Â±3 (Â±3 (Â±3 (Â±3 (Â±3 (Â±7 (Â±7 (Â±7 (Â±7 
Visit window (Days) Screening" days) days) days) days) days) days) days) days) days) days) days) (Â±7 days) 
Pregnancy test k X X X X X X X X X X X X X X 
Hematology and Chemistty 1 X X X X X X X X X X X X X X 
SenunCRP X X X X X X X X X X X X X 
Urinalysi s and urine for X X X X X X biomarkers m 
Quantitative IG X X X 
= Endocrine : FSH , TSH , and X E HbAlc 
"' rr, 
Lipid profile (fasting) 1 X X X X r.r, < 
C' 
0 ... 
'-0 ,Q PK blood sample s 0 X X X X 
.J 
Biomarker Blood Sample s: 
Plasma biomarker, semm X X X X X X X biomarker, trauscriptome , 
TCRIBCR repertoire P 
vfpBMC and Leukocy te subset q X X X X X X X 
Serology X' 
Viral Monitoring â€¢ X X X X 
CONFIDENTIAL Page 99 05 July 2016 
CCIFilgotinib 
Protocol GS-US-417 -030 3 
[COMPANY_009] Sciences Inc. 
EVENT 
Visits 
Visit window (Days) 
Assessment of Adverse Events 
Concomitant Medications 
Randomization /reassignment 
Study Dmgs Dispensation x 
Review entry criteria for LTE (if 
applicable) 
Footnotes Screening" 
X 
X Day lb W2 W4 
(Â±3 (Â±3 
days) days) 
X X X 
X X X 
X 
X X T1Â·eatment Period 
ws W12 W16 W20 
(Â±3 (Â±3 (Â±3 (Â±3 
days) days) days) days) 
X X X X 
X X X X 
X X X X W24 W30 W36 
(Â±3 (Â±7 (Â±7 
days) days) days) 
X X X 
X X X 
X X X W44 
(Â±7 
days) 
X X 
X"' 
X Final 
Amendment [ADDRESS_580369] 
W52 / T.-eatment 
ET< Week4 
(Â±7 
days) (Â±7 days) 
X X 
X X 
X 
a Screening Â·window is [ADDRESS_580370] discontinues before Week 52 
d The follow-up visit will be performed only for subje.cts discontinuing preniaturely from the study and for those completing Week 52 but not entering the LTE. 
e Eligibility criteria check based on the laborat01y results from the Screening visit, TJC/SJC at screening and Day I and for female subjects of childbe aring potential , the urine 
pregnancy test at Day I . 
f Medical History includes smoking status , average weekly alcohol consumption , family history of corona1y heart disease and any other chronic medical conditions or prior 
surgenes 
g At Screening , Week 24 and Week 52 (or at ET), a complete physical should be performed. Symptom driven exams should be pe1fom1ed at all other visits. Height will be 
measured at Screening only . 
h Chest X-ray for TB assessment should be pe1fonned unless pe1fonned in the previous [ADDRESS_580371] at each visit prior to any other visit-related procedures ( other than signing of infonned consent) , as much as 
possible. Questionnaire translations will be provided to subjects when and where availab le. 
J Vital signs are defined as heart rate, respi[INVESTIGATOR_20325]01y rate, blood pressure (systolic and diastolic) and body temperature. 
CONFIDENTIAL Page [ADDRESS_580372] provided in Laboratory assessment table ( Appendix 6).
m Urine samples for biomarker analysis should be collected at Day [ADDRESS_580373] study drug dose in the clinic. P K samples at Week 12 and Week 24 should be collected prior to study 
drug dose (within 2 hours prior to dosing) . The PK sample at Week 52 or ET can be collected at any time during the visit.  
 
 
p Details of biomarker collection are outlined in lab manual
q Only for subjects in [LOCATION_002] and Canada
r Hepatitis B surface Ag and core Ab, reflex Hep B DNA, Hepatitis C Ab, reflex HCV RNA, HIV 1 and 2 at Screening.
s Viral monitoring for HBV or HCV as applicable (see Exclusion criteria, Section 4.3).
t Radiographs perform ed after enrollment may be done +/ - 7days of the scheduled visit. If subject discontinues study early and has had x -rays in the <[ADDRESS_580374] a 20% improvement from Day [ADDRESS_580375] a 20% improvement from Day 1 in TJC and SJC (confirmed at 2 consecutive visits )will discontinue study drugs, but will conti nue with 
study visits and assessments
x Dispensation of study drugs according to IWRS manual .
CCI
CCI
CCII 
I 
Filgotinib 
Protocol GS -US-417-0303 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 102 05July 2016Appendix 3. Management of Clinical and Laboratory Adverse Events 
Grade 1 
~--G-r-ad_e_2_-~ I .... I ___ G _r _ a-de_3_-~ I .... I ____ G _ r _ a_ d_ e _ 4 ___ ___, 
May continue Repeat lab to 
dosing at the confirm toxicity 
discretion of the grade 
investigator 
" 
If confirmed and possibly and/or probably related to 
investigational medicinal products: 
1. Withhold investigational medicinal products until 
!S: Grade 2 
2. Restart all investiirntional medicinal oroducts at full dose 
l 
If Grade 3 or 4 recurrence that is confirmed and possibly or 
probably related to investigational medicinal products, 
discontinue all investigational medicinal products dosing 
oermanentlv l Repeat lab to 
confirm toxicity 
grade 
l If confirmed and 
possibl y or probably 
Ifc onfirmed and unrelated to 
estigational medicinal ---+ related to 
investigational 
medicinal products , 
discontinue 
investiga tional 
medicinal products 
dosing permanently 
and follow at 
periodic intervals at 
least weekl y until a 
return to baseline or 
is otherwise 
explained inv 
pro 
the ducts, dosing may continue at 
discretion of the investigator 
If Grade 3 or 4 recurrence that is considered unrelated to 
investigational medicinal products , continue all 
investigational medicinal products at the same dose at the 
discretion of the investigator 
Filgotinib 
Protocol GS -US-417-0303 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 103 05 July 2016Appendix 4. Common Terminology Criteria for Adverse Events (CTCAE) v4.03
CTCAE v4.03 can be accessed from the below link:
http://www.hrc.govt.nz/sites/def ault/files/CTCAE%20manual%20 -%20DMCC.pdf
The only  modification to the CTCAE criteria is the addition of a Grade 1 upper respi[INVESTIGATOR_204946]:
CTCAE 
v4.0 Term Grade 1
Grade 2 Grade 3 Grade 4 Grade 5CTCAE v4.03 
AE Ter m 
Definition
Upper 
respi[INVESTIGATOR_204947]; 
symptomatic 
relief (eg, 
cough 
suppressant, 
decongestant)Moderate 
symptoms; 
oral 
intervention 
indicated 
(eg,antibiotic, 
antifungal, 
antiviral)IV antibiotic, 
antifungal, or 
antiviral 
intervention 
indicated; 
radiologic,
endoscopic, or 
operative 
intervention 
indicatedLife-
threatening 
consequences; 
urgent 
intervention 
indicatedDeathA disorder 
characterized by 
[CONTACT_204985][INVESTIGATOR_4352] 
(nose, paranasal 
sinuses, pharynx, 
larynx, or 
trache a).
Filgotinib 
Protocol GS -US-417-[ADDRESS_580376] agree to the use of 
highly effective contraception as outlined below.
1)Definitions
a)Definition of Childbearing Potential
For the purposes of this study , a female
-born subject is considered of childbearing potential 
following the initiation of pubert y (Tanner stage 2) until becoming post -menopausal, unless 
permanentl y sterile o r with medically  documented ovarian failure.  
Women are considered to be in a postmenopausal state when they  are > 54 years of age with 
cessation of previously  occurring menses for > 12 months without an alternative cause. In 
addition, women of an y age wi th amenorrhea >12 months may  also be considered 
postmenopausal if their FSH level is in the postmenopausal range at Screening and they  are not 
using hormonal contraception or hormonal replacement therap y.   `
Permanent sterilization includes hy sterectomy ,bilateral oophorectom y, or bilateral 
salpi[INVESTIGATOR_90254] a female subject of an y age.
b)Definition of Male Fertility
For the purposes of this study , a male -born subject is considered fertile after the initiation of 
puberty  unless permanently  sterile b y bilater alorchidectomy  or has medical documentation of 
permanent male infertility.
2)Contraception for Female Subjects
a)Study Drug Effects on Pregnancy and Hormonal Contraception
Filgotinib is contraindicated in pregnancy as there is a possibility  of human 
teratogenicit y/fetotoxicity  in earl y pregnancy based on non- clinical data. A dedicated stud y 
assessing the impact of filgotinib on the efficacy  of hormonally -based contraceptives
(with ovulation inhibition as mechanism of action) has not y et been performed to fully  verify  the 
absence of an y clinically  significant interaction between filgotinib and oral contraceptives.  
Filgotinib 
Protocol GS -US-417-[ADDRESS_580377] the pharmacokinetics of midazolam (a prototy pi[INVESTIGATOR_204948]3A4 substrate). 
Additionally , clinicall y relevant inhibition of CYPs or UGTs during filgotinib treatment is 
unlikely , based on in vitro data.
Based on the totality  of the in vitro and clinical data, clinically  relevant drug interactions 
between filgotinib or GS -829845 with hormonal contr aceptives are not expected. For female 
subjects, hormonal contraceptives will be permitted as a form of contraception when used in 
conjunction with a barrier method (preferably male condom) . For male subjects, male condom 
should be used; for their female p artners of childbearing potential
,an accepted contraceptive 
method should also be considered . Details are outlined below.
Please refer to the latest version of the filgotinib investigatorâ€™s brochure for additional 
information.
b)Contraception for Female Sub jects of Childbearing Potential
The inclusion of female subjects of childbearing potential requires the use of highl y effective 
contraceptive measures.  Women must have a negative serum pregnancy  test at Screening and a 
negative urine pregnancy test on the Baseline/Day 1 visit prior to randomization.  Pregnancy  
tests will be performed at monthly  intervals thereafter.  In the event of a delay ed menstrual 
period ( >one month between menstruations), a pregnancy  test must be performed to rule out 
pregnancy .  This is true even for women of childbearing potential with infrequent or irregular 
periods. Female subjects must agree to use one of the following methods from Screening until 
35days following the last dose of study  drug . 
ï‚·Complete abstinence from intercour se of reproductive potential.  Abstinence is an acceptable 
method of contraception only  when it is in line with the subjectâ€™s preferred and usual 
lifesty le.
Or
ï‚·Consistent and correct use of 1 of the following methods of birth control listed below. 
ï‚¾Intrauterine device (IUD) with a failure rate of <1% per year
ï‚¾Tubal sterilization
ï‚¾Essure micro
-insert sy stem (provided confirmation of success 3 months after procedure)
Filgotinib 
Protocol GS -US-417-0303 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 106 05 July 2016ï‚¾Vasectom y in the male partner (provided that the partner is the sole sexual partner and
had confirmation of surgical success at least 3 months after procedure , with 
documentation of sperm- free ejaculate )
These above described methods are considered preferred methods of highly  effective 
contraception in this protocol.
Female subjects who wish to use a hormonall y based method must agree to useitin conjunction 
with a barrier method (used either b y the female subject or b y her male partner) .  Female subjects 
who utilize a hormonal contraceptive as one of their birth control methods must have
consistently used the same method for at least three months prior to study  dosing .
Hormonally -based contraceptives and barrier methods permitted for use in this protocol are as 
follows:
ï‚·Hormonal methods ( subject must agree to use with a 
barrier method, pr eferably , with a male 
condom )
ï‚¾Oral contraceptives (either combined estrogen/progestin or progesterone only )
ï‚¾Injectable progesterone
ï‚¾Implants of levonorgestrel
ï‚¾Transdermal contraceptive patch
ï‚¾Contraceptive vaginal ring
ï‚·Barrier methods (subject must agree to use with a hormonal method)
ï‚¾Male or female condom, with or without spermicide
ï‚¾Diaphragm with spermicide
ï‚¾Cervical cap with spermicide
ï‚¾Sponge with spermicide
All female subjects must also agree to refrain from egg donation and in vitro fertilization during 
study  participation and for at least [ADDRESS_580378] study  drug dose .
3) Contraception for Male Subjects
It is theoreticall y possible that a relevant s ystemic concentration may  be achieved in a female 
partner from exposure to the male subjectâ€™s seminal fluid.  Therefore, male subjects with female 
partners of childbearing potential must agree to use condoms during study  participation and for 
[ADDRESS_580379] 90 days after the end of dosing.
Filgotinib 
Protocol GS -US-417-0303 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 107 05 July [ZIP_CODE]) Unacceptable Birth Control Methods
Birth control methods that are unacceptable include periodic abstinence (e,g, calendar, ovulation, 
symptothermal, post-ovulation methods), withdrawal (coitus interruptus), spermicides onl y, and 
lactational amenorrhea method (LAM).  Female condom and male condom should not be used 
together.
5)Procedures to be Followed in the Event of Pregnancy
Subjects will be instructed to notify  the investigator if they  become pregnant at any  time during 
the study , or if they  become pregnant within 35days of last study  drug dose.  Subjects who 
become pregnant or who suspect that they  are pregnant during the stud y must report the 
information to the investigator and discontinue study  drug immediatel y. Subjects whose partner 
has become pregnant or suspects she is pregnant during the stud y are to report the information to 
the investigator.
Instructions for reporting pregnancy , partner pregnancy , and pregnancy  outcome are outlined in 
Section [IP_ADDRESS].
Pregnancy Testing 
All females of childbearing potential will have urine pregnancy  testing every  [ADDRESS_580380].
Filgotinib 
Protocol GS -US-417-0303 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 108 05 July 2016Appendix 6. Laboratory Assessment Table
Hem atology Chemistry Urinalysis Other
Hem atocrit
Hem oglobin
Platelet count
Red blood cell (RBC) 
count
Red blood cell indices
White blood cell (WBC) 
count
Differentials (absolute 
and percentage), 
including:
Leukocytes
Monocytes
Neutrophils
Eosinophils
Basophils
Mean corpuscular 
volume (MCV)Alkaline phosphatase
Aspartate aminotransferase 
(AST)
Alanine aminotransferase 
(ALT)
Gamma -glutamyl 
transpeptidase (GGT)
Total bilirubin
Direct and indirect 
bilirubin
Total protein
Albumin
Bicarbonate
Blood urea nitrogen 
(BUN)
Calcium
Chloride
CPK
Serum cr eatinine
Glucose
Phosphorus
Magnesium
Potassium
Sodium
Amylase
Lipase
Uric Acid (screening)
Lipid profile (fasting) : 
Triglycerides
Cholesterol and its 
subfractions (high -density 
lipoprotein [HDL] and 
low-density lipoprotein 
[LDL])Appearance
Blood
Color
Glucose
Leukocyte esterase
Nitrites
pH
Protein
Specific gravity
Urobilinogen
Reflex to microscopic 
urinalysis if dipstick result 
is abnormal.Urine drug screen for:
Amphetamines
Cocaine
Methadone
Opi[INVESTIGATOR_454163]*
Leucocyte subsets*
C-reactive protein (hsCRP )
Rheumatoid factor and anti-
cyclic citrullinated peptide 
(RF/ Anti-CCP)
QuantiFERON -TB GOLD 
Quant itative Ig subclasses at 
Screening, W eek 24 and Week 
52
Endocrine (At 
Screening Only) Serology Pregnancy
Hem oglobin A1c
TSH
FSH (for w omen only)Hepatitis BsAg and core 
Ab (if positive core Ab, 
then reflex Hep B DNA)
Hepatitis C Ab (if positive 
then reflex HCV RNA)
HIVIn females of childbearing 
potential:
Serum Î² -hCG (Screening and 
if positive urine Î² -hCG)
Urine Î² -hCG (all other 
visits)â€ 
*   vfPBMC and Leukocyte subsets US and Canada only.
â€     During the periods where visits are every [ADDRESS_580381] of Joints to be Evaluated ( 66/68 Joint Count )
An overview of the joints assessed is provided below (left and right):
ï‚·Temporomandibular 
ï‚·Sternoclavicular 
ï‚·Acromioclavicular 
ï‚·Shoulder 
ï‚·Elbow
ï‚·Wrist
ï‚·Metacarpophalangeal: first, second, third, fourth, fifth 
ï‚·Proximal interphalangeal: first, second, third, fourth, fifth
ï‚·Distal interphalangeal: second, third, fourth, fifth
ï‚·Hip2
ï‚·Knee 
ï‚·Ankle 
ï‚·Tarsus 
ï‚·Metatarsophalangeal: first, second, third, fourth, fift
h 
ï‚·Proximal interphalangeal (toe) : first, second, third, fourth, fifth
Replaced (or otherwise notassessable) joints should be documented at screening and omitted 
from further evaluation during the stud y.
                                                  
2Assessed for tenderness only
Filgotinib 
Protocol GS -US-417-0303 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 110 05 July 2016Appendix 8. The 2010 Am erican College of Rheumatology â€“European League 
Against Rheumatism Collaborative Initiative Classification Criteria 
for Rheumatoid Arthritis {Aletaha et al 2010
}
Target population (Who should be tested?): Patients who have at least 1 joint with definite 
clinical synovitis (swelling)awith the synovitis not better explained by [CONTACT_204987] (score- based algorithm : add score of categories A -D;
a score of â‰¥ 6/10 is needed for classification of a patient as having definite RA)c
A. Joint involvementd
1 large jointe0
2-10 large joints 1
1-3 sm all joints (w ith or without involvement of large joints)f2
4-10 sm all joints (with or w ithout involvement of large joints) 3
>10 joints (at least 1 small joint)g5
B. Serology (at least [ADDRESS_580382] result is needed for classification)h
Negative RF and negative ACPA 0
Low-positive RF orlow-positive ACPA 2
High -positive RF orhigh-positive ACPA 3
C. Acute -phase reactants (at least [ADDRESS_580383] result is needed for classification)i
Normal CRP andnormal ESR 0
Abnorm al CRP or abnormal ESR 1
D. Duration of symptomsj
<6 w eeks 0
â‰¥6 w eeks 1
a The criteria are aimed at classification of newly presenting patients. In addition, patients with erosive disease typi[INVESTIGATOR_19529] l of 
rheumatoid arthritis (RA) with a history compatible with prior fulfillment of the 2010 criteria should be classified as havin g 
RA. Patients with longstanding disease, including those whose disease is inactive (with or without treatment) who, based on 
retrospectively available data, have previously fulfilled the [ADDRESS_580384] should be consulted.
c Although patients with a score of <6/[ADDRESS_580385] category possible based on the pattern of joint involvem ent.
e "Large joints" refers to shoulders, elbows, hips, knees, and ankles.
f "Small joints" refers to the metacarpophalangeal joints, proximal interphalangeal joints, second through 
fifthmetatarsophalangeal joints, thumb interphalangeal joints, and wrists.
g In this category, at least [ADDRESS_580386] be a small joint; the other joints can include any combination of la rge 
and additional small joints, as well as other joints not specifically listed elsewhere (eg, temporomandibular, 
acromi oclavicular, sternoclavicular).
Filgotinib 
Protocol GS -US-417-0303 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 111 05 July 2016h Negative refers to IU values that are less than or equal to the upper limit of normal (ULN) for the laboratory and assay; 
low-positive refers to IU values that are higher than the ULN but â‰¤[ADDRESS_580387] for the laborator y and assay; 
high-positive refers to IU values that are >[ADDRESS_580388] for the laboratory and assay. Where rheumatoid factor (RF) 
information is only available as positive or negative, a positive result should be scored as low -positive for RF. 
ACPA =anti-citrullinated protein antibody.
i Normal/abnormal is determined by [CONTACT_51091]. CRP = C -reactive protein; ESR = erythrocyte sedimentation rate.
j Duration of symptoms refers to patient self -report of the duration of signs or symptoms of sy novitis (e.g., pain, swelling, 
tenderness) of joints that are clinically involved at the time of assessment, regardless of treatment status.
Filgotinib 
Protocol GS -US-417-0303 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 112 05 July 2016Appendix 9. American College of Rheumatology Response Evaluations/ 
Preliminary Definitio
n of Improvement in Rheumatoid Arthritis 
{Felson et al 1995 }
ACR 20 Required â‰¥20% improvement in tender joint count,  AND
â‰¥ 20% improvement in swollen joint count, AND
â‰¥ 20% improvement in at least 3 of the following 5 items:
ï‚·Patient pain assessment
ï‚·Patient global assessment of disease activity
ï‚·Physician global assessment of disease activity
ï‚·Patientâ€™s assessment of phy sical function (HAQ -DI)
ï‚·Acute -phase reactant (CRP)
The following lists the disease activity measure followed by [CONTACT_454192]
1.Tender joint count
ACR tender joint count is an assessment of 68 total join t
s. The joint count should be done b y 
scoring several different aspects of tenderness, as assessed by  [CONTACT_454193]. T he information on various ty pes of tenderness should then be collapsed 
into a single tender -versus -nontender dichotom y.
2.Swollen joint count
ACR swollen joint count is an assessment of 66 total joints. Joints are classified as either swollen 
or not swollen
3.Patientâ€™s assessment of pain
The pain score from the HAQ -DI will be used to calculate ACR response.
Filgotinib 
Protocol GS -US-417-0303 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 113 05 July [ZIP_CODE].Patientâ€™s global assessment of disease activity
A horizontal, visual analog scale will be used to provide the patientâ€™s overall assessment of how 
the arthritis is doing.
Place a mark on the line below to indicate how you assess your current rheumatoid 
arthritis disease activity:
   No arthritis Severe arthritis
5.
Physicianâ€™s global assessment of disease activity
A horizontal visual analog scale will be used to measure the phy sicianâ€™s assessment of the 
patientâ€™s current disease activity .
Place a mark on the line below to indicate RA disease activity  (independent of the subjectâ€™s 
self-assessment):
No Disease Activity                                                                                 Maximum Disease Activity
6.Patientâ€™s assessment of physical function
The HAQ -DI will be used to provide a patientâ€™s self -assessment of phy sical function.
7.Acute -phase reactant value
C-reactive protein level as measured at the central laboratory
Filgotinib 
Protocol GS -US-417-0303 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 114 05 July 2016Appendix 10. Disease Activity Score (DAS28) { Prevoo et al 1995 }
Assessments of RA in patients by  [CONTACT_204990] (modified to include the 28 joint 
counts according to Smolen* 1995) will be conducted at the meas ured timepoints
. The DAS28 
consists of a composite score of the following variables: tender joint count, swollen joint count, 
CRP, and patient global score. The following equation will be used to calculate the DAS28 -CRP
ï‚·DAS28- CRP ï€½0.56 âˆš TJC28 ï€« 0.28âˆšSJC28ï€«0.36ln( CRP ï€«1) ï€«0.014( patients global VAS) 
ï€«0.96
ï‚·TJC28 = number of joints tender out of 28
ï‚·SJC28 = number of joints swollen out of 28
ï‚·CRP = C -reactive protein
ï‚·Patient global VAS as defined in  Appendix 9
Filgotinib 
Protocol GS -US-417-0303 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 115 05 July 2016Appendix 11. Procedures and Specifications
Complete Physical Examination
A complete ph ysical examination should include source documentation of general appearance, 
and the following bod y systems: Head, neck and thy roid; ey es, ears, nose, throat, mouth and 
tongue; chest (excluding breasts); respi[INVESTIGATOR_696] ; cardiovascular; l ymph nodes, abdomen; skin, hair, 
nails; musculoskeletal; and neurological . . 
Blood Pressure
Assessment of vital signs will include measurement of resting blood pressure, pulse, respi[INVESTIGATOR_2865], and temp erature.
Blood pressure will be measured using the following standardized process:
ï‚·Subject should 
be resting f or ï‚³5 minutes with feet flat on the floor and measurement arm 
supported so that the midpoint of the manometer cuff is at heart level;
ï‚·Use a mercury  sphy gmomanometer or automatic blood pressure device with an appropriately  
sized cuff with the bladder centered over the brachial artery ;
ï‚·Measure and record the blood pressure to the nearest [ADDRESS_580389] whole number on an automatic device.
Creatinine Clearance 
Creatinine clearance is calculated b y the Cockcroft -Gault equation {Cockcroft et al 1976 }using 
actual bod y weight (BW). 
Male: CL cr(mL/min) =
[140 - age (y ears)] ï‚´BW(kg)
72ï‚´Scr
Female: CL cr(mL/min) =[140 -age (y ears)] ï‚´BW(kg) ï‚´0.85
72ï‚´Scr
Scr= serum creatinine (mg/dL)
12-Lead ECG
Subjects 
should be resting in a supi[INVESTIGATOR_19636] ï‚³5minutes prior to making a recording.
The investigator (or qualified designee) should review the ECG traces recorded in real time for 
clinically  significant abn ormalities.  On treatment ECGs should be compared to the subjectâ€™s 
Screening as part of routine safet y monitoring.  